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Summary 
Transmucosal nasal drug delivery is a drug delivery option for challenging clinical situations where 
common drug administrations (e.g., intravenous, intramuscular, or oral) are inapplicable. For drugs 
with constricted oral bioavailability, due to degradation in the intestinal tract or hepatic first-pass 
metabolism, transmucosal nasal delivery is a convenient alternative to intravenous and 
intramuscular drug administration. The considerable blood flow, actually responsible for breath 
conditioning, benefits efficient systemic drug uptake and provides direct access to the systemic 
circulation for transmucosal absorbed drugs. 
Often, in nasal drug delivery the limited nasal capacity is disregarded and the instilled volumes 
exceed the limited capacity of the nose. Consequently, the administered preparations are partially 
swallowed and resulting pharmacokinetic characteristics refer to a combination of transmucosal 
nasal and gastrointestinal drug absorption. Due to low midazolam concentration, the commercially 
available preparations for intravenous administration (e.g. Dormicum®, Roche) is inappropriate for 
transmucosal nasal midazolam delivery. For the optimization of transmucosal nasal midazolam 
delivery minimized administration volumes are essential to prevent swallowing of nasally 
administered preparations. Therefore, nasal preparations with enhanced midazolam concentrations 
need to be provided.  
 
In Project I different preparations for transmucosal nasal midazolam delivery were developed. The 
impact of vehicle and application modality on the pharmacokinetics of nasally applied midazolam 
was studied by administration of the developed preparations to healthy volunteers (Project II). The 
benefit of two nasal midazolam preparations for procedural anxiolysis in anxious patients 
undergoing MRI examinations was compared (Project III). 
 
Project I: Midazolam solubilization with RMβCD (randomized methylated-β-cyclodextrin, a 
cyclodextrin derivative) facilitated compounding of midazolam preparations adjusted to the limited 
volumetric capacity of the nose. RMβCD (added in equimolar or higher concentration to solubilize 
midazolam) reduced midazolam release in drug release studies with semi-permeable cellophane 
membranes (in vitro). Stability data affirmed shelf life of at least 6 months for RMβCD containing 
nasal midazolam preparations. Addition of chitosan hydrochloride (penetration enhancer) affected 
midazolam stability; therefore shelf life of the chitosan containing nasal midazolam preparation was 
reduced. The developed preparations for transmucosal nasal midazolam delivery were the basis to 
study the influence of the vehicle and the application modality on pharmacokinetics and systemic 
bioavailability of nasally applied midazolam (Project II). 
Summary 
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Project II: Pharmacokinetic characteristics following nasal application of 1 mg midazolam 
(Preparation 1, 2, and 3) and 3 mg midazolam (Preparation 4 and 5) were compared with 
pharmacokinetic characteristics of 1 mg i.v. administered midazolam (Dormicum®, Roche). The 
impact of RMβCD (solubilizer), chitosan hydrochloride (penetration enhancer) and the application 
modality (one- versus two-sided nasal administration) was investigated in this open-label study with 
healthy volunteers. Volunteers were asked to describe nasal midazolam administration and to 
classify local irritation after nasal midazolam administration. Pharmacologic effects were assessed 
by computer-controlled self-adjusting reaction time test (CRTT, recording reaction time and 
interstimulus interval) and visual analog scale (VAS). Blood samples were serially obtained until 
6 hours after midazolam administration. Serum concentrations of midazolam and two metabolites 
(α-hydroxymidazolam and 4-hydroxymidazolam) were quantified by liquid chromatography-mass 
spectrometry (LC-MS). Non-compartment and two-compartment pharmacokinetic modeling was 
performed to estimate pharmacokinetic parameters. Bioequivalence testing was performed 
according to the requirements of EMEA (European Agency for the Evaluation of Medicinal 
Products). 
Systemic bioavailability of nasally applied midazolam ranged from 78% (Preparation 5) to 93% 
(Preparation 2), differences of bioavailability were not significant. After nasal administration of 1 mg 
midazolam by Preparation 1, 2, and 3 mean Cmax was, 28.1 ± 9.1 µg/l, 30.1 ± 6.6 µg/l and 
28.9 ± 5.4 µg/l, respectively. After nasal administration of 3 mg midazolam by Preparation 4 and 5 
Cmax was, 72.6 ± 18.2 µg/l, and 82.2 ± 15.8 µg/l, respectively. Following nasal midazolam 
administration tmax was between 7.1 ± 0.6 minutes (Preparation 5) and 11.7 ± 2.4 minutes 
(Preparation 4). All tested nasal administration modalities to deliver 1 mg midazolam proved 
bioequivalence. For Preparation 4 and Preparation 5 bioequivalence was not confirmed. The serum 
concentration time profiles of the midazolam metabolites (α-hydroxymidazolam and 4-
hydroxymidazolam) demonstrated exclusive transmucosal absorption of nasally applied 
midazolam. Swallowing of nasally delivered preparations was prevented and hepatic first-pass 
effect successfully circumvented. Consequently, the assessed pharmacokinetic parameters 
characterized pure transmucosal nasal midazolam delivery. 
Neither RMβCD (equimolar to midazolam) nor application modality (one- or two-sided) changed 
absorption kinetics of nasally administered midazolam, whereas chitosan hydrochloride promoted 
absorption of nasally applied midazolam. Significant higher midazolam serum concentrations were 
achieved faster. The outcome of the pharmacokinetic study emphasizes the decisive role of 
minimized nasal application volume to prevent swallowing of nasally applied preparations and to 
provide for exclusive transmucosal midazolam absorption.  
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Project III: In this randomized multicenter trial with 110 anxious and/or claustrophobic patients 
undergoing MRI examinations, two nasal preparations for low-dose midazolam delivery, 
Midazolam MD Nasal Spray 5 mg/ml (MD) and Midazolam UD Nasal Spray 1 mg (UD), were 
compared. Nasal administration of 1 mg or 2 mg midazolam was provided before MRI examination. 
Within both groups anxiety reduction was significant, but there was no difference in anxiety 
reduction between the MD and UD group. Local irritation following administration of UD nasal spray 
was slightly more intense than local irritation after administration of MD nasal spray. 
Nasal delivery of low-dose midazolam is a safe therapy to provide procedural anxiolysis in patients 
undergoing MRI examinations. The two compared low-dose midazolam preparations for 
transmucosal nasal delivery of midazolam proved therapeutic equivalence. Hence, anxious and/or 
claustrophobic patients equally benefit from procedural anxiolysis during MRI examinations 
following administration of low-dose midazolam by MD nasal spray or UD nasal spray. Concerning 
convenient handling, administration to laying patients, and hygienic aspects the new midazolam 
nasal spray (UD) is superior to the commonly used midazolam multidose nasal spray (MD). 
 
Overall, the presented nasal preparations facilitated characterization of exclusive transmucosal 
nasal absorbed midazolam. In vivo neither RMβCD (equimolar to midazolam) nor administration 
modality changed the pharmacokinetic profile of nasally applied midazolam. Chitosan 
hydrochloride promoted nasal midazolam absorption but clinical relevance (e.g., for the treatment 
of status epilepticus) is to be verified in further clinical investigations. High systemic bioavailability 
of nasally applied midazolam demonstrated the veritable potential of transmucosal nasal drug 
delivery as alternative to invasive drug administration. 
 
  
Background and objectives 
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Background and objectives 
The most popular nasal drug delivery is nasal application of topical decongestants or anti-
inflammatory drugs, to treat rhinitis or allergy related symptoms. In addition, for transmucosal nasal 
absorbed drugs the nasal route provides direct access to the systemic blood circulation. For drugs 
with constricted oral bioavailability, due to degradation in the intestinal tract or hepatic first-pass 
effect, transmucosal nasal delivery is an interesting alternative to intravenous and intramuscular 
drug administration. A challenge in transmucosal nasal drug delivery is the limited volumetric 
capacity of the nasal cavities. Therefore, the entire dose, preferably administered in solution, has to 
be instilled in a limited volume. Consequently, solubility of the drug is one of the critical parameters 
in transmucosal nasal drug delivery. 
Midazolam is a benzodiazepine used for the treatment of anxious patients undergoing diagnostic or 
surgical procedures (procedural anxiolysis and/or sedation in adults and children) and the 
treatment of seizures (epileptic or febrile). These therapeutic indications are clinical situations, in 
which drug administration is potentially difficult and rapid onset of therapeutic effect absolutely 
desirable. Intranasal administration of midazolam has been of particular interest, because of the 
rapid and reliable onset of therapeutic effect and the convenience of administration. Due to low 
midazolam concentration, the commercially available preparation for intravenous administration 
(Dormicum®, Roche) is not optimal for transmucosal nasal midazolam delivery. For the optimization 
of transmucosal nasal midazolam delivery minimized administration volumes are essential to 
reduce the risk of swallowing the administered preparation. Therefore, nasal preparations with 
enhanced midazolam concentrations need to be provided.  
 
The aim of Project I was the development and in vitro characterization of preparations for 
transmucosal nasal midazolam delivery. Several solubilization enhancers were evaluated to reduce 
the administration volume. For the developed midazolam preparations stability testing was 
performed.  
 
The purpose of Project II was the pharmacokinetic characterization of the developed preparations 
for transmucosal nasal midazolam delivery. The influence of the vehicle, namely RMβCD 
(solubilization enhancer) and chitosan hydrochloride (penetration enhancer) on pharmacokinetic 
profile of nasally delivered midazolam was assessed. 
 
In a multicenter trial (Project III) two midazolam preparations for transmucosal nasal midazolam 
delivery were compared in anxious and/or claustrophobic patients undergoing MRI examination.  
 
The objectives of this thesis were to provide preparations for transmucosal nasal midazolam 
delivery (Project I), to assess the pharmacokinetic characteristics of nasally applied midazolam 
(Project II), and to compare the benefit of two nasal midazolam preparations for procedural 
anxiolysis in anxious patients undergoing MRI examinations (Project III).  
 
  
  
 
THEORETICAL SECTION 
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1 Nasal drug delivery 
1.1 Topical and systemic bioavailability of nasally applied drugs  
The rate and extend to which an active substance or active moiety is absorbed from the 
pharmaceutical preparation and becomes available at the site of action, is defined as 
bioavailability by the European Agency for the Evaluation of Medical Products [EMEA 26. July 
2001]. 
In general, drug administration is characterized by the systemic bioavailability (the rate and 
extend the active substance is absorbed into the systemic blood circulation, not taking in 
consideration the site of action). The reasons are ease of blood sampling contrary to the difficulties 
to assess the drug concentration directly at the site of action (e.g., central nervous system). 
Topical drug delivery describes the application of a drug directly on the target organ (e.g., 
application of glucocorticosteroides for dermatological therapies). To study vehicle effects of topical 
drug delivery, both the assessment of topical bioavailability and systemic bioavailability are 
performed. Whereas topical bioavailability allows predicting the therapeutic effect and 
systemic bioavailability reflects the systemic exposure meaning the risk for systemic adverse 
drug reactions.  
 
The term nasal drug delivery refers to topical and systemic nasal drug delivery. For diseases 
of the nasal mucosa, such as infectious rhinitis, allergic rhinitis, and nasal polyposis, the topical 
nasal administration delivers drug directly to the target organ [Salib and Howarth 2003]. Nasal 
applications of topical decongestants or anti-inflammatory drugs are therefore the most popular 
topical nasal drug deliveries.  
Whereas nasal drug delivery for systemic effect means transmucosal drug delivery, and 
provides, for some compounds, direct access to the systemic circulation. Transmucosal 
absorption describes the uptake of a compound into the systemic circulation after application on a 
mucosa (e.g., nasal, buccal, or rectal mucosa). Transmucosal absorption subsumes following 
subsequent processes: drug release, penetration (entry into a layer), permeation (transition of a 
layer), and absorption (uptake into the vascular system).  
The common term nasal bioavailability usually refers to the systemic bioavailability after nasal 
drug delivery and not to the topical bioavailability in the nasal mucosa. 
1. Nasal drug delivery 
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1.2 Transmucosal nasal drug delivery  
The relatively large surface area, the porous epithelial membrane, and the extensive 
vascularization are factors favoring transmucosal absorption of nasally administered drugs [Arora 
et al., 2002]. For transmucosal nasal absorption a surface of approximately 150 cm2 (150 to 
200 cm2) is available [Merkus 2004]. For efficiently transmucosal absorbed compounds therapeutic 
concentrations in the blood circulation are reached within few minutes. This is especially desirable 
for indications requiring fast onset of action (e.g., status epilepticus, acute pain). Furthermore, 
nasally absorbed compounds circumvent the first-pass elimination in the liver. Therefore, nasal 
drug delivery is an attractive alternative to i.v. or i.m. injections. The nose is easily accessible and 
nasal drug delivery is suitable for self-administration. Some of the major advantages offered by the 
nasal route are (modified after [Romeo et al., 1998]): 
 
• rapid absorption (fast onset of therapeutic effect) 
• high bioavailability (for drugs with good permeation abilities) 
• circumventing of liver first-pass metabolism (resulting in higher and less variable 
bioavailability) 
• no gastrointestinal drug degradation 
• non-invasive, therefore reduced risk of infection 
• ease of convenience and self-medication 
• improved patient compliance 
 
Transmucosal nasal drug delivery has been suggested as alternative route for drugs with poor 
systemic bioavailability after oral administration. For drugs extensively metabolized in the 
gastrointestinal tract or in the liver, such as proteins, peptides, and steroid hormones (estradiol, 
progesterone, and testosterone), nasal administration is a convenient alternative. Table 1-1 gives 
an overview of compounds tested for transmucosal nasal drug delivery.  
1. Nasal drug delivery 
 
 
Katja Suter-Zimmermann Page 13 of 188 University of Basel, 2008 
 
 
Table 1-1: Compounds for transmucosal drug delivery 
Compound Indication Reference  
apomorphine Parkinson’s disease (on-off-
symptoms) 
[Kendirci and Hellstrom 2004] 
buserelin prostate cancer [Arora, et al. 2002; Borrego et al., 1995; de 
Voogt et al., 1998; Larsen et al., 1987; 
Matsubara et al., 1995] 
calcitonin osteoporosis [Denis et al., 1989; Matsuyama et al., 2006; 
Schmidt et al., 1998; Torres-Lugo and Peppas 
2000; Wang et al., 2004] 
cobalamin (vitamin B12) substitution of vitamin B12 [Van Asselt et al., 1998] 
desmopressin diabetes insipidus centralis, 
enuresis nocturna 
[Lopes et al., 2001] 
diazepam sedation, anxiolysis, status 
epilepticus 
[Li et al., 2002] 
estradiol substitution of estradiol [van den Berg et al., 2004] 
fentanyl analgesia, postoperative pain 
and agitation in children 
[Borland et al., 2006; Finkel et al., 2001] 
human growth hormone growth hormone deficiency [Hedin et al., 1993] 
insulin diabetes mellitus [Dondeti et al., 1995] 112/270 
ketamine, norketamine analgesia [Yanagihara et al., 2003] 
L-dopa Parkinson’s disease [Kao et al., 2000] 
melatonin jet-lag [Merkus 2004] 
midazolam sedation, anxiolysis, status 
epilepticus 
[Burstein et al., 1997; Burstein et al., 1996; 
Davis et al., 1995; Fösel 1996; Goepfert 1996; 
Griffith et al., ; Gudmundsdottir et al., 2001; 
Jaennet 1999; Jones et al., 1997; Knoester et 
al., 2002; Lejus et al., 1997; Ljung and 
Andreasson 1996; Loftsson et al., 2001; 
Malinovsky et al., 1993; Münte Sinikka 2002; 
Roelofse et al., 2000; Rose et al., 1990; Sonja 
Böttcher 2000; Tschirch et al., 2006; U.Haas 
1998] 
morphine analgesia [Dale et al., 2002; Illum et al., 2002; Merkus 
2004] 
progesterone infertility, amenorrhea [van den Berg, et al. 2004] 
propranolol hypertonia [Hussain et al., 1980a; Hussain et al., 1980b; 
Hussain et al., 1979] 
sildenafil erectile dysfunction [Merkus 2004] 
testosterone substitution of testosterone [Lahat et al., 1998], [Hussain et al., 1984], 
[Hussain et al., 2002] 
 
1. Nasal drug delivery 
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1.3 Challenges in transmucosal nasal drug delivery  
The ideal drug for transmucosal nasal delivery show appropriate aqueous solubility (to deliver the 
entire dose in 25 µl to at most 400 µl), good permeability, no nasal irritation, adequate potency  
(required dose of about 25 mg) and no offensive odor [Romeo, et al. 1998]. 
The physicochemical properties of the compound, nasal mucociliary clearance and penetration 
enhancers are the main factors providing drug absorption through the nasal mucosa. The 
enzymatic metabolism of the nasal mucosa, the physical barrier of the epithelium, the rapid 
mucociliary clearance limiting the time available for absorption, and the mucus layer covering the 
nasal mucosa are further challenges of transmucosal nasal drug delivery [Merkle et al., 1998]. 
Table 1-2 summarizes the most important characteristics to be considered in transmucosal nasal 
drug delivery. Chapter 2 reviews the impact of the anatomy and the physiology on transmucosal 
nasal drug delivery and in chapter 4 preparation related parameters are discussed. 
 
 
Table 1-2: Factors affecting nasal absorption 
anatomy interindividual variability (surface) 
physiology 
blood flow 
nasal secretion 
pH on intranasal surface 
mucocilliary clearance na
sa
l c
av
ity
 
environment temperature, humidity 
compound 
molecular weight 
size 
solubility 
pKa 
concentration 
n
a
s
al
 
pr
e
pa
ra
tio
n
 
vehicle 
pH 
irritability 
osmolality 
viscosity 
adhesion 
residence time 
de
liv
e
ry
 
de
v
ic
e 
drops, spray 
nasal surface with drug contact 
size of droplets 
spreading 
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1.4 Nose to brain-transport 
The blood-brain barrier provides an efficient diffusion barrier especially for polar drugs. Hence, 
limitations are evident in the treatment of diseases of the central nerve system, such as 
Parkinson’s and Alzheimer’s disease. It has been suggested that after intranasal administration, 
some drugs reach the targeted brain structures, circumventing the blood-brain barrier. Lipophilic 
compounds may be transported by neuronal transport of nervus olfactorius. Extend of neuronal 
transport is highly dependent on the physicochemical properties of the drugs, namely the molecular 
weight and the lipophilicity [Illum 2004]. The existence of the olfactory-pathway has been proven for 
some compounds in animal models, but not in human [Illum 2000].  
Since central nervous bioavailability of drugs, transported by the olfactory-pathway is estimated to 
be 0.01% to 0.1%, only very potent drugs may reach therapeutic levels at the central nervous side 
of action by nose to brain-transport. 
Pre-estimating the contribution of the olfactory pathway in drug transport to the brain, the 
differences between the species in respect to localization and extend of the olfactory epithelium 
has to be considered. Furthermore, Graff and Pollak suggested efflux transporters to impair drug 
concentration in the brain after transmucosal nasal administration [Graff and Pollack 2003]. 
In human the olfactory epithelium is situated in the superior conchae and therefore hardly 
moistened by common nasal sprays. To ensure the delivery of a drug to the olfactory epithelium 
some authors propose specially developed delivery devices or application techniques [Dhanda et 
al., 2005].  
Assuming the existence of an olfactory-pathway to the brain in human, it remains unclear to what 
extent it contributes to central nervous availability of a nasally administered drug. 
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2 Impact of anatomy and physiology on transmucosal 
nasal drug delivery 
2.1 Anatomy and physiology of the nose 
The surface of the nasal cavity is enlarged by three nasal conchae (superior, middle, and inferior), 
facilitating purification, humidification and temperature regulation of inspired air [Mygind and Dahl 
1998] (see Figure 2-1). The total surface of both nasal cavities is about 150 cm2 (150-200 cm2) 
[Merkus 2004] of which the respiratory epithelium covers about 130 cm2 (large inferior turbinate) 
and the olfactory region about 2 cm2 to 10 cm2 (superior conchae). 
The narrowest portion of the entire upper airway, the internal naris (nasal valve), is located about 
1.5 cm from the external naris. The nasal valve accounts for approximately 50% of the total 
resistance to respiratory airflow from the nostril to the alveoli. 
 
 
Figure 2-1: Section of the human nasal cavity, from SEER’s web-
based Training Module [SEER, 2007] 
 
Breathing and olfaction are the prime functions of the nasal cavity. Beside these functions, the 
nasal cavity and the paranasal sinuses are important for the resonance of the voice. 
The high vascularization of the submucosa facilitates warming up of the inspired air. The 
submucosal vascular plexus consists of arterioles, capillaries, semi-permeable post capillary 
sinusoids and venules. The post capillary sinusoids regulate resistance and secretory activity of the 
nasal mucosa. Vasodilatation and extravasation of plasma resulting in nasal congestion and 
rhinorrhoea, is induced by histamine, kinins, substance P, platelet-activating factor, and various 
leukotrienes [Foley and Hamid 2006]. 
2. Impact of anatomy and physiology on transmucosal nasal drug delivery 
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2.2 Nasal mucosa and mucociliary clearance 
2.2.1 Morphology of the nasal mucosa 
All mucous membranes are linings of ectodermic origin and are involved in absorption and 
secretion processes. Mucous membranes cover various body cavities exposed to internal organs 
or external environment. At the nostrils, the lips, the ears, the genital area, and the anus, tissue 
changes in a smooth transition from skin (epidermis, dermis) to mucosa. 
From the nostrils to the nasopharynx, the predominant cell types of the nasal mucosa lining are 
changing. Stratified squamous, respiratory (pseudostratified columnar), and transitional epithelium, 
are the different epithelia linings of the nasal mucosa. In the anterior third of the nasal cavity, 
stratified squamous and transitional epithelium precedes respiratory epithelium, which is 
predominant in the posterior two-thirds of the cavity. 
The human olfactory region, situated in the superior conchae, covers only about 10% (about 
10 cm2) of the nasal cavity, while in mice and rats about 50% of the nasal cavity is covered by 
olfactory epithelium [Gizurarson 1993]. The olfactory epithelium is a pseudo stratified columnar 
structure. It consists of specialized olfactory cells, supporting cells, and serous and mucosal glands 
[Romeo, et al. 1998]. 
The respiratory epithelium is the major lining of the human nasal cavity and is essential for cleaning 
of nasal mucosa by the mucociliary clearance. The respiratory epithelium comprises of five cell 
types; ciliated and non-ciliated columnar cells, goblet cells, basal cells, and low numbers of 
neurosecretory cells in the basement membrane, see Figure 2-2. The apical side of the columnar 
and goblet cells reaches the lumen of the nasal cavity. Approximately 20% of the cells in the lower 
turbinante area are ciliated cells, with about 100-300 cilia on the apical surface. Cilia are hair-like 
projections (5-10 µm) on the apical surface of the columnar cells. All cilia beat in a coordinated 
fashion, transporting the mucus towards the nasopharynx.  
Basal cells are adjacent to the basal lamina, on the basolateral side of the epithelium. The lamina 
propria is located beneath the basal lamina and contains many blood vessels, nerves and glands. 
The functions of epithelial cells in the nose can be summarized as follows: (1) building a physical 
barrier for particles and allergens; (2) secretion of mucus, to protect the mucosa and to provide 
efficient conditioning of the inspired air; and (3) responding to various stimuli by producing 
mediators to recruit lymphocytes, eosinophils, and mast cells to the nasal mucosa [Takeuchi et al., 
2006].  
The intense blood flow in the arteriovenous anastomosis and the large surface of the respiratory 
epithelium favors transmucosal nasal drugs absorption. Drug absorption in the olfactory region is 
possibly resulting in direct nose to brain-transport through the nervus olfactorius (q.v. chapter 1.4.) 
[Gizurarson 1993]. 
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Figure 2-2: Respiratory epithelium. The respiratory epithelium is covered by a mucus 
layer (gel and sol layer) and the cell types arising from the basement membrane are: 
ciliated and non-ciliated cells (with microvilli), goblet cell, and basal cell. Modified after 
[Sakane et al., 1991]. 
 
2.2.2 Mucus and mucociliary clearance 
The goblet cells and the submucosal glands secrete about 20 ml to 40 ml mucus per day [Quraishi 
et al., 1998]. The mucus layer protects the underlying tissue from various environmental influences 
and the metabolic effects of enzymes. The mucus layer and hairs in the anterior nose filter 80% of 
particles larger than 12.5 µm out from the inhaled air stream [Jones 2001]. The pH of the mucus 
layer varies from 5.5 to 6.5 in adults and from 5.0 to 7.0 in infants [Arora, et al. 2002]. 
The principal component of the mucus is water (90-95%) containing mucin (2%), electrolytes (1%), 
proteins (1%, mainly albumin, immunoglobulins, and lysozymes), and lipids [Merkus et al., 1998; 
Schipper et al., 1991]. Small molecules not interacting with the components of the mucus layer 
diffuse freely through the water network of the mucous gel. Khanvilkar et al. demonstrated that for 
many compounds, nasal mucus layer adds as little additional resistance as an unstirred water layer 
of equal thickness [Khanvilkar et al., 2001].  
The mucus layer consists of two films with different rheological properties, a preciliary layer (sol 
layer) and a more viscous upper layer (gel layer) covering the tips of the cilia. Responsible for the 
rheological properties are two forms of mucin; soluble mucin and membrane bound mucin. Soluble 
mucin forms viscous gels by intermolecular disulfide bridges [Khanvilkar, et al. 2001]. 
The sol layer with low viscosity is slightly less thick than the length of an extended cilium (5 µm to 
10 µm). The extended cilia dip into the gel layer and, with effective beats, transports the layer to the 
nasopharynx. During the recovery stroke, the cilia move backward through the sol layer. In the 
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nasopharynx, the transported mucus layer with the trapped inhaled particles is swallowed or 
expectorated. Cilia in isolation are sensitive to temperature, optimally working at 35-40°C, and 
below these temperatures, the natural beat frequency drops [Jones 2001]. Increased mucus 
production in the respiratory tract is a symptom of many common diseases, such as the common 
cold.  
Nasal mucociliary clearance describes the removal of inhaled particles, viruses and bacteria by the 
combined function of cilia and mucus layers. Nasal mucociliary clearance is important for the 
protection of the respiratory system [Merkus, et al. 1998]. It takes approximately 20-30 minutes to 
remove the whole mucus layer [Bommer 2002]. Mucociliary clearance is independent of age and 
sex [Kao et al., 1994]. 
Extend of transmucosal nasal drug absorption is related to contact time of the delivered drug with 
the nasal mucosa. Nasal mucociliary clearance limits the residence time of drugs administered into 
the nasal cavities, decreasing the time available for the drug to be absorbed [Merkus, et al. 1998]. 
In the nasopharynx, not absorbed compounds are swallowed, followed by gastrointestinal 
degradation, gastrointestinal absorption, and/or hepatic metabolization.  
Mucociliary clearance can be modified by nasally administered drugs or components of the vehicle 
(viscosity enhancers, mucoadhesive excipients). 
Evaluation of the effects of drugs and additives on nasal mucociliary clearance is an important 
issue, especially in developing preparations for long-term treatments. The measurement of ciliary 
beat frequency in vitro is a very accurate and reproducible technique to determine the effects on 
ciliated epithelium. Therefore, assessment of ciliary beat frequency is a screening method to 
estimate potential toxicity of drugs and excipients and to compare nasal preparations. However, 
ciliary beat frequency data have to be interpreted carefully, because effects of nasal formulations in 
vitro are usually stronger than effects in vivo [Merkus, et al. 1998]. In vivo, the mucus layer protects 
cilia and dilutes the nasally delivered preparations, whereas in vitro, the cilia are in direct contact 
with the formulations. Furthermore, the nasal mucosa continuously regenerates. 
Consequently, it is difficult to predict the effects of chronic application on mucociliary clearance in 
vivo based on ciliary beat frequency assessment in vitro. 
For the term ‘ciliotoxic’ no defined criteria exist and the classification depends on the performed in 
vitro assays. Furthermore, the cilioinhibitory effects of compound or vehicle depend on the applied 
concentration and are often additive [Merkus, et al. 1998]. To predict the safety of nasal drug 
formulations for human use, it is important to investigate the effects of therapeutic concentrations, 
both in vitro and in vivo. 
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2.3 Drug metabolism in the nasal mucosa 
Nasal biotransformation enzymes are responsible for the metabolism of airborne xenobiotics. 
Geravasi et al. demonstrated the human respiratory epithelium of the nose containing a wide array 
of oxidative and non-oxidative enzymes, responsible for bioactivation or detoxication of inhaled 
xenobiotics [Gervasi et al., 1991]. 
Despite recent progresses in identification and characterization of numerous nasal 
biotransformation enzymes in animal models, metabolism in human nasal mucosa has not been 
conclusively characterized [Rahmel 2004; Zhang et al., 2005]. 
Some carcinogens or toxicants arise from metabolic transformation of originally nontoxic xenobiotic 
compounds. Most studies on metabolizing Cytochromes P450 monooxigenases (CYPs) in the 
respiratory tract focus on the role of these enzymes in metabolic toxicity [Ding and Kaminsky 2003]. 
CYPs, detected in extrahepatic tissues, usually, are also expressed in the liver at higher levels. 
Bereziat and Su characterized the sensitivity of tissues to a certain xenobiotic compound by the 
tissue-specific profile of exprimed CYP enzymes [Bereziat et al., 1995; Su et al., 2000]. However, 
the regulation mechanisms, responsible for tissue-specific CYP expression, have not been 
resolved.  
In human nasal respiratory epithel, Rahmel identified different isoforms of CYPs (such as 
CYP 1A1, 1B1, 2A6/7, 2A13, 2B6, 2C8, 2C9, 2C18, 2C19, 2E1, 2F1, 2J2, 2S1, 3A4, 3A5, and 4B1) 
by RT-PCR1. Furthermore, traces of CYP 1A2, 2D6, 3A7, and 4A11 were detected and enhanced 
expression of CYP 1A1, 1B1, and 2S1 was demonstrated in nasal mucosa of smokers. But, only 
the translation of CYP 2A proteins has been confirmed by western blot [Rahmel 2004].  
To estimate the metabolic capacity of nasal mucosa, the actual transcription level of the metabolic 
enzymes or even the metabolic activity should be specified. For loteprednol-etabonate (CYP 3A4 
substrate), testosterone, and ethoxyresorufin (CYP 1A1 substrate) Rahmel demonstrated minimal 
biotransformation in nasal microsomal preparations [Rahmel 2004].  
For nasally delivered substrates of enzymes, expressed in nasal mucosa, metabolism preceding 
systemic absorption is to be expected. To what extend this ‘nasal first-pass effect’ affects the 
systemic bioavailability of nasally delivered drugs, depends on actual enzyme expression. 
Expression of CYP 3A4, mainly responsible for midazolam metabolism, has not been detected in 
human nasal mucosa. Therefore, for nasally delivered midazolam no nasal fist-pass metabolism 
has to be expected. 
                                                     
1
 Reverse Transcription Polymerase Chain Reaction 
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2.4 Common cold and seasonal allergic rhinitis 
Common cold is the most frequent of all human diseases, infecting adults at an average rate of up 
to 4 infections per year, and school aged children as many as 12 times per year. 
By infecting the upper respiratory system numerous viruses (mainly rhinoviruses, coronaviruses, 
certain echoviruses, paramyxoviruses, and coxsackieviruses) cause common cold. Colds last 
typically three to five days, with residual coughing lasting up to three weeks. The nasal symptoms 
include sneezing, runny nose, and congestion. All this symptoms potentially affect transmucosal 
nasal drug delivery by diverse mechanisms. 
Although common cold is a frequent affection, only little is known about the pathohistology and 
pathophysiology. In vitro experiments showed rhinovirus induced sloughing of epithelial cells 
[Mygind and Dahl 1998]. During a common cold, the number of ciliated cells decelerates and 
reduces mucociliary clearance [Hoorn and Tyrrell 1969].  
Winther et al. described, that although many epithelial cells are sloughed, the epithelial lining is not 
destroyed, and scanning electron microscopy shows a continuous epithelial surface [Winther et al., 
1983]. 
Little data on the effect of common cold on the pharmacokinetics of intranasal administered drugs 
is available [Mygind and Dahl 1998]. 
Allergic rhinitis is part of a systemic disease complex. Examination of nasal epithelial integrity by 
light microscopy and electron microscopy has not revealed any epithelial damage in allergic rhinitis 
[Takeuchi et al. 2006]. Furthermore, improved functional tightness of the airway mucosa in allergic 
rhinitis has been shown by Greiff et al. Consequently, lumenal entry of plasma exudates in airway 
diseases is not necessarily coupled with an increased permeability for administered drugs [Greiff et 
al., 1997].  
The efficient and rapid epithelial restitution in vivo may support the assumption that rhinitis (allergic 
or inflamed) does not mandatory prime enhanced permeability of the nasal mucosa [Erjefalt et al., 
1995]. The common notion that increased mucosal absorption characterizes allergic and inflamed 
airways is poorly supported by in vivo studies. The influence of nasal diseases on transmucosal 
nasal drug delivery has not conclusively been characterized [Mygind and Dahl 1998]. 
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3 Midazolam 
3.1 Physicochemical characterization 
Midazolam base (white or light yellow crystalline powder) is a lipophilic compound with low 
solubility in water. Solubility of midazolam is highly pH dependent [Andersin 1991]. The alkaline 
nitrogen in position 2 of the imidazobenzodiazepine ring system enables midazolam to form water-
soluble salts with acids (e.g., hydrochloric, maleic, or lactic acid), see Figure 3-1. Dissociation 
constant pKa1 is 1.7 (protonization of nitrogen in position 2). The pKa2 value for the protonization of 
the nitrogen in position 5 is about 6 (6.15 to 5.50 [DAV 2006]). Under acidic conditions, midazolam 
is present as an equilibrium mixture of the closed-ring form and an open-ring structure, formed by 
the acid catalyzed ring opening of the 4,5-double bond of the diazepine ring. Above pH 5, at least 
99% of midazolam molecules are in the closed-ring form. Under physiologic conditions (pH 7.5, 
37°C), the open-ring form reverts to the physiologi cally active, lipophilic, closed-ring form (t1/2 3.9 
min [Loftsson, et al. 2001]).  
For the present work (Project I – III) midazolam hydrochloride was used. The empirical formula of 
midazolam hydrochloride is C18H13ClN3•HCl, and the molecular weight is 362 g/mol (midazolam 
base: 326 g/mol). 
 
pH > 4
pH < 4
BA
 
Figure 3-1: The closed (A) structure of midazolam and the corresponding open-
ring form (B). 
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3.2 Pharmacologic effects, metabolism and elimination2 
The pharmacologic effects of midazolam, an imidazobenzodiazepine, are basically the classic 
effects of all benzodiazepines. Midazolam has sedative and sleep-inducing effects of pronounced 
intensity. It also exerts anxiolytic, anticonvulsant, and muscle-relaxant effects. Anterograde 
amnesia3 of short duration is reported, especially for administrations providing fast rising plasma 
concentrations (e.g., i.v. or i.m. injection). Midazolam stands out against the other benzodiazepines 
because of its rapid onset of clinical effects and shorter duration of action because of fast metabolic 
transformation as well as low activity and short half-life of the main active metabolite (α-
hydroxymidazolam). 
The pharmacologic effects of benzodiazepines results from a reversible interaction with the 
gamma-amino butyric acid (GABA) receptor. GABA is the major inhibitory neurotransmitter in the 
central nervous system. The benzodiazepine receptor antagonist, flumazenil, readily reverses the 
action of midazolam. Midazolam is mainly metabolized by CYP 3A4 isoenzyme to major metabolite 
α-hydroxymidazolam, see Figure 3-2.  
 
                                                     
2
 [Documed 2006] 
3
 The patient does not remember events that occurred during the maximal activity of the 
compound. 
 
The unconjugated metabolite α-
hydroxymidazolam is pharmacologically active, 
and contributes about 10% to the 
pharmacological effect of midazolam. The 
glucuroconjugated α-hydroxymidazolam is 
excreted in urine (60-80% of injected 
midazolam). Less than 1% of the injected 
midazolam dose is recovered in urine as 
unchanged drug. The terminal elimination half-
life of α-hydroxymidazolam is about 1 hour. 
Due to the almost exclusive metabolism 
mediated by CYP3A4 isoenzyme, especially 
co-administration of CYP3A4 inhibitors and 
inducers result in pharmacokinetic interactions. 
Because of changed pharmacokinetics 
resulting in prolonged elimination half-life, in 
neonates, children, elderly, obese, patients with 
hepatic or renal impairment, critically ill 
patients, and patients with cardiac insufficiency, 
midazolam application is to be performed with 
caution.  
midazolam
glucuronide
glucuronide glucuronide
α-hydroxymidazolam
α-4-hydroxymidazolam4-hydroxymidazolam
 
Figure 3-2: Metabolism of midazolam. CYP 3A4 
metabolizes midazolam to the main metabolite α-
hydroxymidazolam, 4-hydroxymidazolam, and to 
α-4-hydroxymidazolam. All metabolites are 
urinary excreted as glucuronides. 
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3.2.1 Indications and doses 
The short-acting and sleep-inducing properties of midazolam facilitate the use of midazolam for 
different therapeutic indications. The Committee for Proprietary Medical Products (CPMP) of the 
EMEA summarizes the indications and doses of midazolam as displayed in Table 3-1. 
 
Table 3-1: Therapeutic indication and dosage of midazolam, published by the Committee for Proprietary Medical 
Products (CPMP) of the EMEA 
Adults 
Indication Children < 60 years ≥ 60 years / 
debilitated or 
chronically ill 
Conscious sedation 
before and during diagnostic 
or therapeutic procedures 
with or without local 
anesthesia 
6 months to 5 years 
(i.v.) 
- initial: 0.05-0.1 mg/kg 
- total: < 6 mg 
6 to 12 years (i.v.) 
- initial: 0.025-0.05 mg/kg 
- total: <10 mg 
>6 months (rectal) 
- 0.3-0.5 mg/kg 
1-15 years (i.m.) 
- 0.05-0.15 mg/kg 
i.v. 
- initial: 2-2.5 mg 
- titration: 1 mg 
- total: <3.5-7.5 mg 
 
 
i.v. 
- initial: 0.5-1 mg 
- titration: 0.5-1 mg 
- total: <3.5 mg 
 
 
Anesthesia premedication >6 months (rectal) 
- 0.3-0.5 mg/kg 
1-15 years (i.m.) 
- 0.08-0.2 mg/kg 
 
i.m. 
- 0.07-0.1 mg 
 
i.m. 
- 0.025-0.05 mg 
 
Anesthesia induction not used i.v. 
- 0.012-0.2 mg/kg 
 
i.v. 
- 0.01-0.2 mg/kg 
 
Sedation in ICU 
(Intensive Care Unit) 
i.v. in neonates < 32 
weeks gestational age 
- 0.03 mg/kg/h 
i.v. in neonates > 32 
weeks gestational age 
<6 months 
- 0.06 mg/kg/h 
i.v. >6 months 
- loading dose: 0.05-
0.3 mg/kg/h 
- maintenance dose: 0.06-
0.12 mg/kg/h 
 
 
i.v. 
- loading dose: 0.03-0.3 mg/kg 
- titration: 1-2.5 mg 
- maintenance dose: 0.03-0.2 mg/kg/h 
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3.2.2 Conscious sedation 
The guidelines for conscious sedation of the Society for the Advancement of Anesthesia in 
Dentistry (SAAD) defines conscious sedation as: “Technique in which the use of a drug or drugs 
produces a state of depression of the central nervous system enabling treatment to be carried out, 
but during which verbal contact with the patient is maintained throughout the period of sedation.  
The level of sedation must be such that the patient remains conscious, retains protective reflexes, 
and is able to respond to verbal commands”.  
MRI (magnetic resonance imaging) examinations are common diagnostic procedures. But many 
patients refuse this helpful diagnostic proceeding because of claustrophobia or unspecific anxiety. 
Anxiety in patients undergoing MRI examinations is a multifaceted phenomenon involving fear of 
enclosed places (claustrophobia), pain, the unknown situation, as well as apprehension about what 
the test might reveal [Katz et al., 1994]. For clear diagnostic MRI images the cooperation of the 
patient is essential (breathing on command during investigations of the upper abdomen). 
Therefore, anxiolysis without sedating the patient is desired. Conscious sedation is one of the most 
important approaches to help claustrophobic and anxious patients to cope with MRI examinations 
[Tschirch, et al. 2006]. 
Before and during diverse diagnostic or therapeutic procedures with or without local anesthesia, 
conscious sedation facilitates completing unpleasant procedures and increases patient’s comfort. 
In a review de Visser et al. evaluated published testing methods to assess effects of anxiolytic 
benzodiazepines in healthy volunteers. Even numerous psychopharmacology tests have been 
described to assess anxiolytic effects in human, no validated testing method exists. Furthermore, 
tests to assess anxiolysis are usually not specific enough to distinguish anxiolytic effects from 
sedating effects [de Visser et al., 2003]. Because standardized assessments for anxiolytic effects 
are leaking, no correlation of midazolam blood concentrations and anxiolytic effect has been 
established. For the evaluation of the benefit of an anxiolytic therapy in the clinical practice, 
phase III studies with anxious patients have to be performed.  
3.3 Undesirable effects  
The characteristic undesirable effects of benzodiazepines are reported also for midazolam. 
Sedation, amnesia, impaired attention, and impaired muscular function may adversely affect the 
ability to drive or use machines. 
Paradoxal reaction such as agitation, involuntary movements, hyperactivity, hostility, rage 
reactions, aggressiveness, paradoxal excitement, and assault, have been reported. This reaction 
occurs mainly with high doses and/or when the injection is given rapidly. The highest risk for 
paradox reaction has been reported for children and elderly patients [Weinbroum et al., 2001], as 
well as patients with actual or amnestic psychiatirc diseases and patients with alcohol addiction 
[Mancuso et al., 2004]. Furthermore paradoxal reaction is often related to high midazolam doses 
[Litchfield 1981]. 
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Administration of high midazolam doses, overdoses or in situations with impaired 
pharmacokinetics, the most vital symptoms to be monitored are areflexia, hypotension, 
cardiorespiratory depression, and apnea. Higher risk for cardiorespiratory depression, apnea, and 
areflexia is reported for co-administration of other central nervous acting drugs and inhibitors of 
CYP 3A4. 
3.4 Midazolam delivery  
In Switzerland, midazolam (Dormicum® 1 mg/ml and 5 mg/ml) is approved for intravenous or 
intramuscular injection or oral administration as tablets (Dormicum® 7.5 mg and 15 mg). Rectal 
administration of Dormicum® (1 mg/ml and 5 mg/ml) is also compendial, but not widely used. 
Because of pain and distress, injections for drug administration are not popular and patients (adults 
and children) usually prefer alternative drug administration. 
Oral midazolam delivery, the most popular drug administration route, is associated with 
considerable first-pass effect (bioavailability only 30-50% [Documed 2006]). Furthermore, oral 
midazolam administration is disposed to a delayed onset of action, additionally impaired by 
ingestion. Due to the fluctuant bioavailability, the pharmacological effect is hard to predict and the 
dose to be applied difficult to define. 
The pharmacokinetic disadvantages of rectally applied midazolam are analog to the oral 
administration a slow onset of action and a low peak plasma concentration [Malinovsky et al., 
1993]. 
Table 3-2 summarizes the characteristics of the different modes of midazolam delivery. Commonly, 
intravenous or intramuscular injection of midazolam is performed if rapid onset of action is desired 
[Burstein et al., 1997, Uygur-Bayramicli, 2002]. As a convenient and reliable alternative to 
intravenous and intramuscular administration, nasal midazolam delivery has received considerable 
attention not only for pediatric patients (see Table 3-4). 
Intranasal drug delivery is painless, results in rapid drug absorption and circumvents hepatic first 
pass metabolism. Additionally, the convenient administration results in high acceptance by the 
patients. A number of studies report the beneficial effects of nasal delivered midazolam in patients, 
both children and adults (see Table 3-4). 
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Table 3-2: Benefits and limitations of different administration routes for midazolam application 
Administration Benefit Limitation 
Oral 
(solid form) 
- convenient, painless application  
- well accepted by patients 
 
- dose: 7.5 mg or 15 mg 
- delayed onset of therapeutic effect 
- inappropriate for emergency care  
- only 30-50% bioavailability (relevant 
interindividual variability) 
Oral 
(liquid 
preparation) 
- individual dosing of syrup or drops 
- well accepted (if bitter taste of midazolam is 
masked) 
- convenient, painless application 
- delayed onset of therapeutic effect 
- children sometimes refuse oral 
medication 
- inappropriate for emergency care  
- only 30-72% bioavailability (relevant 
interindividual variability) 
- no liquid oral midazolam preparation 
commercially available in Europe 
Rectal - no swallowing  - not well accepted (adults and children) 
- 10-20% of children refuse rectal 
administration  
Intravenous - fast onset of therapeutic effect 
- no swallowing 
- emergency care (if veins are accessible) 
 
- painful 
- veins are not accessible during status 
epilepticus 
- children and some adults detest 
injections 
Intramuscular - fast onset of therapeutic effect 
- no swallowing 
- painful 
- risk of tissue necrosis at the site of 
injection 
Nasal - fast onset of therapeutic effect 
- no swallowing 
- individual dosing is limited 
- no nasal preparation commercially 
available 
 
 
3.4.1 Pharmacokinetic parameters of transmucosal delivered midazolam  
In Table 3-3 pharmacokinetic parameters of transmucosal delivered midazolam are summarized. It 
has to be taken in consideration, that for transmucosal nasal midazolam delivery different 
formulations were used.  
Several clinical investigators have used midazolam solution for injection at a concentration of 
5 mg/ml (Dormicum®, 5 mg/ml) for nasal delivery [Bjorkman et al., 1997; Burstein, et al. 1997; 
Connors and Terndrup 1994; Fösel 1996; Goepfert 1996; Ljung and Andreasson 1996; Ljungman 
2000; Malinovsky et al., 1995; Münte 2002; Tolksdorf and Eick 1991; Uygur-Bayramicli et al., 
2002]. In the cited studies, doses of 0.06 mg/kg to 0.6 mg/kg midazolam were administered by 
instilling Dormicum® (5 mg/ml) into the nose. The administered volume reached from 0.1 ml to 5 ml 
according to the bodyweight of patients. By exceeding the commonly recommended application 
volumes of 0.05 ml to 0.2 ml, the excess formulation tends draining off into the nasopharynx, where 
it is swallowed. The swallowed portion of the nasally delivered midazolam dose is absorbed in the 
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gastrointestinal tract and due to considerable first-pass effect bioavailability is impaired. 
Furthermore, the absorption is delayed and depends on ingestion [Burstein, et al. 1997]. 
Pharmacokinetic parameters of transmucosal nasally delivered drugs depend on many-sided 
interaction of different preparation and administration related parameters. Therefore, to compare 
the outcome of different investigations of nasal midazolam delivery, it is not enough to consider the 
administered doses. It is important to compare also the administered volume and the drug delivery 
device (spray or droplets), which determine the swallowed portion. In nasal drug delivery, the 
impact on pharmacokinetic parameters of the vehicle and other administration related 
characteristics (e.g., drug delivery device) is enormous. Therefore, the cited pharmacokinetic 
parameters are only of trend-setting character and cannot be generally assigned to transmucosal 
nasal midazolam delivery. In Appendix 10.1.1 published data on nasal midazolam delivery is 
summarized. 
 
Table 3-3: Dose, bioavailability, and onset of therapeutic effect of transmucosal administered midazolam. This 
parameters were assessed by nasal delivery of different preparations (in some publications the administered 
preparation was no specified). 
Delivery Dose per kg body weight Bioavailability 
Onset of 
effect Reference 
Oral 0.3-0.6 mg 31-72% 10-20 min [Allen 1991; Connors and Terndrup 1994; Cote et 
al., 2002; Gizurarson 1993; Goepfert 1996; 
Malinovsky, et al. 1995; Tolksdorf et al., 1989; 
Tolksdorf and Eick 1991] 
Nasal 0.2-0.4 mg 50-83% 5-10 min [Connors and Terndrup 1994; Fösel 1996; 
Goepfert 1996; Malinovsky, et al. 1993; Münte 
Sinikka 2002; Münte 2002; Roelofse, et al. 2000; 
Tolksdorf and Eick 1991] 
Rectal 0.3-0.5 mg no data  10-16 min [Documed 2006; Goepfert 1996; Malinovsky, et al. 
1995; Tolksdorf, et al. 1989; Tolksdorf and Eick 
1991] 
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Table 3-4: Indications and clinical situations where nasal administration of midazolam is beneficial 
Indication/clinical situation Reference 
Premedication before anesthesia 
 
children: [Davis, et al. 1995; Geldner et al., 1997; Griffith, et al.; 
Jaennet 1999; Kogan et al., 2002; Lejus, et al. 1997; Ljung and 
Andreasson 1996; Rey et al., 1991; Rose, et al. 1990] 
adults: [U.Haas 1998] 
Emergency  children: [Goepfert 1996] 
adults: [Wolfe and Bernstone 2004] 
Status epilepticus children: [Fisgin et al., 2000; Fisgin et al., 2002; Jaennet 1999; 
Kutlu et al., 2000; Lahat, et al. 1998] 
adults: [Gilat et al., 2003; Kendall et al., 1997; Lahat et al., 1992; 
Scheepers et al., 2000; Scheepers et al., 1998; Scott et al., 1999; 
Scott et al., 1997] 
(Febrile) childhood seizure 
 
[Johnson 2001; Koren 2000; Lahat et al., 2000] 
Short surgical procedures 
 
adults: [Ljungman 2000; Malinovsky, et al. 1993; Saint-Maurice 
et al., 1990] 
MRI examinations adults: [Moss et al., 1993; Münte Sinikka 2002; Schweizer et al., 
1992] 
Upper gastrointestinal endoscopy adults: [Uygur-Bayramicli, et al. 2002] 
Dental surgery children:[Abrams et al., 1993; al-Rakaf et al., 2001; Fuks et al., 
1994; Hartgraves and Primosch 1994; Kaufman et al., 1994; 
Kupietzky et al., 1996; Lloyd et al., 2000] 
adults: [Burstein, et al. 1996; Fukuta et al., 1993; Fukuta et al., 
1994; Fukuta et al., 1997; Kaufman, et al. 1994; Roelofse et al. 
2000] 
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4 Compounding of nasal midazolam preparations 
4.1 Regulatory requirements for nasal preparations [Ph. Eur. 5.5] 
Nasal preparations are liquid, semi-solid, or solid preparations intended for administration to the 
nasal cavities for systemic or local effect. Nasal preparations are, as far as possible, non-irritating 
and do not adversely affect the function of the nasal mucosa and its cilia. Aqueous nasal 
preparations are usually isotonic and may contain adjuvants to modify the viscosity of the 
preparation, to adjust or stabilize the pH, to increase the solubility of the active compound, or for 
other technological purposes.  
4.2 Excipients for nasal midazolam preparations 
In nasal preparations, adjuvants have different purposes. Beside adjuvants to solubilize the active 
substance and excipients to adapt the preparation to the local physiological conditions, viscosity 
modifiers, bioadhesives, and penetration enhancers are added to modify bioavailability. Viscosity 
enhancers and mucoadhesive excipients transiently modify mucociliary clearance. But, the 
modification of the mucociliary function needs to be reversible and should not adversely affect the 
functions of the nasal mucosa and its cilia. 
All drugs must possess some degree of aqueous solubility to be pharmacologically active, and 
most drugs need to be lipophilic to be able to permeate biological membranes by passive diffusion. 
How water-soluble a given drug needs to be is determined by its potency (i.e., the required dose) 
and type of formulation.  
4.2.1 Solubilizers 
Due to restricted residence time (mucociliary clearance) and limited solvent (water) in nasal 
cavities, drugs are preferably administered in solutions. The ideal volume range is 25 µl to 150 µl 
with an upper limit of 200 µl per nostril [Romeo, et al. 1998]. Therefore, the entire dose of a nasal 
delivered drug is to be administered in a volume of 50 µl to 400 µl (25 µl to maximal 200 µl per 
nostril). If the delivered volume exceeds the recommended volume, particularly liquid, little viscous 
preparations, tend to flow in the nasopharynx and are swallowed. 
Different approaches have been explored to enhance drug solubility in nasal preparations. The use 
of solubilizers increases the aqueous solubility of insoluble compounds and some can even 
promote nasal drug absorption. 
The challenge in compounding nasal midazolam preparations is the limited and highly pH 
dependent midazolam solubility (see chapter 3) 
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Due to the limited nasal capacity the whole midazolam dose has to be administered within 50 µl to 
400 µl. To deliver therapeutic midazolam doses, nasal preparations with midazolam concentration, 
exceeding solubility of midazolam in water need to be developed. For example, to deliver the dose 
of 3 mg midazolam by instilling a volume of 100 µl, concentrations of 30 mg/ml midazolam are 
required. Suitable solvents and solubilizers are needed to compound preparations for nasal 
midazolam delivery. Table 4-1 lists some solubilizers, which have been described in literature to 
solubilize midazolam for nasal administration.  
Table 4-1: Different approaches to solubilize midazolam for nasal administration 
Solubilizer Midazolam 
concentration 
Comment Reference 
Propylene glycol 26%, 
benzyl alcohol 1% 
27.8 mg/ml 2% propylene glycol is isotonic with serum [Knoester 
et al. 2002] 
β-cyclodextrin 10 mg/ml Less nasal irritation compared with nasal 
administration of Dormicum® for injection 
5mg/ml (Roche, Basel, Switzerland)  
[Roelofse 
et al. 2000] 
Sulfobutylether-β-
cyclodextrin (Captisol®, 
CyDex, USA)  
30 mg/ml, pH 3 Different cyclodextrin derivates were 
investigated to solubilize midazolam. Above 
pH 5 the maximal midazolam concentration is 
5 mg/ml. 
[Loftsson 
et al. 2001] 
 
4.2.2 Bio- and mucoadhesive excipients 
Bioadhesion and mucoadhesion describe adhering of synthetic or natural macromolecules to 
biological or mucosal surfaces. Most biological surfaces of interest for drug administration are 
mucosal surfaces and the epithelial cells are covered with a mucus layer. Mucus is a complex 
hydrated gel-like material containing the large glycoprotein mucin. The term mucoadhesion 
describes molecules binding to a mucus layer, whereas bioadhesion describes the direct 
interaction of macromolecules with the cell surfaces. But, these two mechanisms of adhesion can 
hardly be differentiated; furthermore, many bioadhesives interact with biological surfaces by a 
combination of these two mechanisms. The term specific bioadhesion refers to specific 
interaction with defined structures. Specific bioadhesion is applied to target defined structures of 
the cell surface [Woodley 2001]. 
The mechanism of non-specific bioadhesion is supposed to result form electrostatic interaction of 
negatively charged cell surfaces and cationic macromolecules (e.g., chitosan see also chapter 4.4). 
For anionic bioadhesive molecules, the interaction with the biologic surface is composed of 
hydrophobic interaction, H-bonds, and Van der Waals interactions. 
Addition of bioadhesive excipients to nasal preparation elongates the nasal residence time of 
nasally delivered preparations. The prolonged residence time favors, complete release of the drug 
from the preparation and thereby efficient transmucosal absorption [Dondeti et al., 1996].  
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For ocular, gastrointestinal, vaginal, and nasal drug administration bioadhesives are popular 
excipients. In preparations for transmucosal drug delivery, bioadhesion enforces the contact of the 
administered preparation with the mucosa, promoting transmucosal drug absorption. 
4.3 Cyclodextrins 
4.3.1 Chemical structure 
Cyclodextrins are cyclic oligosaccharides, which are generated from starch by enzymatic 
cyclisation. There are several unsubtistuted (native) cyclodextrins, the most common are α-
cyclodextrin (6 cyclo-α-(1,4)-anhydroglucose units), β-cyclodextrin (7 cyclo-α(1,4)-anhydroglucose 
units), and γ-Cyclodextrin (8 cyclo-α(1,4)-anhydroglucose units.  
 
A B
 
Figure 4-1: Chemical structure (A) and toroidal shape (B) of β-cyclodextrin (7 cyclo-α(1,4)-
anhydroglucose units). After [Loftsson and Brewster 1996] 
 
To change the physicochemical properties (particularly solubility) of native cyclodextrins, different 
derivatives have been synthesized (Table 4-2). The characteristics of the substituents determine 
the physicochemical properties of the modified cyclodextrin (lipo-/hydrophilicity profile). 
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Table 4-2: Unsubstituded cyclodextrins and some derivates 
Cyclodextrin  Abbr. R Substitution1 MW [Da] 
Solubility 
in water 
[mg/ml] 
Delivery 
α-cyclodextrin αCD -H - 972 145 oral, 
parenteral, 
topical 
β-cyclodextrin βCD -H - 1135 18.5 oral, 
topical 
randomly methylated 
β-cyclodextrin 
RMβCD 
-CH3 1.7-1.9 1310 > 500 oral2, 
topical 
2-Hydroxypropyl-β-
cyclodextrin 
HPβCD -CH2CHOHCH3 0.65 1400 > 600 oral, 
parenteral, 
topical 
β-cyclodextrin 
sulfobutyl ether 
sodium salt 
SBEβCD -(CH2)4SO3-Na+ 0.9 2163 > 500 oral, 
parenteral, 
topical 
γ-Cyclodextrin γCD -H - 1297 232 oral, 
parenteral3, 
topical 
2-Hydroxypropyl-γ-
cyclodextrin 
HPγCD -CH2CHOHCH3 0.6 1576 > 500 oral, 
parenteral, 
topical 
1 degree of substitution (per anhydroglucose unit) 
2 maximal 1 mg per kg body weight, Wacker Chemie AG, Burghausen, Germany 
3 limited amounts 
 
 
4.3.2 Pharmaceutical application of cyclodextrins 
Due to the hydrophilic outer surface and the lipophilic central cavity, cyclodextrins are able to form 
inclusion complexes with lipophilic molecules in aqueous solutions.  
Inclusion complexes are chemical complexes, where one molecule is enclosed within another. This 
kind of complexation enhances the apparent solubility of lipophilic molecules in aqueous solutions 
[Davis and Brewster 2004; Loftsson et al., 2002]. If any molecule entirely or at least partially enters 
into the cavity of a cyclodextrin, an inclusion complex is formed [Manosroi et al., 2005].  
In pharmaceutical preparations cyclodextrins are added to improve the solubility and dissolution 
rate of hardly water soluble drugs, to enhance physical and chemical stability of the active 
compound, and to modify the bioavailability.  
In aqueous solutions, cyclodextrins form inclusion complexes by taking up some hydrophobic 
moieties of drug molecules into the central cavity. No covalent bonds are formed or broken during 
the complex formation. In solution, drug molecules complexed with cyclodextrins are in dynamic 
equilibrium with free molecules [Irie and Uekama 1997; Loftsson and Brewster 1996; Rajewski and 
Stella 1996]. 
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The driving force of complex formation is the release of enthalpy rich water molecules from the 
cyclodextrin cavity. The total energy of the drug-cyclodextrin complex decreases by displacing 
enthalpy rich water molecules by hydrophobic guest molecules [Loftson 1995]. Van der Waals 
forces, hydrogen bonds, and hydrophobic interactions stabilize the drug-cyclodextrin complex. The 
complexation ratio depends on the physicochemical properties, especially surface character and 
size of the guest molecule. Most of the drugs form 1:1 complexes with cyclodextrin [Szente and 
Szejtli 1999]. 
Generating of solid cyclodextrin-drug complexes is more sophisticated, 3 methods (complexation in 
solution followed by freeze drying, complexation as a paste, and complexation in organic solvents) 
are proposed by Wacker Fine Chemicals (Burghausen, Germany). Before applying solid drug-
cyclodextrin complexes, for compounding of solid preparations (e.g., tablets) the complex formation 
needs to be verified (e.g., by X-ray diffractometry). Benefit of solid cyclodextrin-drug complexes in 
compounding of solid preparations are improved chemical stability, modified dissolution 
characteristics, or masking of unpleasant taste and/or odor. 
Due to chemical structure of cyclodextrins (i.e., the large number of hydrogen donors and 
acceptors), the molecular weight and their low octanol/water partition coefficient cyclodextrins and 
the drug-cyclodextrin complexes do not readily permeate biological membranes. Only the free form 
of the drug is able to permeate the biological membrane.  
The drug-cyclodextrin complex diffuses to the lipophilic membrane, where the drug (without 
hydratisation) penetrates directly into the membrane, whereas the cyclodextrin remains in the 
aqueous phase [Gröger 2001]. Figure 4-2 shows the equilibrium drug complexation and drug 
release in the aqueous environment of a lipophilic biologic membrane. Competitive displacement of 
the drug molecule contributes to efficient release of the drug from drug-cyclodextrin complexes 
[Stella et al., 1999]. 
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Figure 4-2: Release of a lipophilic drug from a cyclodextrin-drug 
complex in the aqueous environment of a biological membrane. Form 
[Loftsson et al. 2005] 
 
 
The solubilizing effect of cyclodextrins is usually related to improved drug absorption [Illum 2002]. 
But the impact of cyclodextrins on bioavailability is controversially discussed in literature. Loftsson 
reduces the effect of cyclodextrins on drug transport through and into skin to true carriers keeping 
the hydrophobic drug in solution [Loftson 1995]. In aqueous vehicles, cyclodextrins act as 
penetration enhancers by solubilizing lipophilic water-insoluble drug molecules. 
For optimal permeation Loftsson and Jarho recommend to add exactly enough cyclodextrin to 
solubilize the drug [Jarho et al., 1996; Loftson 1995]. This recommendation is based on the findings 
of in vitro studies from Jarho (Figure 4-3), demonstrating impaired permeation by excess of 
cyclodextrins [Jarho et al. 1996].  
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Figure 4-3 : Optimal cyclodextrin concentration. Jarho et 
al. demonstrated exceeding cyclodextrin concentration to 
impair permeation of drug through cornea of pigmented 
rabbits. Figure modified after [Jarho et al. 1996].  
 
 
 
Permeation of drug molecules from aqueous cyclodextrin containing vehicles through semi-
permeable membranes follows the same pattern as permeation through lipophilic biomembranes 
[Loftsson et al. 2002]. Determination of drug fluxes through semi-permeable membranes have 
been used to characterize release of drugs from cyclodextrin containing vehicles as well as to 
assess stability constants of drug-cyclodextrin complexes [Masson et al., 1999; Ono et al., 1999]. 
 
4.3.3 Cyclodextrins in transmucosal nasal drug delivery  
In nasal formulations, cyclodextrins are used to increase the aqueous solubility of lipophilic drugs. 
However, cyclodextrins can also interact with biological membranes, acting as penetration 
enhancers, especially in nasal delivery of peptides [Marttin et al., 1998]. Numerous studies have 
demonstrated that methylated cyclodextrins are efficient absorption enhancers, and therefore well 
established in nasal drug delivery [Merkus 1999]. The first cyclodextrin-based nasal formulations 
contained steroidal hormones and peptides. The results were promising and the most effective 
cyclodextrins, methylated cyclodextrin derivates, increased the bioavailability of progesterone 
threefold with suspension of the same compound [Hermens et al., 1990; Matsubara et al. 1995; 
van den Berg et al. 2004]. The estradiol nasal spray Aerodiol® (Servier S.A, Meyrin Switzerland). 
represents the successful use of cyclodextrins in nasal applications.  
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4.3.4 Safety and toxicology of cyclodextrins 
Irie and Uekama reviewed the toxicological profile of cyclodextrins. In general, orally administered 
cyclodextrins are non-toxic, due to lack of absorption from the gastrointestinal tract. Furthermore, a 
number of safety evaluations have shown that HPβCD, SBEβCD, γCD, and HPγCD are suitable for 
parenteral as well as for oral administration [Irie and Uekama, 1997].  
Asai et al. studied the effect of different cyclodextrin derivates on the nasal mucosa of rats. 
Thereby, the nasal cavity of the rats was incubated for 60 minutes with 10% RMβCD or 
10% HPβCD in water. No impairment of the nasal mucosa was detected by microscope. Repeated 
nasal application of RMβCD (20%) had no toxic effect [Asai et al., 2002]. No histological changes 
were caused by repeated nasal or ocular administration of 7.5% RMβCD, for 28 days twice daily in 
dogs, rabbits, and guinea pigs (Servier S.A, Meyrin Switzerland, Aerodiol® Nasal Spray). In animal 
models (rats) the acute histological effects of the lipophilic methylated cyclodextrins, were close to 
physiological saline [Marttin et al., 1999]. 
Reeuwijk et al. detected only 2.5% to 4% of nasally administered dimethyl-βCD in the urine 
[Reeuwijk et al., 1993]. Furthermore, the amount of cyclodextrins delivered by the nasal route is 
limited by the volume instillable to the nasal cavities.  
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4.4 Chitosan hydrochloride 
4.4.1 Chemical structure and production 
Chitosan is a linear polysaccharide, composed of glugosamine and N-acetylglucosamine, produced 
by partial deacetylation of chitin by alkaline or enzymatic hydrolysis. Chitin is the major component 
of the exoskeleton of crustaceans, insects, cell wall of fungi and yeast. For the commercial 
production, chitin from shells of prawns, crabs, or other crustacean is used [Shahidi and 
Abuzaytoun 2005]. The most remarkable difference between chitin and chitosan is their solubility 
characteristics. There are few solvents for chitin and most of them are toxic and therefore 
inappropriate for pharmaceutical applications. Chitosan is insoluble at neutral and alkaline pH, but 
forms positively charged salts with inorganic and organic acids (e.g., glutaminic acid, hyaluronic 
acid, lactic acid, and acetic acid), whereas the positive charge of the protonated amine group 
promotes solubility in aqueous solutions. Chitosan is available in a wide range of different 
molecular weights (50 kDa-2000 kDa) and degrees of deacetylation (40%-98%). The most 
commonly used forms of chitosan salts are chitosan glutamate and chitosan hydrochloride [Illum 
1998]. Chitosan features different conformations of the molecule for high and low deacetylated 
chitosan. At a high degree of deacetylation (highly charged) chitosan has extended conformation 
with a more flexible chain, whereas at low degree of deacetylation the molecule adopts a more 
coiled shape due to lower charge. The amino group in chitosan has a pKa value of ~6.5, thus, 
chitosan is positively charged and soluble in acidic to neutral solutions [Shahidi and Abuzaytoun 
2005]. Chitosans with a relative low degree of deacetylation (40%) are soluble only at pH < 6.5 
[Illum 1998]. 
 
 
Figure 4-4: Linear polysaccharide chitin and the derivative chitosan 
resulting of deacetylation. 
Chitosan 
Chitin 
N-Acetyl function 
Amine function 
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4.4.2 Applications of chitosan 
Chitosan is a multifunctional excipient with a wide rang of industrial applications (e.g., flocculant for 
wastewater clarification, chelating of heavy metals, clarification of fruit juices and beers, and 
fungicide in agriculture) [Shahidi and Abuzaytoun 2005]. Further, in food industry, chitosan is a 
popular dietary supplement, particularly in Japan. In addition, chitosan is used for ophthalmic 
applications, such as contact lens coating or as the contact lenses material itself and in cosmetic 
industry chitosan is also a very popular excipient (e.g., for hair care products). 
Chitosan is a versatile excipient for miscellaneous pharmaceutical applications. Chitosan is 
adjuvant in direct compressed tablets, for controlled release matrix tablets, in the process of wet 
granulation, in gels, films, and emulsions, as well as wetting and coating agent, and for the 
production of microspheres and microcapsules. Chitosan is used also in newer research areas like 
nasal vaccine delivery and DNA delivery [van der Lubben et al., 2001; Xu et al., 2004]. The 
European Pharmacopoeia describes the requirements for chitosan hydrochloride used in 
pharmaceutical products. 
 
4.4.3 Chitosan in transmucosal nasal drug delivery  
Davis et al. were the first to demonstrate the cationic polymer chitosan to promote the 
transmucosal adsorption of challenging drugs, particularly with regard to improved nasal delivery. 
In animal and human models, chitosan generated a remarkably higher bioavailability [Davis and 
Illum 2003]. Illum et al found, that the addition of chitosan to a nasal formulation of insulin caused 
plasma glucose to fall to 43% of basal level compared to 83% without the addition of chitosan [Illum 
et al., 1994]. Similar effects on bioavailability have been achieved for polar low-molecular-weight 
drugs (e.g., morphine and antimigraine drugs). Chitosan is an effective nasal absorption enhancer 
in liquid and powder formulations. Chitosan improve bioavailability in nasal and pulmonal drug 
delivery [Illum 1998; Illum et al., 2002; Martinac et al., 2005; Yu et al., 2004]. 
In liquid formulations for nasal drug delivery, concentrations of 0.5-1.0% chitosan proved to 
promote absorption [Davis and Illum 2003]. 
Unlike common penetration enhancers, chitosan is neither membrane active nor a classical 
surfactant and is not transmucosal absorbed. The clearance of chitosan formulations from the 
nasal cavity of sheep and humans has been shown to be significantly slower compared with 
aqueous solutions [Soane et al., 1999; Soane et al., 2001]. 
The mucoadhesion results of the interaction between the linear cationic polysaccharide chitosan 
and the negatively charged mucosa. This mechanism decelerates the nasal clearance [Aspden et 
al., 1997]. 
The extended time of contact of the formulation and the nasal mucosa favors the transmucosal 
drug absorption [Pavis et al., 2002]. Studies with CaCo-2 cell monolayer suggest cationic polymers 
(e.g., chitosan) to modify permeability of the monolayer by interaction with the gating mechanism of 
tight junction, causing a transient opening [Artursson et al., 1994]. Dodane et al. demonstrated 
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complete reversibility of the transient opening of the tight junctions and showed the function of the 
nasal mucosa to be unimpaired [Dodane et al., 1999]. Consequently, the impact of chitosan on 
pharmacokinetics of transmucosal delivered drugs results of the prolonged drug mucosa contact by 
bioadhesion [Soane et al. 1999; Soane et al. 2001] and a transient completely reversible opening 
of tight junctions [Dodane et al. 1999].  
4.4.4 Safety and toxicology of chitosan 
In a review Dodane and Vilivalam characterized chitosan as safe and effective permeation 
enhancer for nasal drug delivery of systemic drugs [Dodane and Vilivalam 1998]. 
Concentrations of 0.5% chitosan hydrochloride improved absorption of different nasally 
administered compounds. The nasal mucosa was not affected.  
Illum et al. demonstrated, that neither nasal nor intravenous delivered chitosan caused any 
humoral immune reaction [Illum 1998]. It has been shown that the absorption-promoting effect of 
chitosan on the mucosal membrane is transient, with the effect declining between 30 minutes and 
45 minutes after application of a liquid formulation [Illum 1998]. 
In a clinical trial with 14 cancer patients, break-through pain was treated with morphine nose sprays 
containing chitosan. All observed adverse effects (bitter taste, tiredness) were correlated with 
morphine [Pavis et al. 2002]. 
Aspden et al. examined the effect of an aqueous chitosan solution (0.25%) on the nasal mucosa in 
vitro and in vivo with 10 healthy volunteers. After 7 days treatment with aqueous chitosan solution 
(0.25%) no markers of inflammation were detected neither by endoscopic investigation of the nasal 
mucosa (in vivo), nor by light-microscopic investigation (in vitro). All treated volunteers tolerated 
nasal application well. Furthermore, Aspeden et al. showed that chitosan has a transient and 
completely reversible effect on mucocilliary transport rate. Chitosan is bioadhesive and able to 
interact with the nasal mucus layer and with the nasal epithelial cells [Aspden, et al. 1997] 
Chitosan is not absorbed, non toxic, biocompatible, and neither irritating nor allergenic [Dodane 
and Vilivalam 1998]. 
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5 Project I: Development of preparations for 
transmucosal nasal midazolam delivery 
5.1 Introduction 
The key issue in development of preparations for transmucosal nasal midazolam delivery is the 
relatively poor and highly pH-dependent solubility of midazolam. Solubilization enhancers ideally 
promote midazolam solubility independent of pH. Several approaches to enhance solubility of 
midazolam have been described in literature (see Table 4-1). Knoester et al. proposed a nasal 
midazolam preparation based on propylene glycol and benzyl alcohol [Knoester, et al. 2002] and 
other groups enhanced midazolam solubility by different cyclodextrin derivatives [Loftsson, et al. 
2001; Roelofse, et al. 2000]. Loftsson et al. accentuated the importance of keeping the drug 
cyclodextrin ratio close to one and just adding as much cyclodextrin as required for drug 
solubilization. To investigate drug release from cyclodextrin complexes porous semi-permeable 
cellophane membranes with defined pore size (i.e., molecular weight cut off, MWCO) are used.  
The residence time on the nasal mucosa of nasal delivered preparations is limited and therefore 
drug uptake has to proceed before the preparation is removed by mucociliary clearance.  
Chitosan is reported to promote transmucosal nasal drug absorption by bioadhesion (prolongation 
of contact time) and transient opening of tight junctions (penetration enhancer). In a study with 
12 healthy volunteers Illum et al. demonstrated penetration enhancing effect of chitosan in 
transmucosal nasal delivery of morphine [Illum, et al. 2002].  
In order to discover eventual stability problems as early as possible, accelerated stability testing is 
accomplished already during development of pharmaceutical preparation. According to the current 
guideline of the International Conference on Harmonization (ICH), accelerated stability testing 
provides preliminary information about the compound and the vehicle. For the approval of a 
medicinal product, authorities generally require data from real-time stability testing [Gil-Alegre et 
al., 2001]. To determine the shelf life of a medicinal product, real time stability testing at the 
intended storage conditions has to be accomplished. As the determined shelf life is dependent of 
packaging, real time stability testing has to be generated with the bottled product. 
This project comprises the development and in vitro characterization of midazolam preparations for 
transmucosal nasal midazolam delivery. Providing of stability data was prerequisite to use the 
developed preparations in clinical trials (Project II and Project III). 
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5.2 Materials and methods 
5.2.1 Materials 
Midazolam hydrochloride was purchased from Fährhauspharma (Hamburg, Germany), RMβCD 
(methylated-β-cyclodextrin, Cavasol® W7M Pharma), HPβCD (hydroxypropyl-β-cyclodextrin, 
Cavasol® W7HP Pharma), and HPγCD (hydroxypropyl-γ-cyclodextrin, Cavasol® W8HP Pharma) 
from Wacker Chemicals (München, Germany), chitosan hydrochloride for preliminary testing from 
Kraeber GmbH & Co (Ellerbek, Germany), chitosan hydrochloride for pharmaceutical preparations 
from NovaMatrix FMC BioPolymer (Oslo, Norway).  
For the preliminary experiments all chemicals were of analytical reagent grade and obtained from 
commercial sources. Preparations for stability testing, were produced with chemicals of 
pharmaceutical quality (see also Project II and Project III). 
Semi-permeable cellophane membranes (Spectra/Por® Dialysis Tubing, MWCO 2000 from 
regenerated cellulose) were obtained from Spectrum Europe (Breda, The Netherlands). Unit dose 
nasal sprays, delivering 0.1 ml, were obtained from Ing. Erich Pfeiffer GmbH (Radolfzell, Germany) 
and multidose nasal sprays, delivering 0.1 ml per pump, from E. Anwander & Cie. AG (Oberwil, 
Switzerland). 
5.2.2 HPLC-Method 
The quantification of midazolam was performed by HPLC, Waters Alliance HPLC System (2690 
Separation Module, 996 Photodiode Array Detector, Millenium32 Software), Waters Corporation, 
(Millford, Massachusetts, USA). Table 5-1 shows the chromatographic conditions. 
Table 5-1: Chromatographic condition for midazolam analysis 
Parameter Setting 
column ACE RP18 3µm, 4.0 x 75 mm  
mobile Phase buffer pH 5.5/ACN 
flow rate 0.8 ml/min 
running time 10 min 
temperature 30°C 
injection volume 10 µl 
midazolam quantification wavelength 223 nm 
 
5.2.3 Solubility studies 
To assess the pH-dependent solubility and the effects of different cyclodextrins, midazolam 
hydrochloride was added in excess amounts to Britton-Robinson buffer (BR buffer, 40 mM boric 
acid, 40 mM acetic acid, 40 mM phosphoric acid pH, adjusted to pH 3.0, 3.5, 4.0, 4.5, 5.0, and 7.4 
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with 1.0 M sodium hydroxide), containing no solubilization enhancer, 10% RMβCD, 10% HPβCD, 
or 10% HPγCD. The suspensions were equilibrated at room temperature for 3 days. The 
suspensions were filtered (0.45 µm) and midazolam content assessed by HPLC. All samples were 
prepared in triplicates. 
5.2.4 Drug Release 
For drug release of midazolam from RMβCD-midazolam complexes aqueous solutions trough 
semi-permeable cellophane membranes, diffusion cells (see Figure 5-1) were used. A semi-
permeable cellophane membrane (Spectra/Por® Dialysis Tubing, MWCO 2000 from regenerated 
cellulose) was inserted into diffusion cells with a surface area of 2.3 cm2.  
In a preliminary drug release study Dormicum® 5 mg/ml, 10 mg/ml midazolam solubilized with 
20% RMβCD, and 10 mg/ml midazolam solubilized with equimolar amount of RMβCD (4%) were 
filled in donor compartments.  
For drug release 5 mg/ml midazolam in water; 5 mg/ml, 15 mg/ml, and 30 mg/ml midazolam solved 
with equimolar amount of RMβCD; and 5 mg/ml and 30 mg/ml midazolam with threefold molar 
amount of RMβCD were filled into donor compartment. Osmolality of all preparations for midazolam 
release studies was adjusted to 300mOsmol/kg with sodium chloride.  
The receiver compartment contained 0.9% sodium chloride in water. Both compartments contained 
8.0 ml and were stirred during the release experiments (see Figure 5-1 A and B). The diffusion 
cells were immersed in a water bath maintained at 37°C. Samples were withdrawn from the 
receptor compartment replaced with aliquots of 0.9% sodium chloride. Midazolam release per 
minute was assessed from the slope of the midazolam concentration time plot. 
A B
Figure 5-1 A and B: Picture of a diffusion cell (A) and 2 diffusion cells mounted, ready for drug release 
experiment. The arrow indicates the position of the cellulose membrane. 
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5.2.5 Specification and stability testing 
Specification and quality control of the investigational products 
For all investigational products (Preparation 1 to 5, see Table 5-4) GMP-conform specifications 
(see Appendix 10.2.4 to 10.2.9 ), instructions for manufacturing, and instructions for quality control 
were provided according to the quality management system of Hospital Pharmacy of the University 
Hospital Basel. 
Accelerated stability testing 
Accerlerated stability testing was accomplished for the Preparation 3 and 4 (see Table 5-4). The 
preparations were bottled in sealed vials and stored protected from light at room temperature, 
40°C, 50°C, and 60°C for 30 days. Midazolam content , pH, and aspect (color, precipitate) was 
assessed every 3 days. 
Real time stability testing 
For stability testing the nasal sprays for Project II (Preparations 1a, 2, 4, 5) were stored at room 
temperature for 6 months and the nasal sprays for Project III (Preparations 1b and 3) were stored 
at room temperature for 10 months. 
Aspect (visual), pH (pH Meter 780, Metrohm AG, Herisau AR, Switzerland), tonicity (The 
AdvancedTM Micro Osmometer Model 3300, Norwood, MA, USA), and midazolam content (HPLC, 
see Table 5-1), were analyzed according to the specifications (Appendix 10.2.4 to 10.2.9) of the 
investigational products. 
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5.3 Results 
5.3.1 Solubility studies 
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Figure 5-2: pH-dependent solubility of midazolam. In 
BR buffer (40 mM boric acid, 40 mM acetic acid, 40 mM 
phosphoric acid; pH, adjusted with 1.0 M sodium 
hydrochloride) with and without solubilizer (10% RMβCD, 
10% HPβCD, and 10% HPγCD). 
Figure 5-2 shows pH-dependent 
solubility of midazolam in BR buffer 
and in BR buffer with 10% RMβCD, 
10% HPβCD, and 10% HPγCD.  
All tested cyclodextrin derivatives 
enhance midazolam solubility, but not 
independent of pH. 
In Table 5-2 maximal midazolam 
concentrations in BR buffer and 
BR buffer with 10% RMβCD, 
10% HPβCD, and 10% HPγCD are 
listed. 
 
 
 
 
 
 
Table 5-2: Midazolam solubilized with 10% RMβCD, 10% HPβCD, and 10% HPγCD. 
Midazolam hydrochloride solubility (mg/ml) in: pH 
RB buffer (pH 3.5) + 10% RMβCD + 10% HPβCD + 10% HPγCD 
3.0 56.4 68.1 70.3 68.0 
3.5 3.4 --- --- --- 
4.0 3.8 42.4 33.3 52.8 
4.5 1.5 --- --- --- 
5.0 0.5 10.0 4.4 2.6 
7.4 --- 2.53 0.8 0.6 
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Figure 5-3: Saturated midazolam concentration in water, 
10% RMβCD, 10% HPβCD, and 10% HPγCD (n=3). 
Midazolam solubility was 
9.1 mg/ml, 26.2 mg/ml, 
33.1 mg/ml, and 40.8 mg/ml in 
water, 10% HPβCD, 10% RMβCD, 
and 10% HPγCD, respectively. 
The calculated ratio of cyclodextrin 
and midazolam in the saturated 
solutions was 1 to 1.13, 1 to 1.33, 
and 1 to 1.97 for HPβCD-
midazolam, RMβCD-midazolam, 
and HPγCD-midazolam 
complexes, respectively. Figure 
5-3 displays the solubility of 
midazolam without and with 
solubilization enhancer 
(10% HPβCD, 10% RMβCD, and 
10% HPγCD). 
 
5.3.2 Drug Release 
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Figure 5-4: Midazolam Release from Dormicum® (5 mg/ml 
midazolam), 10 mg/ml midazolam solubilized with 
equimolar amount of RMβCD (4%) and 10 mg/ml midazolam 
solubilized with 20% RMβCD. 
Midazolam release in preliminary 
drug release studies was 
1.258 µg/min, 1.150 µg/min, and 
0.461 µg/min from Dormicum® 
(5 mg/ml midazolam), 10 mg/ml 
midazolam solubilized with 
equimolar amount of RMβCD (4%) 
and 10 mg/ml midazolam 
solubilized with 20% RMβCD, 
respectively. 
Midazolam release did not 
correlate with the total midazolam 
concentration. In Figure 5-4 the 
results of the preliminary drug 
release study is displayed. 
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Figure 5-5 (A, B, and C): Midazolam release 
(µg/min ± SD) from RMβCD-midazolam complexes 
through semi-permeable cellophane membrane 
(SpectraPor®, MWCO 2000). Total midazolam 
concentration was 5 mg/ml, 15 mg/ml, and 
30 mg/ml and RMβCD was added in equimolar 
(2%, 6%, and 12%) amount and threefold (6%, 
36%) amount of midazolam (base). Drug release 
experiments were accomplished in triplicates. 
 
 
Figure 5-5 (A-C) show the midazolam release from preparations with and without solubilization 
enhancer (RMβCD). Midazolam release does not correspond to the total midazolam concentration 
available in the donor compartment. With increasing excess of RMβCD, midazolam release 
decreases. 
 
A
B 
C
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Table 5-3 and Figure 5-5 summarize midazolam release from RMβCD-midazolam complexes 
assessed by permeation experiments with semi-permeable cellophane membranes (SpectraPro®, 
MWCO 2000). 
 
Table 5-3: Midazolam release (µg/min ± SD) from RMβCD-midazolam complexes. Total midazolam 
concentration was 5 mg/ml, 15 mg/ml, and 30 mg/ml and RMβCD was added in equimolar amount and 
threefold amount of midazolam (base). Drug release experiments were accomplished in triplicates 
Ratio RMβCD to midazolam Total midazolam 
concentration No RMβCD 1 to 1 1 to 3 
5 mg/ml 1.067 ± 0.058 µg/min 0.850 ± 0.354 µg/min 0.150 ± 0.050 µg/min 
15 mg/ml --- 1.133 ± 0.808 µg/min --- 
30 mg/ml --- 1.375 ± 0.436 µg/min 0.567 ± 0.306 µg/min 
 
 
Midazolam release decrease with addition of RMβCD and is 1.067 ± 0.058 µg/min, 
0.850 ± 0.354 µg/min, and 0.150 ± 0.050 µg/min for midazolam 5 mg/ml, 5 mg/ml with equimolar 
RMβCD, and 5 mg/ml with threefold molar amount of RMβCD, respectively.  
For 30 mg/ml observed midazolam release was 1.375 ± 0.436 µg/min and 0.567 ± 0.306 µg/min for 
30 mg/ml midazolam with equimolar RMβCD, and 30 mg/ml with threefold molar amount of 
RMβCD, respectively. The observed midazolam release was not proportional to the total 
midazolam concentration present in the donor compartment. Half of the midazolam concentration 
(15 mg/ml midazolam solved with equimolar amount of RMβCD) did not result in half of midazolam 
release compared with the release of 30 mg/ml midazolam solved with equimolar amount of 
RMβCD. 
Midazolam release did not correlate with the total midazolam concentration in the donor 
compartment. Three fold amount of RMβCD did considerably reduce midazolam release for both 
tested (total) midazolam concentrations 5 mg/ml and 30 mg/ml. 
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5.3.3 Specification and stability testing 
Table 5-4 shows the composition of the preparations provided for Project II and III. All preparations 
are aqueous solutions and osmolality is adjusted with sodium chloride to 300mOsmol/kg. Table 5-5 
displays the specification of all midazolam nasal sprays prepared for Project II and Project III. For 
all investigational products a shelf life of 6 months was proposed. 
Table 5-4: Preparations for nasal midazolam delivery provided for Project II and Project III. All preparations are 
aqueous solutions and osmolality is adjusted to 300mOsmol/kg with sodium chloride. 
Nr. Preparation Midazolam (base) RMβCD 
Chitosan 
HCl Preservatives 
Dose 
(Volume) Device
1
 Project 
1a 
Midazolam UD 
Nasal Spray 
0.5 mg 
5 mg/ml --- --- --- 1 mg (2 x 0.1 ml) UD II 
1b 
Midazolam MD 
Nasal Spray 
5 mg/ml  
5 mg/ml --- --- Yes2 1 mg (2 x 0.1 ml) MD III 
2 
Cyclodex-
Midazolam UD 
Nasal Spray 
0.5 mg 
5 mg/ml 2% --- --- 1 mg (2 x 0.1 ml) UD II 
3 
Cyclodex-
Midazolam UD 
Nasal Spray 
1 mg 
10 mg/ml 4% --- --- 1 mg (0.1 ml) UD II / III 
4 
Cyclodex-
Midazolam UD 
Nasal Spray 
3 mg 
30 mg/ml 12% --- --- 3 mg (0.1 ml) UD II 
5 
Chitosan-CD-
Midazolam UD 
Nasal Spray 
3 mg 
30 mg/ml 12% 0.5% --- 3 mg (0.1 ml) UD II 
 
1 UD: unit dose system, MD: multidose nasal spray 
2
 benzalconium chloride and sodium EDTA 
 
Table 5-5: Specification of the clinical test samples. 
Nr. Preparation Aspect Identity Midazolam  
Content 
[mg/ml] pH 
Osmolality 
[mOsmol/kg] 
1a Midazolam UD Nasal Spray 0.5 mg 
Clear, colorless 
solution conform 4.50-5.50 3.0-3.5 270-330 
1b Midazolam MD Nasal Spray 5 mg/ml  
Clear, colorless 
solution conform 4.50-5.50 3.0-3.5 270-330 
2 Cyclodex-Midazolam UD Nasal Spray 0.5 mg 
Clear, colorless 
solution conform 4.50-5.50 3.5-4.5 270-330 
3 Cyclodex-Midazolam UD Nasal Spray 1 mg 
Clear, colorless 
solution conform 9.00-11.0 3.5-4.5 270-330 
4 Cyclodex-Midazolam UD Nasal Spray 3 mg 
Clear, colorless 
solution conform 27.0-33.0 3.0-4.5 270-330 
5 Chitosan-CD-Midazolam UD Nasal Spray 3 mg 
Clear, colorless 
solution conform 27.0-33.0 3.0-4.5 270-330 
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Accelerated stability testing 
In Preparation 3 (10 mg/ml) midazolam content was constant and no precipitation or discoloring 
occurred during storage at room temperature 40°C, 5 0°C, and 60°C, for 30 days.  
In Preparation 4 (30 mg/ml) midazolam content was constant and no precipitation occurred during 
storage at room temperature 40°C, 50°C, and 60°C, f or 30 days. At storage temperature of 60°C 
Preparation 4, originally colorless solution turned slightly yellow. For all storage conditions pH was 
constant in both preparations (Preparation 3 and 4), the measured values are listed in 
Appendix 10.2.2 and 10.2.3. 
Real time stability testing 
To perform real-time stability testing Preparation 1 and 3 were stored for 10 months and 
Preparations 2, 4, and 5 were stored for 6 months at room temperature. In Table 5-5 the 
specification of Preparation 1a to 5 are listed. To fulfill the stability requirements all analyzed 
parameters had to comply with the specified limits. In Table 5-6 and Table 5-7 the outcome of 
stability testing of 6 months and 10 months, respectively is summarized. Stability reports, including 
original data, are shown in Appendix 10.2.10 to 10.2.15. 
Acquired stability data confirm specified shelf life of 6 months for Preparation 1a, 1b, 2, 3, and 4 but 
not for Preparation 5. After 10 months storage at room temperature Preparation 3 fulfills all 
specified quality requirements. 
Table 5-6: Outcome of stability testing: 6 months 
Nr. Preparation Aspect Identity Midazolam 
Content 
[mg/ml] pH 
Osmolality 
[mOsmol/kg] 
Shelf life 
6 months 
1a Midazolam UD Nasal Spray 0.5 mg  
    o.k. 
1b Midazolam MD Nasal Spray 5 mg/ml  
     o.k. 
2 Cyclodex-Midazolam UD Nasal Spray 0.5 mg 
     o.k. 
3 Cyclodex-Midazolam UD Nasal Spray 1 mg 
     o.k. 
4 Cyclodex-Midazolam UD Nasal Spray 3 mg 
     o.k. 
5 Chitosan-CD-Midazolam UD Nasal Spray 3 mg 
     not o.k. 
 analyzed parameter fulfills specification 
 analyzed parameter below specified limits 
Table 5-7: Outcome of stability testing: 10 months 
Nr. Preparation Aspect Identity Midazolam  
Content 
[mg/ml] pH 
Osmolality 
[mOsmol/kg] 
Shelf life 
10 months 
1b Midazolam MD Nasal Spray 5 mg/ml  
     not o.k. 
3 Cyclodex-Midazolam UD Nasal Spray 1 mg 
     o.k. 
 analyzed parameter fulfills specification 
 analyzed parameter above specified limits 
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5.4 Discussion 
Different cyclodextrin derivatives were evaluated to solubilize midazolam for development of 
preparations for transmucosal nasal midazolam delivery. Drug release studies were performed to 
assess the effect of the selected solubilizer (RMβCD) on midazolam release in vitro. Furthermore, 
accelerated and long term stability testing was performed. 
Besides presystemic drug elimination (intestinal and hepatic first-pass metabolism), the most 
important parameters affecting bioavailability are aqueous solubility and permeability of the drug. 
The Biopharmaceutical Classification System (BCS) was introduced by the FDA as binning system 
for oral drugs, and classifies all drugs into four groups based on their ability to permeate biologic 
membranes and their aqueous solubility. A given drug substance is considered ‘highly soluble’ 
when the highest dose strength is soluble in ≤ 250 ml water, and ‘highly permeable’ when the 
extent of oral absorption in humans is determined to be ≥ 90% of an administered dose (in 
solution). According to this definition, midazolam salts are rated as ‘highly soluble’, because the 
highest oral dose strength (15 mg midazolam) is soluble in ≤ 250 ml water. For transmucosal nasal 
drug delivery the definition of ‘high’ and ‘poor’ solubility has to be adjusted to the characteristics of 
the nasal cavities. Obviously, in the nose there is only very little solvent available to solubilize 
administered drugs. Therefore, drugs preferably are delivered as solutions. Since the capacity of 
the nasal cavities is limited, delivery of extended volumes results in swallowing of surplus liquid 
preparations. Consequently, minimizing of nasally instilled volumes is essential to provide for 
exclusive transmucosal nasal drug uptake. In transmucosal nasal drug delivery, drugs may be 
rated as ‘highly soluble’ if the highest dose to be nasally delivered is soluble in ≤ 0.2 ml aqueous 
solutions. According to this definition, for transmucosal nasal delivery midazolam is to be classified 
as poorly soluble. Transmucosal nasal drug delivery is particularly feasible for drugs with high 
potency. Furthermore, for efficient transmucosal nasal drug delivery the compound needs to be 
‘highly permeable’. Overall ideal characteristics of drugs for transmucosal nasal delivery are: high 
solubility, high permeability and adequate potency. 
Since systemic bioavailability of transmucosal nasal absorbed midazolam is not affected by 
presystemic metabolization (hepatic first-pass effect), the doses to be nasally administered are 
lower than doses for oral application. Midazolam proved excellent permeation ability 
[Gudmundsdottir, et al. 2001], therefore, the key issue in compounding nasal preparations for 
transmucosal nasal midazolam delivery is the relatively poor and highly pH-dependent solubility of 
midazolam. 
Different approaches to enhance midazolam solubility have been described in literature. Knoester 
et al. proposed a nasal midazolam preparation with 26% propylene glycol, but the administration of 
this hypertone preparation resulted in local irritation [Knoester, et al. 2002]. Less local irritation has 
been reported for nasal administration of midazolam preparations with cyclodextrins as solubilizer 
[Gudmundsdottir, et al. 2001]. Therefore, in the presented project different cyclodextrin derivatives 
were evaluated to solubilize midazolam in preparations for nasal midazolam delivery. To prevent 
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local irritation, preparations for nasal administration should as far as possible be adapted to the 
intranasal physiology concerning pH as well as tonicity. 
In aqueous solutions cyclodextrin derivatives spontaneously form water-soluble complexes with a 
wide range of compounds. Since increased compound solubility stands for effectual complexation, 
verification of cyclodextrin-midazolam complexes was not performed. In order to successfully 
generate midazolam solutions, by complexation with different cyclodextrin derivatives (RMβCD, 
HPβCD, and HPγCD), it was essential to solubilize cyclodextrins first and then to add midazolam 
hydrochloride. Hardly soluble agglomerates resulted by inverting the procedure (adding 
cyclodextrins to midazolam suspensions). 
All tested cyclodextrins (RMβCD, HPβCD, and HPγCD) improved the solubility of midazolam in 
aqueous solutions. Despite successful complexation with RMβCD, HPβCD, or HPγCD midazolam 
solubility remained pH-dependent and above pH 4 to 5 midazolam precipitated.  
Despite superior solubilization ability of 10% HPγCD (midazolam concentration 40.8 mg/ml) 
compared to RMβCD (midazolam concentration 33.1 mg/ml solubilized with 10% RMβCD), RMβCD 
was selected to compound preparations for nasal midazolam delivery, because RMβCD is adjuvant 
in Aerodiol® (Servier, Meyrin, Switzerland) and approved by the authorities of several European 
countries.  
The calculated ratio of different cyclodextrin derivatives and midazolam (1 to 1.13, 1 to 1.33, and 
1 to 1.97 for saturated midazolam solutions with 10% RMβCD, 10% HPβCD, and 10% HPγCD, 
respectively) indicates that in saturated midazolam solutions not only 1 to 1 complexes are formed. 
The 1 to 1.97 ratio calculated for HPγCD-midazolam complexes implies the formation of 1 to 2 
complexes (one HPγCD molecule complexes two midazolam molecules). But complex 
characteristics can not conclusively be described by calculated ratios of cyclodextrin and 
solubilized compound.  
The effect of cyclodextrins on drug release, absorption kinetics, and consequently bioavailability of 
transmucosal delivered drugs is controversially discussed. Based on Fick’s first law, the 
fundamental equation describing passive diffusion is represented by Equation 1: 
 
J = P * A * (c1 – c2) (Equation 1) 
 
Where J is the resulting drug flux through the membrane, P is the permeability coefficient of the 
drug through the membrane (characterizing the ability of a given drug to permeate a specific 
membrane), c1 refers to the drug concentration in the donor compartment, c2 refers to the drug 
concentration in the receptor compartment, and A is the area of the membrane available for drug 
flux. As usually c2 << c1, only c1 is itemized (see Equation 2).  
 
J = P * A * c1 (Equation 2) 
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Assuming constant permeability coefficient (identical membrane and drug) and indifferent area, 
doubling the drug concentration in the donor compartment (2*c1) results in doubled drug flux (2*J), 
according to Equation 2. Generally, Equation 1 and 2 describe passive diffusion (in vitro and in 
vivo) of any substance (e.g., drug, adjuvant) through any membrane (e.g., biomembrane or artificial 
membrane), for in vitro and in vivo situations. 
Roelofse et al. published pharmacokinetic characterization of nasal midazolam (dose 7.5 mg) 
delivered by a test preparation (20% βCD to solubilize 10 mg/ml midazolam, nasal administration 
volume 0.75ml) or Dormicum® 5 mg/ml (nasal administration volume 1.5 ml) [Roelofse, et al. 2000]. 
The maximal midazolam plasma concentration and the systemic bioavailability were considerably 
lower for midazolam delivered by the test preparation (20% βCD, 10 mg/ml midazolam). 
Based on the solubility study, the published data from Loftsson et Jarho [Loftsson 1995, Jarho, 
1996], and the outcome of the in vivo study of Roelofse et al., the excess of cyclodextrin was 
supposed to reduce midazolam release. To confirm this assumption (in vitro) midazolam release 
studies were performed with preparations containing 20% RMβCD and 4% RMβCD (equimolar 
amount) to solubilize 10 mg/ml midazolam and compared with midazolam release from Dormicum® 
5 mg/ml (no RMβCD). Despite half midazolam concentration, midazolam release from Dormicum® 
5 mg/ml was superior to midazolam release from RMβCD containing preparations (total midazolam 
concentration 10 mg/ml). Furthermore, midazolam release from preparations with 20% RMβCD 
(10 mg/ml midazolam) was lower as midazolam release from preparation with equimolar RMβCD 
(4%) to solubilize 10 mg/ml midazolam.  
In further drug release studies with semi-permeable cellophane membranes (in vitro) the effect of 
RMβCD on midazolam release was investigated with 5 mg/ml, 15 mg/ml, and 30 mg/ml midazolam 
solubilized with equimolar and threefold amounts of RMβCD. Due to limited midazolam solubility 
drug release studies without RMβCD were performed only for 5 mg/ml midazolam. 
Midazolam release from RMβCD containing preparations did not correlate with the absolute 
midazolam concentration in the donor compartment (5 mg/ml, 15 mg/ml, and 30 mg/ml). The 
impaired midazolam release from preparations with higher RMβCD concentrations (ratio RMβCD to 
midazolam, 3 to 1) indicated that less free midazolam molecules are available for permeation. 
According to the law of mass action, high concentration of one educt (i.e., RMβCD) promotes the 
formation of the product (i.e., RMβCD-midazolam complexes), see Equation 3. In addition, huge 
excess of cyclodextrins is reported to promote non-conventional cyclodextrin complexes (i.e., non-
inclusion complexes) and molecular aggregation [Loftsson, et al. 2005], consequently reducing free 
midazolam concentration available for permeation. 
 
[RMβCD] + [free midazolam] ↔ [RMβCD-midazolam complexes] + [RMβCD] + [free midazolam] 
 
 
(Equation 3) 
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J = P * A * (cfree midazolam) (Equation 4) 
 
Midazolam release (in vitro) did not correlate with the total midazolam concentration in the donor 
compartment; consequently Equation 2 does not exactly correspond with data assessed in the drug 
release studies. The results of the drug release studies suggest that only free midazolam 
concentration controls permeation through the artificial membrane (see Equation 4). The more 
RMβCD is available for midazolam complexation, the more midazolam release was reduced. 
Consequently, to minimize the influence of RMβCD on midazolam release in vivo, equimolar 
amount of RMβCD was used to solubilize midazolam in preparations for nasal midazolam delivery. 
The pH of the developed preparations (Preparation 1 to 5) is not adjusted to physiologic pH. In the 
nasal preparation proposed by Roelofse et al. (ratio cyclodextrin to midazolam was 5 to 1, for 20% 
βCD to solubilize 10 mg/ml midazolam) pH was 5.8. The above discussed drug release studies are 
in accordance with the outcome of in vitro investigations of Loftsson et Jarho [Loftsson 1995, 
Jarho, 1996] and underline the importance of adequate cyclodextrin-compound ratio. Therefore, 
cyclodextrin excess to solubilize midazolam was considered as inappropriate; even pH could have 
been approached to physiologic pH. 
Results of accelerated stability testing affirmed stability of midazolam solubilized with RMβCD. 
Proven stability of midazolam enables the storage of the tested midazolam preparations at room 
temperature. For all midazolam preparations with RMβCD (Preparation 2, 3, and 4) and without 
RMβCD (Preparation 1a and 1b) stability data confirmed shelf life of 6 months. Preparation 5, 
additionally containing chitosan hydrochloride, was not stable concerning midazolam content. 
During 6 months storage at room temperature midazolam content decreased from originally 
29.5 mg/ml to 25.1 mg/ml, not complying with the specified requirements for midazolam content. 
Apparently, chitosan hydrochloride impaired midazolam stability. The preparation has to be 
prepared immediately before use. Concerning pH, after 10 months storage Preparation 1b does not 
comply with the specified limits for pH (3.0 to 3.5). As with arising pH midazolam risks to 
precipitate, prolongation of shelf life for Preparation 1b is not reasonable. For Preparation 3 
prolongation of shelf life from 6 months to at least 10 months is supported by long term stability 
data. 
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5.5 Conclusions 
Nasal midazolam preparations, adjusted to the limited volumetric capacity of the nose, were 
compounded by addition of RMβCD. In drug release studies with semi-permeable cellophane 
membranes (in vitro) RMβCD reduced midazolam release. The reliability of in vitro drug release 
studies to predict drug release and absorption kinetics in vivo is to be verified (Project II). 
The stability data acquired for all RMβCD containing nasal midazolam preparations affirm a shelf 
life of at least 6 months. Addition of chitosan hydrochloride impaired midazolam stability and 
therefore shelf life of chitosan containing nasal midazolam preparations is reduced. 
The developed preparations for transmucosal nasal midazolam delivery are the basis to study the 
influence of vehicle and application modality on the pharmacokinetics of nasally applied midazolam 
(see Project II). 
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6 Project II: Pharmacokinetic of transmucosal nasal 
delivered midazolam – impact of adjuvants 
6.1 Introduction 
Fast onset of action, complete independence of ingestion, and the needle-less application render 
nasal application of midazolam to a convenient alternative to common application modes 
[Bjorkman, et al. 1997; Goepfert 1996; Malinovsky, et al. 1995; Münte 2002; Tschirch, et al. 2006; 
Uygur-Bayramicli, et al. 2002]. Although no nasal midazolam preparation is commercially available, 
numerous authors report on successful nasal delivery of midazolam. In most studies and case 
reports, Dormicum® for i.v. application is instilled nasally. Often the volumetric capacity of the nose 
(0.1 ml to 0.4 ml per nostril [Penkler 2001]) is exceeded and therefore, a portion of the nasal 
administered preparation is swallowed. Consequently, the resulting pharmacokinetic profile is a 
combination of nasal and gastrointestinal drug absorption.  
To minimize the volume to be applied for nasal delivery of midazolam, preparations with higher 
concentration than 5 mg/ml midazolam need to be provided. Addition of solubilization enhancers 
(e.g., cyclodextrins) facilitates compounding of midazolam preparations with increased midazolam 
concentrations; this allows delivering therapeutic doses by instilling minimized volumes into nasal 
cavities. 
The solubilization enhancing effect of cyclodextrins, by forming inclusion complexes, is well 
established (see chapter 4.3 and Project I). However, the impact of cyclodextrins on 
pharmacokinetics of transmucosal delivered drugs is controversially discussed [Illum 2002] and is 
assumed to depend on the drug cyclodextrin ratio, as well as on the solubility and the permeation 
ability of the compound. 
Mucociliary clearance restricts contact time of nasal administered preparations and nasal mucosa; 
consequently the period for transmucosal nasal drug absorption is limited. For efficient drug 
uptake, absorption promoting or bioadhesive excipients are added to preparations for transmucosal 
nasal drug delivery. Chitosan features both, bioadhesion and absorption promoting (see chapter 
4.4.3). In addition, Zerrouk et al. showed the synergistic effect of cyclodextrins and chitosan on 
drug absorption [Zerrouk et al., 2006]. 
The aim of this clinical trial was to characterize the impact of the vehicle (RMβCD and chitosan 
hydrochloride) and the application modality (e.g., one-sided versus two-sided nasal administration) 
on pharmacokinetics of transmucosal nasal delivered midazolam. Pharmacokinetic and 
pharmacodynamic parameters of i.v. delivered midazolam (Dormicum®, Roche) and nasally applied 
midazolam (5 different preparations) were assessed in healthy volunteers. 
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6.2 Methods 
According to the study protocol (see Appendix 
10.3.1) non-smoking, healthy volunteers (all 
men) age 18 years to 45 years and body mass 
index of 18 kg/m2 to 30 kg/m2 were recruited for 
this open-label trial accomplished at the 
University Hospital of Basel (for study design 
see Figure 6-1). Before enrollment, volunteers 
were conclusively informed about the study 
protocol and all subjects gave written consent. 
All interested volunteers then underwent a 
medical screening procedure, including 
physical examination, medical history, clinical 
laboratory testing, and electrocardiogram, 
according to the protocol (see Appendix 10.3.2 
to 10.3.4). Subjects with acute or chronic nasal 
symptoms, clinically significant previous nasal 
surgery, nasal trauma or polyps, or any 
systemic illness were excluded from 
participation. Only volunteers complying with 
all inclusions criteria were enclosed. The 
volunteers were fasting and abstaining from 
beverages containing caffeine from midnight 
and until four hours after administration of 
study medication. Sugar free beverages were 
allowed. Volunteers received six different 
treatments (i.v., Dormicum®, Roche and nasal 
Preparation 1 to 5). All preparations for nasal 
administration (Preparation 1 to 5) are 
described in Chapter 1. For nasal delivery unit 
dose nasal spray (Pfeiffer, GmbH Radolfzell), 
delivering 0.1 ml, were used. In Table 6-1 the 
applied preparations, midazolam 
concentrations, vehicles, the administered 
doses, and the application modality are 
specified. Two days washout was scheduled 
between midazolam administrations.  
 
Volunteers
(healthy, male, 18-45 years, 
non-smoking, BMI 18-30)
Enrollment
Information
Written consent
Inclusion and exclusion criteriaSc
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g
1 to maximal 2 weeks
Follow-up
1 
m
g 
m
id
az
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m
Dormicum®
1 mg/ml
 1 ml i.v.
Preparation 1
5 mg/ml
 2 x 0.1 ml nasal
Preparation 2
5 mg/ml + CD
 2 x 0.1 ml nasal
Preparation 3
10 mg/ml + CD
 0.1 ml nasal
3 
m
g 
m
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o
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m
Preparation 4
30 mg/ml + CD
 0.1 ml nasal
Preparation 5
30 mg/ml + CD + CHI
 0.1 ml nasal
2 days
2 days
2 days
2 days
2 days
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m
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Figure 6-1: Study design for pharmacokinetic 
characterization of nasally applied midazolam. 
Administration of study medication was 
separated by two days washout (CD: RMβCD, 
CHI: chitosan hydrochloride). 
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Table 6-1: Specification, midazolam concentrations, vehicles, administered doses, and application modality of the 
preparations administered to healthy volunteers for pharmacokinetic characterization of nasally applied midazolam. 
Preparation 
Nr. Specification RMβCD 
Chitosan 
HCl 
Midazolam 
(base) Dose 
Delivered volume, one-
sided (0.1 ml) or two-
sided (2 x 0.1 ml) 
--- Dormicum®, Roche --- --- 1 mg/ml 1 mg 1.0 ml i.v. 
1 Midazolam UD Nasal Spray 0.5 mg --- --- 5 mg/ml 1 mg 
2 x 0.1 ml 
nasal, two-sided 
2 Cyclodex-Midazolam UD Nasal Spray 0.5 mg 2% --- 5 mg/ml 1 mg 
2 x 0.1 ml 
nasal, two-sided 
3 Cyclodex-Midazolam UD Nasal Spray 1 mg 4% --- 10 mg/ml 1 mg 
0.1 ml  
nasal, one-sided 
4 Cyclodex-Midazolam UD Nasal Spray 3 mg 12% --- 30 mg/ml 3 mg 
0.1 ml 
nasal, one-sided 
5 Chitosan-CD-Midazolam UD Nasal Spray 3 mg 12% 0.5% 30 mg/ml 3 mg 
0.1 ml 
nasal, one-sided 
 
 
Hospital Pharmacy of University Hospital Basel produced the nasal preparations for midazolam 
delivery according to current GMP guidelines. A clinician administered Dormicum® 1 mg/ml i.v. 
(1 ml), on the opposite arm of the indwelling catheter used for blood sampling. Venous blood 
samples of 7.5 ml were obtained predose, 1, 2.5, 5, 10, 15, 20, 30, and 45 minutes and 1, 2, 3, 4, 
and 6 hours after midazolam administration. The blood samples were centrifuged at 3000 G for 
10 minutes, the resultant serum was stored at -20°C  until analysis. Quantification of midazolam and 
midazolam metabolites (α-hydroxymidazolam, and 4-hydroxymidazolam) was performed at the 
Institute of Forensic Medicine of the University Basel, according to the method published by Dussy 
et al. [Dussy et al., 2005]. 
Volunteers were asked to describe nasal midazolam administration (indifferent, tolerable, 
disagreeable, or painful) and to classify local irritation (no irritation, very slight, slight, intermediate, 
strong, or very strong) 1, 5, 15, 30, and 240 minutes after nasal midazolam administration. In 
addition, volunteers rated subjective fatigue and drowsiness on a visual analog scale (VAS), a 
100 mm non-graduated line, the left end referring to “no pharmacological effect” (no fatigue and/or 
drowsiness) and the right end referring to “very intense pharmacological effect” (falling asleep). 
Furthermore, reaction time (RT) and interstimulus interval (ISI) was assessed by a computer-
controlled self-adjusting reaction time test (CRTT, BonnDet), developed by Langewitz et al. 
[Langewitz 1987]. Flashing colored lights had to be answered by pushing a corresponding button. 
ISI (i.e., working speed) and RT were registered. The computer controled a fast on-line feedback 
loop between performance and work speed as to yield a constant failure rate of 50% over 
540 stimuli. 
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Blood pressure, oxygen saturation, and heart rate were monitored. To treat severe adverse 
reactions flumazenil (Anexate®, Roche, Basel) was available.  
The local Ethics Committee and the national authorities (Swissmedic) approved the protocol of this 
pharmacokinetic trial. The study was carried out at Clinical Research Unit of University Hospital 
Basel according to national regulation and the current Declaration of Helsinki. 
Serum concentration time profiles were analyzed with WinNonlin (Version 3.1, Pharsight 
Corporation, Mountain View, CA, USA) and pharmacokinetic parameters were assessed by 
applying non-compartmental (for all midazolam applications) and two-compartmental (for nasal 
administration of 3 mg of midazolam) models. Terminal elimination constant was assessed by 
logarhythmic-linear regression of terminal part of the concentration time profile. Secondary 
pharmacokinetic parameters were derived from assessed primary parameters according to 
standard proceedings. 
Bioequivalence was accepted, for mean and 90% confidence interval of the pharmacokinetic 
parameters (test preparation) lying within the boundaries of 80% (lower boundaries) and 125% 
(upper boundaries) of the corresponding pharmacokinetic parameter of the reference preparation 
according to the requirements of EMEA [EMEA 2001]. 
Normal distribution of parameters was tested, and if adequate analyzed by repeated measures 
ANOVA, not normal distributed parameters by not parametric testing (Friedman’s Test). Statistical 
analysis was performed by SPSS (Version 13.0 for Windows Microsoft). As level of significance 
p=0.05 was accepted. 
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6.3 Results 
 
From 14 screened subjects, 3 did not meet 
the inclusion criteria, and two subjects had 
withdrawn their consent before participating 
on a study day. Finally 9 subjects were 
enrolled into the study. After attending the 
first study day one volunteer had withdrawn 
his consent and dropped out.  
Demographic characteristics of all volunteers 
who completed the study are presented in 
Table 6-2. Figure 6-2 displays subject 
proceeding during Project II. 
 
Table 6-2: Demographic characteristics of subjects 
completing the study (n=8). 
Characteristics (n=8) 
Age, years (SD) 24 (3.2) 
Weight, kg (SD) 74 (5.4) 
Body height, cm (SD) 180 (4.0) 
BMI, kg/m2 (SD) 23 (1.3) 
 
Drop out (n=1)
consent withdrawn (n=1)
Screening (n=14) Excluded
- exclusion criteria (n=3)
- consent withdrawn (n=2)Enrolled (n=9)
- male
- 24 ± 3 years
- BMI 23 ± 1
Study day 1 (n=9)
Dormicum®
Study day 2 (n=8)
Preparation 1
Study day 3 (n=8)
Preparation 2
Study day 4 (n=8)
Preparation 3
Study day 5 (n=8)
Preparation 4
Study day 6 (n=8)
Preparation 5 
Follow-up (n=8)
Final analysis (n=8)
 
Figure 6-2: Subject proceedings during clinical 
study; screened n=14, excluded (exclusion 
criteria n=5, withdrawal of consent n=2), 
enrolled n=9, drop out after study day n=1, 
completed study n=8. 
 
 
 
 
Immediately after nasal administration of Preparation 1 to 5 (overall 40 nasal applications), 
volunteers classified the nasal administration as indifferent, tolerable, disagreeable, or painful. 
Overall 4 times nasal administration of study medication was classified as indifferent, 26 times as 
tolerable, and 8 times as disagreeable (see Figure 6-3). Nasal administration of the study 
medication never was classified as painful. Nasal administration of Preparation 5 most often 
(4 times) was classified as disagreeable. Local irritation of Preparation 5 set in about 30 seconds to 
60 seconds after administration.  
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indifferent tolerable disagreeable painful
Figure 6-3: Tolerability of nasal administration of Preparation 1 to 5 to 8 healthy volunteers. 
Immediately after administration volunteers classified the nasal administration of Preparation 1 to 5 as 
indifferent, tolerable, disagreeable, or painful. 
 
 
Nasal administration of midazolam (Preparation 1 to 5) caused some irritation in the nose or throat 
area immediately after administration (see Figure 6-4).  
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Figure 6-4: Local irritation immediately after nasal administration of Preparation 1 to 5 (P1, P2, P3, P4, 
and P5). Volunteers (n=8) rated the intensity immediately after nasal administration of the study 
medication. 
 
Changes of local irritation assessed immediately to 4 h after nasal administration of study 
medication is shown Appendix 10.3.5. and 10.3.6. 
Within 30 minutes after nasal administration (Preparation 1 to 5) nasal irritation was completely 
reversible. Nasal irritation after administration of Preparation 1, 2, and 3 (nasal delivery of 1 mg 
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midazolam) decreased within 5 minutes after administration (very slight to slight) and 15 minutes 
after administration of Preparation 3 only one volunteer indicated very slight nasal irritation.  
Irritation in the throat after administration of Preparation 1, 2, and 3 (nasal delivery of 1 mg 
midazolam) was never rated as strong immediately after administration (very slight, slight or 
intermediate). Irritation in the throat was once described as strong (scratching in the throat) 
15 minutes after administration of Preparation 3. Generally, 15 minutes after nasal administration of 
1 mg midazolam local irritation has almost disappeared and later (30 minutes and 4h) volunteers 
indicated no local irritation at all. Nasal irritation after administration of Preparation 4 and 5 (nasal 
delivery of 3 mg midazolam) decreased within 15 minutes after administration (very slight to slight) 
and lasted until 30 minutes after administration of Preparation 4. Preparation 5 caused more 
irritation in the throat area which lasted until 30 minutes after nasal administration. Four hours after 
nasal administration of study medication no local irritation was left. 
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Figure 6-5: Teary eyes after nasal administration 
of Preparation 1 to 5 (P1, P2, P3, P4, and P5) to 
8 Volunteers (n=8) rated. One-sided nasal 
administration (P3, P4, and P5) caused teary eye 
only on the side of administration. 
 
Some subjects complained about teary eyes 
(see Figure 6-5), bitter or unpleasant taste, or 
nasal prickling immediately after nasal 
administration of study medication. One-
sided nasal administration of midazolam 
(Preparation 3, 4, and 5) caused teary eye 
only on the side of administration. 
No relevant changes in blood pressure, heart 
rate, and oxygen saturation were observed 
after i.v. and nasal administration of 
midazolam (1 mg and 3 mg). 
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Figure 6-6 shows the midazolam serum concentration time profile following i.v. administration of 
1 mg midazolam (Dormicum®), nasal administration of 1 mg midazolam (Preparation 1, 2, and 3) 
and nasal administration of 3 mg midazolam (Preparation 4 and 5). In the elimination phase all 
midazolam time profiles are parallel (see inserted semilogarithimic concentration time profile in 
Figure 6-6). Figure 6-7 focuses on midazolam serum concentration time profile until 60 minutes 
after midazolam administration. Nasal administration of 3 mg midazolam resulted in higher serum 
concentration levels than nasal administration of 1 mg midazolam. Maximal midazolam serum 
concentrations following nasal administration of 3 mg midazolam were in the same range as 
maximal midazolam serum concentrations following i.v. administration of 1 mg midazolam.  
Midazolam serum concentration following i.v. and nasal application were approximating 10 minutes 
after administration of 1 mg midazolam. Original data and midazolam serum concentration time 
profiles of all subjects are displayed Appendix 10.3.7 to 10.3.10. 
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Figure 6-6: Midazolam serum concentration (mean) following i.v. and nasal administration of 1 mg 
midazolam (Preparation 1, 2, and 3) and nasal administration of 3 mg midazolam (Preparation 4 and 5) 
to 8 volunteers. Midazolam concentration was assessed predose and 1, 2.5, 5, 10, 15, 20, 30, 45, 60, 
180, 240, and 360 minutes after midazolam administration. Inserted figure shows semilogarithimic 
concentration time profile. 
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Figure 6-7: Midazolam serum concentration (mean) following i.v. and nasal administration of 1 mg 
midazolam (Preparation 1, 2, and 3) and nasal administration of 3 mg midazolam (Preparation 4 and 5) 
to 8 volunteers. This figure displays midazolam concentrations asessed predose, 1, 2.5, 5, 10, 15, 20, 
30, 45, and 60 minutes after midazolam administration. 
 
Table 6-3 summarizes the assessed pharmacokinetic parameters following i.v. and nasal 
midazolam delivery. Time to reach maximal midazolam serum concentration (tmax) after nasal 
administration of Preparation 1 to 5 ranged from 7.1 ± 0.6 min (Preparation 5) to 11.7 ± 2.4 min 
(Preparation 4). Mean systemic bioavailability (F) of midazolam after nasal administration of test 
preparation varies from 93% (Preparation 2) to 78% (Preparation 5). 
Differences of systemic midazolam bioavailability following nasal midazolam administration were 
not significant. Clearance (Cl) and half life (t1/2) were constant and independent of midazolam 
administration modality.  
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Table 6-3: Pharmacokinetic parameters (mean and SD) following i.v. (Dormicum® 1 mg/ml, 1 mg) and nasal 
application of midazolam (1 mg by Preparation 1 to 3 and 3 mg by Preparation 4, 5); n=8. 
Preparation 
Nr. Specification 
tmax 
[min] 
Cmax 
[µg/l] 
AUC0-∞ 
[µg*min/l] 
Cl 
[l/min] 
t1/2 
[min] F 
1 
m
g 
i.v
.
 
--- Dormicum®, Roche 2.1 (0.8) 
87.6 
(58.7) 
2798.5 
(508.9) 
0.37 
(0.07) 
113.5 
(25.9) 
100% 
 
1 Midazolam UD Nasal 
Spray 0.5 mg 
10.6 
(5.0) 
28.1 
(9.1) 
2461.0 
(627.8) 
0.43 
(0.11) 
114.2 
(23.0) 
88% 
(17) 
2 
Cyclodex-Midazolam 
UD Nasal Spray 
0.5 mg 
9.4 
(3.2) 
30.1 
(6.6) 
2596.4 
(680.4) 
0.41 
(0.13) 
113.0 
(22.8) 
93% 
(15) 
n
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3 Cyclodex-Midazolam 
UD Nasal Spray 1 mg 
11.3 
(4.4) 
28.9 
(5.4) 
2510.5 
(541.4) 
0.42 
(0.11) 
105.4 
(17.7) 
90% 
(16) 
4 Cyclodex-Midazolam 
UD Nasal Spray 3 mg 
11.7 
(2.4) 
72.6 
(18.2) 
7324.8 
(1599.5) 
0.43 
(0.10) 
120.9 
(32.9) 
86% 
(8) 
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5 
Chitosan-CD-
Midazolam UD Nasal 
Spray 3 mg 
7.1 
(0.6) 
82.2 
(15.8) 
6580.6 
(1358.4) 
0.48 
(0.12) 
113.9 
(20.8) 
78% 
(10) 
 
1
 for two-compartment modeling data from Subject 1 had to be excluded 
 
 
Mean serum concentration time profiles following nasal administration of 1 mg were congruent and 
demonstrated equal absorption kinetics independent of the delivered preparation (Preparation 1, 2, 
and 3) and the administration modality (one- versus two-sided), see Figure 6-8 A, B, and C. Intra-
individual variability of midazolam serum concentration profiles following nasal administration of 
1 mg midazolam (Preparation 1, 2, and 3) is shown in Appendix 10.3.9. 
Midazolam serum concentration time profile following nasal administration of Preparation 5 is 
shifted compared to the profile resulting of nasal administration of 3 mg midazolam by 
Preparation 4, see Figure 6-8 D. 
Faster increasing midazolam serum concentrations were detected in all subjects after nasal 
administration of Preparation 5 (3 mg midazolam plus chitosna) than after nasal administration of 
Preparation 4 (3 mg midazolam without chitosan), see Appendix 10.3.10. Modeling of midazolam 
serum concentration time profiles following nasal administration of Preparation 4 and 5 was 
performed by applying a two-compartment pharmacokinetic model (see Figure 6-9). Range 
(interindividual variability) of AUC (4349.7 µg*min/l), Cmax (38.8 µg/l), and tmax (1.9 min) following 
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nasal administration of Preparation 5 were closer than the range of AUC (4668.5 µg*min/l), Cmax 
(52.5 µg/l), and tmax (6.7 min) following nasal administration of Preparation 4.  
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Figure 6-8 (A-D): Overlaid profiles of midazolam serum concentrations following administration of 
Preparation 1 and 2 (A), Preparation 1 and 3 (B), Preparation 2 and 3 (C), and Preparation 4 and 5 (D). 
The displayed midazolam serum concentrations refer to the mean serum concentrations (n=8). 
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Figure 6-9: Modeling of the midazolam concentration time profile was performed by applying a 
two-compartment pharmakokinetic model for midazolam serum concentrations after 
administration of Preparation 4 (n=7) and Preparation 5 (n=7). 
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Bioequivalence testing was performed for nasal delivery of 1 mg (Preparation 2 and 3) and 3 mg 
(Preparation 5) with reference Preparation 1 and Preparation 4, respectively (Table 6-4 and Table 
6-5). Nasal delivery of 1 mg midazolam by administration of Preparation 1, 2 and 3 was 
bioequivalent, according to the requirements for bioequivalence defined by the EMEA [EMEA 26. 
July 2001] (see Table 6-4). 
 
Table 6-4: Bioequivalence testing for nasal delivery of 1 mg midazolam. Boundaries (lower 80% and upper 125% for 
AUC0-∞, Cmax,) and mean are indicated for reference (Preparation 1), 90% confidence intervals and means of AUC0-∞, 
Cmax of Preparation 2 and 3 are listed. wb: within boundaries, : 90% confidence interval and mean of test 
preparation fulfill the requirements of EMEA for bioequivalence. 
Boundaries of reference 
(mean) 
90% confidence interval 
(mean) Parameter 
Preparation 1 Preparation 2 wb Preparation 3 wb 
AUC0-∞, [µg*min/l] 1969 – 3076 (2461) 
2140 – 3052 
(2596)  
2148 – 2873 
(2510)  
Cmax [µg/l] 22.5 – 35.2 (28.1) 
25.6 – 34.5 
(30.5)  
25.3 – 32.5 
(28.9)  
 
None of the tested pharmacokinetic parameters (AUC, Cmax, and tmax) Preparation 4 and 5 did fulfill 
the requirements for bioequivalence, see Table 6-5. The difference between AUC following 
administration of Preparation 4 and 5 was not significant, whereas differences of Cmax (p=0.008) 
and tmax (p=0.008) were significant. The range of AUC (4349.7 µg*min/l), Cmax (38.8 µg/l), and tmax 
(1.9 min) following nasal administration of Preparation 5 were closer than the range of AUC 
(4668.4 µg*min/l), Cmax (52.5 µg/l), and tmax (6.7 min) following nasal administration of 
Preparation 4. 
 
Table 6-5: Bioequivalence testing for nasal delivery of 3 mg midazolam. Boundaries (lower 80% and upper 125% for 
AUC0-∞, Cmax,) and mean are indicated for reference (Preparation 4), 90% confidence intervals and means of AUC0-∞, 
Cmax of Preparation 5 are listed. wb: within boundaries, no: 90% confidence interval and mean of test preparation 
does not comply with the requirements of EMEA for bioequivalence. 
Boundaries of reference 
(mean) 
90% confidence interval 
(mean) Parameter 
Preparation 4 Preparation 5 wb 
AUC0-∞, [µg*min/l] 5860 - 9156 (7325) 
5583 – 7578 
(6581) 
no 
Cmax [µg/l] 58.1 – 90.8 (72.6) 
68.3 – 88.6 
(78.5) 
no 
tmax [min] 9.3 – 14.6 (11.7) 
6.6 – 7.5 
(7.1) 
no 
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Figure 6-10 shows the serum concentration time profiles of α-hydroxymidazolam (main metabolite 
of midazolam) following i.v. and nasal delivery of 1 mg midazolam (Preparation 1, 2, and 3) and 
nasal delivery of 3 mg midazolam (Preparation 4 and 5).  
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Figure 6-10: Serum concentration of α-hydroxymidazolam after i.v. (Dormicum®) and nasal delivery of 
1 mg midazolam (Preparation 1, 2, and 3) and nasal delivery of 3 mg midazolam (Preparation 4 and 5); 
P: Preparation. 
 
Table 6-6 summarizes pharmacokinetic parameters of α-hydroxymidazolam following i.v. 
(Dormicum®, 1 mg) and nasal application of midazolam (1 mg by Preparation 1, 2, and 3 and 3 mg 
by Preparation 4 and 5). 
There is no significant difference between dose adjusted AUC of α-hydroxymidazolam following i.v. 
and nasal delivery of 1 mg midazolam (Dormicum®, Preparation 1, 2, and 3) and nasal delivery of 
3 mg midazolam (Preparation 4 and 5). Following nasal midazolam administration, maximal α-
hydroxymidazolam serum concentrations were reached after 33.3 ± 13.3 min (Preparation 5) and 
41.3 ± 13.3 min (Preparation 4). Following i.v. midazolam administration maximal α-
hydroxymidazolam serum concentrations were reached 22.5 ± 11.6 min after midazolam injection. 
Maximal 4-hydroxymidazolam (second midazolam metabolite) concentration detected were 
0.6 µg/l, 0.2 µg/l following nasal delivery of 3 mg midazolam and administration of 1 mg midazolam 
(i.v. and nasal), respectively. Often, 4-hydroxymidazolam was detected, but below LOQ (0.2 µg/l), 
see Appendix 10.3.7. 
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Table 6-6: Pharmacokinetic parameters of α-hydroxymidazolam following i.v. (Dormicum® 1 mg/ml, 
1 mg) and nasal application of midazolam (1 mg, Preparation 1 to 3 and 3 mg, Preparation 4 and 5); 
n=8, (SD): standard deviation 
Preparation 
Nr. 
Tmax 
[min] 
Cmax 
[µg/l] 
AUC0-∞ 
[µg *min/l] 
T1/2 
[min] 
Cal 
[l/min] F 
1 
m
g 
i.v
.
 
--- 
22.5 
(11.6) 
1.7 
(0.8) 
293.8 
(73.0) 
118.0 
(23.4) 
3.6 
(0.8) 100% 
1 39.4 (11.2) 
1.4 
(0.4) 
305.0 
(67.0) 
131.0 
(27.6) 
3.4 
(0.8) 
104% 
(9.0) 
2 35.6 (7.8) 
1.4 
(0.6) 
316.6 
(129.5) 
146.7 
(33.1) 
3.6 
(1.3) 
106% 
(11.5) 
1 
m
g 
n
as
al
 
3 41.3 (10.6) 
1.5 
(0.6) 
311.0 
(81.6) 
142.2 
(41.8) 
3.4 
(0.8) 
106% 
(11.5) 
4 41.3 (13.3) 
3.8 
(1.2) 
292.5* 
(81.6) 
122.8 
(41.4) 
3.7 
(1.0) 
100% 
(18.2) 
3 
m
g 
n
as
al
 
5 33.3 (13.3) 
4.4 
(1.3) 
279.5* 
(53.0) 
112.3 
(9.8) 
3.7 
(0.6) 
97% 
(14.5) 
 
* dose adjusted AUC 
 
Reaction Time (RT) and Interstimulus Interval (ISI) were assessed by Computer-controlled self-
adjusting reaction time test (CRTT). Figure 6-11 displays RT and ISI assessed during the test runs 
(day 1 before predose run) and predose (all study days). Mean inter test difference of RT and ISI 
was 19 ± 9 ms and 22 ± 10 ms, respectively. Delta RT and delta ISI refer to the difference of the 
assessed RT and ISI at 20 min, 120 min, and 240 min after midazolam administration and the 
corresponding parameter assessed previous to midazolam administration. 
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Figure 6-11: Three test runns and predose RT and ISI assessed by CRTT. Overall mean inter test 
difference of RT and ISI was 19 ± 9 ms and 22 ± 10 ms, respectively (n=8). 
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Delta RT and delta ISI refer to the difference of the assessed RT and ISI at 20 min, 120 min, and 
240 min after midazolam administration and the corresponding parameter assessed previous to 
midazolam administration. In Figure 6-12 and Figure 6-13 delta RT and delta ISI assessed after 
administration of study medication are displayed. 
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Figure 6-12: Delta interstimulus interval (ISI) assessed by CRTT. Delta interstimulus interval refers to 
the difference between the ISI at 20 min, 120 min, and 240 min after midazolam application and the 
corresponding ISI.  
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Figure 6-13: Delta reaction time (RT) assessed by CRTT. Delta RT refers to the difference between the 
RT assessed 20 min, 120 min, and 240 min after midazolam application and the corresponding RT 
assessed predose.  
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Figure 6-14 shows the correlation of midazolam serum concentration time profile and performance 
of CRTT (delta RT and delta ISI). 
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Figure 6-14: Correlation of midazolam serum concentration and outcome of CRTT performance (delta 
reaction time and delta Interstimulus interval), n=8. 
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Figure 6-15 shows correlation of midazolam serum concentration time profile and subjective rating 
of fatigue and drowsiness on VAS4. Maximal VAS score was reached within 30 minutes after 
midazolam administration.  
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Figure 6-15: Subjective rating of fatigue and drowsiness on VAS (mean). Rating was provide 5 min, 
15 min, 30 min and 120 min after nasal midazolam administration of Preparation 1 (n=3), Preparation 2 
(n=6), Preparation 3 (n=8), Preparation 4 (n=8), and Preparation 5 (n=8).  
                                                     
4
 The missing data of assessed fatigue and drowsiness score is due to delayed implementation of this score. Therefore, 
only 3 and 6 volunteers rated their fatigue and drowsiness for Preparation 1 and Preparation 2, respectively. For 
Preparation 3, Preparation 4, and Preparation 5 all volunteers rated their fatigue and drowsiness (n=8) 
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6.4 Discussion 
Five different nasal midazolam preparations and i.v. midazolam (Dormicum®) were administered to 
healthy volunteers to provide pharmacokinetic characterization of nasally applied midazolam. 
Preparation 1, 2, 3, 4, and 5 were nasally applied to assess the impact of RMβCD (solubilizer), 
chitosan hydrochloride (penetration enhancer), and the application modality (one- versus two-
sided) on systemic bioavailability and pharmacokinetics of nasal delivered midazolam. 
Pharmacologic effects were assessed by visual analogue scale (VAS) and computer-controlled 
self-adjusting reaction time test (CRTT, measuring reaction time and interstimulus interval).  
 
Nasal midazolam administration was well tolerated and never rated as painful. Nasal irritation was 
reversible within 30 minutes. Local irritation (nose, throat area, and teary eyes) was more intense 
following nasal administration of chitosan containing preparation (Preparation 5).  
 
All tested nasal administration modalities for nasal delivery of 1 mg midazolam proved 
bioequivalence. The administration volume of the unit dose system is predetermined (0.1 ml). To 
deliver total dose of 1 mg midazolam by one- and two-sided administration, midazolam 
concentration had to be adapted (concentration was halved and consequently the application 
volume was doubled by spraying 0.1 ml into each nostril). Congruence of midazolam serum 
concentration time profiles, assessed pharmacokinetic parameters, and bioequivalence testing 
proved equal pharmacokinetic characteristics resulting of following administration modalities for 
nasal delivery of 1 mg midazolam:  
• two-sided administration of 0.5 mg midazolam without solubilizer (Preparation 1) 
• two-sided administration of 0.5 mg midazolam with equimolar RMβCD (Preparation 2) 
• one-sided administration of 1 mg midazolam solubilized with equimolar RMβCD (Preparation 3) 
Consequently, neither RMβCD (equimolar to midazolam) nor application modality (one- or two-
sided) changed absorption kinetics of nasally administered midazolam. 
 
Systemic bioavailability of midazolam following one-sided administration of escaled doses (3 mg 
midazolam, Preparation 4, and Preparation 5) was equal to bioavailability following nasal 
administration of 1 mg midazolam. This demonstrated nasal residence time to be long enough for 
complete midazolam uptake. Consequently, midazolam dose can easily be doubled to 2 mg and 
6 mg nasal midazolam by two-sided administration of Preparation 1 for 2 mg and Preparation 4 and 
Preparation 5 for nasal administration of 6 mg midazolam. 
Since systemic bioavailability of nasally applied midazolam was 86% to 93%, nasal administration 
of 6 mg midazolam correspond to about 5 mg midazolam i.v. administered and to about 10 mg to 
16 mg orally applied midazolam (systemic bioavailability of oral midazolam is 30% to 50% 
[Documed 2006]). 
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Transmucosal nasal midazolam absorption was promoted by chitosan hydrochloride. Chitosan 
hydrochloride modified absorption kinetics (Cmax and tmax) of nasally applied midazolam (3 mg), but 
overall systemic bioavailability was not enhanced.  
Furthermore, smaller ranges for AUC, tmax, and Cmax observed after nasal administration of 3 mg 
(Preparation 5) refer to less interindividual variability and therefore reproducible pharmacokinetics.  
Bioequivalence testing was performed for all assessed pharmacokinetic parameters (AUC, tmax, 
and Cmax) following nasal administration of Preparation 4 (reference preparation) and Preparation 5 
(test preparation). None of the tested parameters (AUC, tmax, and Cmax) following nasal 
administration of Preparation 5 fulfilled the requirements of the EMEA for bioequivalence. 
Accordingly, bioequivalence was not confirmed for Preparation 4 (3 mg midazolam, no chitosan 
hydrochloride) and Preparation 5 (3 mg midazolam, 0.5% chitosan hydrochloride). 
Chitosan hydrochloride (Preparation 5) promoted absorption kinetics of nasally applied midazolam 
and significant higher midazolam serum concentrations were faster achieved. Chitosan 
hydrochloride proved valuable penetration enhancer abilities in transmucosal nasal midazolam 
delivery. Chitosan hydrochloride potentially facilitates optimization of nasal midazolam preparation 
for indications requiring fast onset of therapeutic effects (e.g., status epilepticus). Chitosan 
containing nasal midazolam preparations are a promising therapeutic alternative to i.v. delivered 
midazolam for the treatment of status epilepticus. Providing reliable anticonvulsive therapy the 
more intense nasal irritation, of chitosan containing nasal midazolam preparation (Preparation 5) is 
of secondary importance compared to the benefit of needle-free drug delivery. 
 
The congruent metabolite profile after nasal and i.v. administration of 1 mg midazolam supports the 
presumption of direct midazolam uptake through nasal mucosa into the systemic circulation. Apart 
from slightly earlier peak concentration after i.v. administration, the metabolite profiles after nasal 
and i.v. administration of 1 mg midazolam are congruent. In addition, the constant AUC (dose 
adjusted) of α-hydroxymidazolam following nasal and i.v. administration of midazolam attests 
effective bypassing of the first-pass metabolism. Thus, serum concentration time profiles of the 
midazolam metabolites (α-hydroxymidazolam and 4-hydroxymidazolam) demonstrated exclusive 
transmucosal absorption of nasally applied midazolam.  
Nasal administration of 0.1 ml prevented swallowing of the nasally delivered preparation, 
gastrointestinal midazolam uptake, and reduction of systemic bioavailability by hepatic first-pass 
metabolism. Consequently, the assessed pharmacokinetic parameters characterized pure 
transmucosal nasal midazolam delivery. 
This interpretation of metabolite profiles is in accordance with the findings of Heizmann et al., who 
demonstrated higher plasma levels for α-hydroxymidazolam following oral administration of 
midazolam compared to i.v. midazolam delivery [Heizmann et al., 1983]. Illum et al. were the first 
who proved direct transmucosal nasal drug uptake based on the characterization of drug and 
metabolite concentration time profiles [Illum, et al. 2002]. 
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Constant decreasing of the reaction time (RT) and interstimulus interval (ISI) assessed predose 
demonstrated the continuous learning effect of repeated performance of CRTT (computer-
controlled self-adjusting reaction time test). Due to this constant learning effect delta RT and delta 
ISI was calculated to estimate the pharmacological effect. Following nasal administration of 1 mg 
midazolam improved performance (negative difference for delta ISI and RT) refers to the learning 
effect emerging of repeated performances of CRTT 120 minutes after midazolam administration. 
RT and ISI assessed 20, 120, and 240 minutes after nasal administration of 3 mg midazolam was 
reduced compared to RT and ISI assessed predose. Consequently, performance of the volunteers 
was still impaired 4 h after nasal administration of 3 mg midazolam. This finding is of clinical 
relevance assuming that fitness to drive needs more than 4 h to be restored after nasal 
administration of 3 mg midazolam.  
Maximal score for fatigue and drowsiness was achieved within 30 minutes after midazolam 
administration and was delayed compared to maximal midazolam serum concentration.  
Generally, maximal midazolam serum concentrations preceded maximal pharmacologic effects 
assessed by CRTT and VAS.  
 
6.5 Conclusions 
Neither RMβCD (equimolar to midazolam) nor application modality (one- or two-sided) changed 
absorption kinetics of nasally administered midazolam. Chitosan hydrochloride promoted 
absorption kinetic of nasally applied midazolam and significant higher midazolam serum 
concentrations were faster achieved. Nasal delivery of midazolam in a minimized volume provided 
exclusive transmucosal nasal midazolam uptake and thus direct access to the systemic blood 
circulation. Consequently, gastrointestinal midazolam uptake was avoided and first-pass 
metabolism circumvented. 
Pharmacokinetic profile and high systemic bioavailability following transmucosal nasal midazolam 
delivery distinguish this drug administration option as veritable alternative to invasive midazolam 
administration.  
 
  
 
 
 
7. Project III: Transmucosal nasal delivery of low-dose midazolam – evaluation of two preparations for procedural anxiolysis 
 
Katja Suter-Zimmermann Page 83 of 188 University of Basel, 2008 
 
7 Project III: Transmucosal nasal delivery of low-dose 
midazolam – evaluation of two preparations for 
procedural anxiolysis 
7.1 Introduction 
During MRI (magnet resonance imaging) examinations up to 30% of patients experience moderate 
to severe anxiety and 10% of al MRI examinations cannot successfully be completed because of 
claustrophobia [Münte Sinikka 2002].  
For radiological investigations anxiolysis usually is provided by oral or intravenous application of 
benzodiazepines (e.g., lorazepam or midazolam). Claustrophobic patients who are afraid or even 
panic before or during MRI examination profit from conscious sedation, which helps them to cope 
with the situation in the narrow MRI tunnel. Conscious sedation refers to anxiolysis and only slight 
sedation, not impairing patient’s ability to maintain his airways and to respond appropriately to 
physical stimulation and verbal commands [Merrick and Ramsby 1994]. This is required for 
procedural anxiolysis during MRI examinations because some examinations require the 
cooperation of the patients (e.g., in- and exhaling on command). Nasal application of low-dose 
midazolam has been reported to be effective in procedural anxiolysis (conscious sedation), 
furthermore the rapid onset is considered beneficial for MRI workflow [Moss, et al. 1993; Münte 
2002]. Compared to oral application of 7.5 mg midazolam, the benefit of nasal delivered low-dose 
midazolam (1-2 mg) was faster onset of anxiolysis and the absence of deep sedation. Therefore, 
patients were able to follow the instructions during MRI examinations [Tschirch, et al. 2006]. For 
nasal application of low-dose midazolam, no preparation is commercially available. Usually, 
midazolam formulations for i.v. application are administered nasally or local Hospital Pharmacy 
provides nasal midazolam preparations according to the monograph of NRF [NRF 2002]. 
The aim of this multicenter trial was to compare the benefit of two different preparations for nasal 
delivery of low-dose midazolam to provide procedural anxiolysis during MRI examinations. 
7.2 Methods 
The ethics committees of Zurich and Basel and the national authorities (Swissmedic) approved the 
clinical protocol of this multicenter trial, that was carried out at Center A (Institute of Diagnostic 
Radiology, University Hospital Zurich), Center B (Institute of Radiology, Kantonsspital Winterthur), 
Center C (Imamed Radiologie Nordwest, Basel), and Center D (Department of Radiology, 
Orthopedic University Hospital Balgrist, Zurich). Coordination and monitoring was performed in 
collaboration with Akroswiss AG, Zurich. 
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Figure 7-1: Study design of multicenter trial with 
nasal low-dose midazolam. Anxious and/or 
claustrophobic patients, scheduled for MRI 
examinations at the study centers (A, B, C, and 
D), were invited to participate in this multicenter 
trial with nasal low-dose midazolam. MD: 
multidose nasal spray (treatment), UD: unit dose 
nasal spray (comparator). 
 
 
Patients and study design 
Patients, scheduled for MRI examinations at 
the study centers and desiring anxiolysis, 
because of general anxiety and/or 
claustrophobia, were invited to participate in 
this clinical trial with nasal low-dose 
midazolam. Radiologists conclusively informed 
the interested patients and handed out written 
information about the clinical study protocol. 
Before enrollment, patients gave written 
consent. Figure 7-1 displays the study design 
of the multicenter study with nasal low-dose 
midazolam. 
Exclusion criteria were age <18 years, general 
contraindications for MRI (e.g., cardiac 
peacemaker, neurostimulators, or 
ferromagnetic implants), pregnancy, breast 
feeding, drug or ethanol abuse, general 
contraindications for midazolam or other 
benzodiazepines (e.g., myasthenia gravis, 
known allergic or previous paradox reaction 
after benzodiazepine administration), 
simultaneous therapy with midazolam or other 
benzodiazepines, simultaneous participation in 
another clinical trial, and otorhinolaryngeal 
diseases (e.g., status post surgery, rhinitis, 
nasal polyposis), see case report form in 
Appendix 10.4.1 and 10.4.2. When consent 
had been obtained and all inclusion criteria 
were met, patients were randomly allocated to 
treatment or comparator group. 
Treatment (MD) and Comparator (UD) 
Midazolam MD Nasal Spray 5 mg/ml (MD) and Midazolam UD Nasal Spray 1 mg (UD) were 
produced at the Hospital Pharmacy, University Hospital Basel, according to the current guidelines 
for Good Manufacturing Practice (GMP). Midazolam hydrochloride was purchased from Fährhaus 
Pharma (Hamburg, Germany), randomly methylated-β-cyclodextrin (RMβCD, Cavasol® W7M 
Pharma) from Wacker (Munich, Germany), sodium chloride and 0.1 N hydrochloric acid were of 
pharmaceutical quality according to Ph.Eur. 5.4.  
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Midazolam MD Nasal Spray 5 mg/ml was produced according to the NRF monograph for nasal 
midazolam preparation [NRF 2002]. Midazolam MD Nasal Spray 5 mg/ml (preservative: 
benzalconium chloride and sodium ethylenediaminetetraacetic acid) was provided in a multidose 
nasal spray, delivering 0.1 ml per pump (0.5 mg midazolam base per pump). To prepare the 
multidose nasal spray for exact dosing, the pump had to be pressed five times previous to first 
nasal administration. The application had to be provided in sitting patients, because the upright 
position of the multidose nasal spay is essential for exact dosing. 
Patients were administered 1 pump (0.1 ml) per nostril of Midazolam MD Nasal Spray 5 mg/ml 
immediately prior to MRI examination (total administered dose: 1 mg midazolam base). If the 
administered dose of 1 mg midazolam was not enough to provide sufficient anxiolysis to perform 
MRI examination, administration was allowed to be repeated (1 pump per nostril, additional 
administration of 1 mg midazolam).  
Midazolam UD Nasal Spray 1 mg (preservative-free, solubilizer: 4% RMβCD) was provided in unit 
dose nasal sprays (Pfeiffer GmbH, Radolfzell, Germany), delivering 1 single pump of 0.1 ml (1 mg 
midazolam base per pump), independent of the actual position. Therefore, the application was 
provided to the patients lying on the MRI table. For detailed information about the nasal midazolam 
preparations see Table 5-4, Table 5-5 (Project I), and Appendix 10.2.4 to 10.2.9. 
Additional dose and therapy failure 
If anxiolysis of the initial treatment with 1 mg midazolam was not enough to provide MRI 
examination an additional dose of 1 mg midazolam was offered to patients of both groups (MD and 
UD). Administration of the additional dose was no exclusion criteria. 
Anxiety score and subjective experience 
Patients were asked to rate their anxiety on a visual analog scale (VAS) before medication 
(VASbefore) and after completing MRI examination (VASafter). VAS to rate anxiety was a non-
graduated 100 mm line, the left end labeled ‘not anxious at all’ and the right end labeled ‘extremely 
anxious’.  
In addition, after completing the MRI examination patients were interviewed about their 
experiences and whether they would repeat the MRI examination again with analog anxiolytic 
treatment receiving during the study. 
Assessment of radiologic technician 
The radiologic technician rated the comportment and cooperation of the patient during the 
proceedings (calm and good cooperation, agitated insufficient cooperation, patient felt asleep, 
slightly anxious, and very anxious) and classified the proceeding as normal proceedings, 
interruption of the examination, or MRI examination not feasible and named the reasons for 
incomplete examinations. If MRI examination was not feasible or had to be interrupted, the therapy 
was judged as failed (therapy failure).  
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MRI image quality 
The radiologists assessed the image quality of each MRI examination, according to following five-
grade scale: (1) excellent image quality (ideal image quality for diagnosis), (2) good image quality 
(very little motion artifacts), (3) satisfactory image quality (diagnosis possible, despite some motion 
artifacts), (4) poor image quality (diagnostic information is affected by motion artifacts), and very 
poor image quality (no diagnosis because of extensive motion artifacts). 
Local irritation and adverse drug reactions 
Radiologic technicians were instructed to register all spontaneous reports on local irritation and 
adverse effects. Patients were asked to classify the intensity of the local irritation (mild, 
intermediate, strong) and the time for recovery was noted. The radiologists were instructed to treat 
serious adverse reactions with flumazenil (Anexate®). 
Analysis and statistics 
Two tailed t-tests for differences in continuous variables and χ2-tests (image quality) of trends for 
ordinal variables were performed. Statistical significance was accepted for p<0.05. The anxiety 
scores were compared by means of the Mann-Whitney test. Analysis of the questionnaire 
concerning the willingness to repeat the MRI examination was made by Fisher’s exact test. 
Monitoring and study material supply 
Before delivering the clinical study material to the study centers all collaborating radiologic 
technicians and radiologists were instructed (see also instruction material in Appendix 10.4.4.). To 
assure consistent application of the nasal sprays the handling of the nasal sprays (multidose and 
unit dose) was explained and demonstrated. 
On a colored flowchart (see Appendix 10.4.3) the different forms and questionnaires were 
displayed. All forms (questionnaires) were of different colors, corresponding to the color code of the 
flowchart (patient information: white, consent form: green with white carbon copy, questionnaire to 
check the inclusion and exclusion criteria and the assessment of image quality: blue, and the 
questionnaire for the assessment by the patient and radiologic technicians: yellow). The duties and 
responsibilities of radiologic technicians and radiologists were labeled.  
To monitor the rate of recruitment and the compliance with the guidelines for Good Clinical Practice 
the study centers were visited once per months.  
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7.3 Results 
Study population 
Between May 2006 and February 2007, overall 110 patients were recruited and randomly assigned 
to either treatment (MD, n=56) or comparator group (UD, n=54). There were no significant 
differences between patients recruited in the study centers A, B, C, and D. 
Regarding age (MD 51 ± 16 years, UD 51 ± 13 years), weight (MD 72 ± 15 kg, UD 77 ± 16 kg) and 
sex (MD m18/f38, UD m19/f35) was no significant difference between treatment (MD) and 
comparator group (UD).  
The MRI examinations were classified into three groups: investigations of a limb (body and head 
outside of the MRI tunnel), investigation of head and neck (only head and neck inside the MR 
tunnel), and whole body investigations (whole body inside the MR tunnel). There was no significant 
difference between the classification of MRI examinations of treatment and comparator group. 
Table 7-1: Demographic and clinical characteristics of the study population (n=110). 
Characteristics Treatment group MD (n=56) 
Comparator group 
UD (n=54) 
Age, y (SD)1 51 (16) 51 (13) 
Weight, kg (SD) 72 (15) 77(16) 
Sex (m/f) 18/38 19/35 
VASbefore 0.72 (0.23) 0.66 (0.25) 
Center A 15 15 
Center B 13 12 
Center C 13 12 
Center D 15 15 
Duration of MRI examination, min (SD) 31 (13) 3 31 (11) 4 
Acquired sequences (SD) 7 (4) 3 6 (2) 4 
Total body examination 41 3 37 4 
Head/neck examination 12 3 12 4 
Limb examination 3 3 3 4 
Contrast agent, i.v. 14 3 7 4 
Arthroscopy2 14 3 11 4 
1
 a 16 year-old patient was enclosed, after her mother signed consent form. This protocol deviation was 
tolerated and the acquired data entered the final analysis 
2
 intra-articular injection of contrast agent 
3
 n=53, no data for therapy failures or dropout 
4
 n=52, no data for therapy failure and protocol deviation 
 
Additional dose and therapy failure 
All patients treated only with the initial dose of 1 mg midazolam (MD n=52, UD n=49) completed 
MRI examination. Additional administration of 1 mg midazolam (total administered dose of 2 mg) 
was required of total 17 patients (MD n=13, UD n=4). This additional midazolam dose was not 
judged as therapy failure, but if MRI examination was not possible or had to be interrupted the 
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therapy was declared as failed. Overall, therapy failed in 3 patients (MD n=2, UD n=1). All therapy 
failures occurred within patients receiving 2 mg midazolam. Acquired data of one patient of the 
treatment group was excluded from final analysis, because of protocol deviation (after nasal 
administration of 1 mg midazolam the patient has withdrawn his consent and desired intravenous 
anxiolysis). Due to protocol deviation (application of false medication) one patient of comparator 
group had to be excluded from final analysis. 
Final analysis was performed with data acquired from 105 patients, completing MRI examination 
(MD n=53, UD n=52). Figure 7-2 displays the number of enrolled, randomized, and excluded 
patients.  
 
Dropout (n=1)
i.v. anxiolysis
Therapy failure (n=1)
MRI not possible
Therapy failure (n=1)
MRI stopped
Therapy failure (n=1)
MRI not possible
Protocol deviation 
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+1mg midazolam
(n=4)
Final analysis (n=53)
Included (n=110)
(A: 30, B:25, C:25, D: 30)
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Comparator, UD (n=54)
1mg midazolam nasal
(UD, n=54)
VASbefore
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1mg midazolam nasal
(MD, n=56)
VASbefore
MRI examination
(n=12)
- VASafter
- Assessmet RT
- Image quality
MRI examination
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- VASafter
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- Image quality
MRI completed
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MRI examination
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- Image quality
MRI examination
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- VASafter
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- Image quality
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(n=49)
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Figure 7-2: Flow diagram of subject process through randomized study – evaluation of two 
preparations for nasal delivery of low-dose midazolam; enrolled n=110 (center A: 30, B: 25, C: 25, and 
D: 30); randomized n=110 (MD n=56, UD n=54); dropout n=1 (MD); protocol deviation n=1 (UD); therapy 
failure n=3 (MD n=2, UD n=1); additional dose n=17 (MD n=13, UD n=4); MRI completed n=105 (MD 
n=53, UD n=52), and final analysis n=105 (MD n=53, UD n=52). MD: multidose nasal spray (treatment), 
UD: unit dose nasal spray (comparator), VASbefore/after: Visual analog scale before and after MRI 
examination, RT: radiologic technician. 
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Patient experience and anxiety reduction 
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Figure 7-3: Reduction of anxiety in treatment 
(MD, n=53) and comparator group (UD, n=52). 
For both groups anxiety score assessed before 
medication was significant higher than score 
assessed after MRI examination. There was no 
difference in anxiety reduction between the two 
groups. VASb: VASbefore, VASa: VASafter, 
(*): significant (p<0.05), n.s: not significant 
(p>0.05),  
 
 
Anxiety score of all patients, who completed 
the MRI examination (n=105), are displayed 
in Figure 7-3. 
Between treatment and comparator group, 
there was no significant difference in anxiety 
score assessed before midazolam 
administration (VASbefore).  
In both groups (MD and UD) reduction of 
anxiety (VASbefore-VASafter) was significant 
(p<0.05). But, there was no significant 
difference of anxiety reduction between 
treatment (MD) and comparator group (UD). 
From 105 patients, who completed MRI 
examination, all but one indicated in the 
interview after the MRI examination less 
anxiety. Figure 7-4 displays anxiety score of 
all patients, receiving 1 mg or 2 mg 
midazolam by MD or UD application. 
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Figure 7-4: Anxiety score before midazolam administration (VASbefore) and after MRI examination 
(VASafter) of patients receiving 1 mg midazolam (MD n=42, UD n=49) and patients receiving 2 mg 
midazolam (MD n=11, UD n=3). Difference of anxiety reduction of all groups was not significant. 
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From 105 patients, who completed the MRI examination 94% (n=99; MD n=50, UD n=49) would 
agree to repeat the MRI examination with analog anxiolytic medication, they received as study 
medication. From patients, who would refuse to repeat the MRI examinations with the same 
anxiolytic medication, 2 were treated with 2 mg midazolam. 
Assessment of radiologic technician 
All completed MRI examinations (n=105, MD n=53, and UD n=52) were rated as normally 
accomplishable. In general, patients were judged as calm and cooperative during MRI proceedings 
(MD n=44 [85%] and UD n=47 [92%]), 8 patients were very anxious (MD 5 [9%], UD 3 [6%]) and no 
patient has fallen asleep during MRI examination. 
Image quality 
All completed MRI examinations (n=105, MD n=53, and UD n=52) generated image sets of 
excellent quality (MD n=36 [68%] and UD n=44 [85%]) or good quality (MD n=17 [32%]) and UD 
n=8 [15%]). No MRI image was of satisfying, poor, or very poor quality. All generated image sets 
were suitable for diagnosis. The difference of image rating between MD and UD group was not 
significant, see Figure 7-5. 
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Figure 7-5: Assessment of image quality (n=105, MD n=53, UD n=52). All MRI images were of excellent 
(MD n=36 [68%]) and UD n=44 [85%]) or good quality (MD n=17 [32%]) and UD n=8 [15%]). MRI image 
quality of all image sets (n=105) was suitable for diagnostics. 
 
7. Project III: Transmucosal nasal delivery of low-dose midazolam – evaluation of two preparations for procedural anxiolysis 
 
Katja Suter-Zimmermann Page 91 of 188 University of Basel, 2008 
 
Local irritation and adverse drug reactions 
Of total 110 patients receiving study medication, 53 patients (MD n=27 [48%], UD n=26 [52%]) 
spontaneously reported local irritation. Intensity of local irritation was rated as mild (MD n=22 
[39%], UD n=13 [24%]), moderate (MD n=5 [9%], UD n=9 [17%]), or strong (MD n=0, UD n=4 
[7%]), see Figure 7-6.  
Besides burning (burning in the nose MD n=14 [52%], UD n=15 [58%] and burning in the throat 
area MD n=3 [11%], UD n=1 [4%]), patients sporadically reported on watery eyes and coughing. 
Local irritation was reported to vanish within few minutes and never had to be treated.  
No severe adverse reaction occurred and hence flumazenil never had to be administered. Other 
mentioned discomfort (e.g., noise, pain in the back or hip) were related to the MRI examination or 
disease of the patient. 
 
 
Figure 7-6: Spontaneous reports on local irritation; in both groups 52% of the patients did not report 
on any local irritation. The intensity of the local irritation was rated as mild (MD: 39%, UD 24%), 
moderate (MD: 9%, UD: 17%), and strong (MD: 0%, UD: 7%). 
 
Monitoring 
Two months after study start, difficulties in patient recruitment in two study centers (B, C) were 
detected. Patients often admitted their fear only at the beginning or even during MRI examination. 
To avoid delay of day’s schedule, patients admitting their fear only during MRI examination, were 
not invited to enter the study and the routine anxiolytic treatment was offered. 
To call attention for the possibility of treatment options for claustrophobia and general anxiety, we 
designed posters and attached them in the waiting room of Centre B and C. 
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7.4 Discussion 
This multicenter trial was accomplished to compare two preparations for transmucosal nasal 
delivery of low-dose midazolam. This trial was implemented at three radiologic departments and 
one private radiologic institution. The indication of interest was procedural anxiolysis during MRI 
examinations. The purpose was to investigate therapeutic equivalence of the two preparations. 
Midazolam (oral, i.v., or nasal) is commonly used for procedural anxiolysis during MRI 
examinations. In several radiologic departments (e.g., Institute of Diagnostic Radiology, University 
Hospital Zurich Institute of Radiology, Kantonsspital Winterthur) midazolam nasal spray, prepared 
according to the monograph of NRF [NRF 2002], is routinely offered to anxious and/or 
claustrophobic patients for procedural anxiolysis. 
 
The presented study was designed to compare two preparations (today’s routine nasal spray MD 
and new UD nasal spray) and not for the quantitative assessment of efficacy in prevention of 
claustrophobia during MRI examinations. The design of a clinical trial to prove efficacy of nasal 
delivered low-dose midazolam in prevention of procedural anxiety and/or claustrophobia, is 
supposed to be randomized, placebo controlled, and preferably double blinded. For such a 
placebo-controlled study it would be essential, that the administration of the placebo nasal spray is 
identical concerning sensation of application and local irritation. 
For the present trial, blinding was not feasible, due to different shapes of the two nasal sprays (MD 
and UD nasal spray). Furthermore, the application characteristics were integral part of the 
comparison of the two nasal sprays. The only option for blinding would have been a double-dummy 
study design, and consequently simultaneous nasal administration with both nasal sprays: in 
treatment group midazolam by multidose nasal spray and placebo by unit dose nasal spray and in 
comparator group vice versa, placebo by multidose nasal spray and midazolam by unit dose nasal 
spray. But because of the limited volumetric capacity of the nose, double-dummy design is not 
reasonable for nasal administration of liquid preparations. Hence, doubled application volume 
(placebo and treatment or placebo and comparator) would certainly result in swallowing of the 
midazolam preparation diluted by placebo. 
 
Patients, self-assessing to be anxious and/or claustrophobic, were invited for participation in this 
trial with nasal midazolam. No standardized diagnostic tool was applied to identify claustrophobic 
patients. Intensity of anxiety and/or claustrophobia was rated by visual analog scale. McIsaac et al. 
assumed one single item to detect claustrophobia to be insufficient for predicting intense anxiety 
reactions during MRI examinations [Mc Isaac et al., 1998].  
An elaborate claustrophobia questionnaire (with 29 items) for diagnosis of claustrophobia was 
proposed by Randomsky et al. [Radomsky et al., 2001], but in day-to-day operations at radiologic 
departments interviewing patients by this extensive questionnaire is to time-consuming. To help 
anxious patients to complete MRI examinations successfully it is not necessary to conclusively 
diagnose their claustrophobia. Therefore, Mc Isaac et al. reduced the extensive claustrophobia 
questionnaire to 6 items and suggested this screening tool for the identification of patients who are 
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most likely to experience claustrophobic fear or panic during MRI examinations. But this reduced 
questionnaire has not been validated yet and therefore reliability is still unsettled. 
Because day’s schedule in radiologic departments is tight, the accomplishment of a clinical trial 
should not affect work flow. Therefore, to successfully run a clinical trial in clinical everyday life it is 
crucial to deliver well structured self-explanatory study material. The documentation should be as 
less time-consuming as possible. 
 
Schweizer et al. demonstrated in a pilot study the anxiolytic effect of low-dose midazolam (0.5-
1 mg) in prevention of panic reactions [Schweizer, et al. 1992]. In addition, nasal delivery of low-
dose midazolam proved to be efficient and safe for conscious sedation during MRI examinations 
[Tschirch, et al. 2006]. Nasally administered doses of 1 mg to 2 mg midazolam provided anxiolysis 
without sedation (i.e., conscious sedation) and therefore the patients were able to follow the 
instructions given during MRI examinations. Based on these findings for the present study the dose 
of 1 mg nasal midazolam (initial dose) was set with the possibility of delivering another 1 mg nasal 
midazolam if anxiolysis was not provided. 
 
The composition and the multidose delivery device of the test preparation 
(Midazolam MD Nasal Spray 5 mg/ml) refer to the commonly used midazolam nasal spray, 
prepared by the local hospital pharmacies. Complying with monograph for nasal preparations of 
Ph.Eur., this aqueous nasal preparation, supplied in multidose delivery systems, is preserved. The 
multidose nasal spray used in this trial, delivers 0.1 ml per pump. But for correct dosing at least 
1 ml preparation has to be filled into the delivery device. As for the administration of 1 mg to 2 mg 
midazolam only 0.2 ml to 0.4 ml are delivered, the major portion of the preparation is wasted. 
Furthermore, to get the multidose nasal spray ready for exact dosing, the pump needs to be 
prepared by pressing the pump several times previous to nasal administration. Preparing the pump 
inhalation of the atomized midazolam preparation is to be prevented. Since the upright position of 
the multidose nasal spay is essential for exact dosing, administration to lying patients is not 
possible. As used multidose nasal sprays do not look different from unused multidose nasal sprays, 
there is a certain risk for unhygienic multiple application to different patients. 
The comparator (Midazolam UD Nasal Spray 1 mg) is supplied in a single-dose delivery device and 
is preservative-free. The dose of 1 mg midazolam is delivered within 0.1 ml by one-sided 
administration. For the administration of an additional dose, 0.1 ml is sprayed into the opposite 
nostril by applying a second unit dose nasal spray. The unit dose nasal spray system contains 
0.125 ml nasal preparation, thereof 0.1 ml is delivered independent of the position. Therefore, the 
unit dose system allows nasal administration of the anxiolytic treatment directly to patients lying on 
MRI table, ready to be introduced into the MRI tunnel. As often patients declare their anxiety only at 
the moment they are introduced into the MRI tunnel, administration independent of position is 
advantageous.  
Many patients presenting to radiologists for MRI examination admit anxiety and/or claustrophobia, 
but only few of them are willing to participate in a clinical trial. Finally, 110 patients gave consent to 
enter the trial with nasal midazolam. One patient dropped out because of withdrawal of consent. 
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Due to his excellent experiences with i.v. anxiolysis during a former MRI examination, after 
administration of the initial nasal dose of midazolam he requested i.v. application of an anxiolytic 
treatment. 
Generally, if anxiolysis of the initial treatment with 1 mg midazolam (MD or UD) was not sufficient to 
perform MRI examination, one additional dose of 1 mg midazolam was administered. 
All patients, refusing or interrupting the MRI examinations (therapy failures, n=3) were treated with 
2 mg midazolam. Probably in these cases, diffuse anxiety and/or claustrophobia were too intense 
to be cured with low-doses of midazolam (1-2 mg). But due to small number of patients requiring 
2 mg midazolam, statistical analysis of the intensity of anxiety is not reasonable. 
Acquired data of one patient had to be excluded from final analysis, because of protocol deviation. 
This patient of the comparator group was initially treated with UD nasal spray but the additional 
dose was administered by MD nasal spray. 
As anxious patients are generally agitated they tend to move during MRI examination impairing 
image quality by generating motion artifacts. In a prospective double-blind placebo controlled 
randomized trial Hollenhorst et al. demonstrated significant reduction of MRI related anxiety in 
patients receiving nasal midazolam, and the reported anxiety reduction correlated with improved 
image quality. In the present multicenter study with nasal midazolam, overall 91 patients (MD n=42 
and UD n=49) were treated 1 mg nasal midazolam (initial dose). All of them successfully completed 
MRI examination and the generated MRI images were of good or even excellent quality.  
No patient fell asleep and therefore all patients were able to appropriately respond to instructions 
given during MRI examination. All MRI examinations were rated as normally feasible by radiologic 
technician. Beside local irritation for both tested midazolam nasal spray no adverse drug reaction 
was reported. 
The parameters to assess the benefit of nasal anxiolysis for anxious patients undergoing MRI 
examination were: anxiety score before medication and after completing of the MRI examination, 
tolerance of nasal administration, local irritation, and willingness to repeat the MRI examination with 
the analog medication receiving in the study. 
Regarding subjective anxiety reduction, willingness to repeat the procedure, and diagnostic image 
quality, the tested nasal sprays (MD and UD) were equivalent. Concerning convenience of 
administration (i.e., delivery independent of position) and hygienic security UD nasal spray was 
rated as superior to MD nasal spray.  
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7.5 Conclusions 
Nasal delivery of low-dose midazolam is a safe therapy to provide procedural anxiolysis in patients 
undergoing MRI examinations. 
The two compared midazolam preparations for transmucosal nasal delivery of low-dose midazolam 
showed therapeutic equivalence. Hence, anxious and/or claustrophobic patients equally benefit 
from procedural anxiolysis during MRI examinations provided by administration of low-dose 
midazolam with MD nasal spray or UD nasal spray. 
Concerning convenient handling, administration, and hygienic aspects the new midazolam nasal 
spray (UD) is superior to the commonly used midazolam multidose nasal spray (MD). 
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8 Overall discussion 
The objectives of this thesis were to provide preparations for transmucosal nasal midazolam 
delivery (Project I), to assess the pharmacokinetic characteristics of nasally applied midazolam 
(Project II), and to compare the benefit of two nasal midazolam preparations for procedural 
anxiolysis in anxious patients undergoing MRI examinations (Project III).  
 
Pharmacokinetic parameters of nasally delivered drugs depend on many-sided interactions of 
different preparation and administration related parameters. If the nasally delivered volumes 
exceed the recommended volume of about 0.2 ml per nostril, little viscous preparations tend to flow 
in the nasopharynx and are swallowed. To compare the outcome of different pharmacokinetic trials 
on nasal drug delivery, the nasally administered volumes need to be regarded. In foregoing 
research on nasal midazolam delivery the commercially available midazolam preparation for i.v. 
use (Dormicum® 5 mg/ml) has been instilled into the nostrils, and often the doses (i.e., the 
administered volumes) exceeded the volumetric capacity of the nose (see Appendix 10.1.1). 
Therefore, published pharmacokinetic characteristics of nasal midazolam delivery often refer to a 
combination of transmucosal nasal and gastrointestinal drug absorption [Burstein, et al. 1997]. 
To study exclusive transmucosal nasal midazolam delivery, not falsified by gastrointestinal 
absorption of the swallowed portion, nasal midazolam preparations adapted to the limited nasal 
capacity were developed (Project I). Addition of RMβCD facilitated compounding of aqueous 
preparations with high midazolam concentrations (up to 30 mg/ml midazolam base). This allowed 
administration of therapeutic doses (1 mg to 6 mg midazolam) by nasal application of a minimized 
volume (0.1 ml per nostril). Since systemic bioavailability of nasally applied midazolam was 86% to 
93%, nasal administration of 6 mg midazolam corresponds to about 5 mg i.v. administered 
midazolam. Hence, the range of midazolam doses (1 mg to 6 mg midazolam), delivered by the 
presented nasal midazolam preparations (Preparation 1 to 5), facilitates nasal midazolam 
administration to provide different dose related effects (e.g., anxiolysis, sedation, or 
anticonvulsion). 
 
High midazolam concentrations and thus reduction of nasal administration volumes successfully 
prevented swallowing of nasally administered preparations (Project II). The profile of midazolam 
metabolites (α-hydroxymidazolam and 4-hydroxymidazolam) demonstrated effective by-passing of 
first-pass effect and hence exclusive transmucosal nasal absorption of nasally applied midazolam. 
Consequently, transmucosal nasal midazolam delivery (bioavailability 86% to 93%) proved higher 
systemic bioavailability than oral midazolam delivery (bioavailability 30% to 50% [Documed 2006]).  
Pharmacokinetic parameters assessed for transmucosal nasal midazolam delivery proved 
comparable characteristics as pharmacokinetics following i.v. administration of midazolam. Hence, 
transmucosal nasal delivered midazolam demonstrated suitable administration and 
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pharmacokinetic characteristics to provide midazolam therapy in clinical situations where common 
drug delivery methods (e.g., i.v. or i.m. administration) are inappropriate but fast onset of 
therapeutic effect is required (e.g., anticonvulsive treatment of status epilepticus). 
In particular, the tested chitosan hydrochloride containing nasal midazolam preparation 
(Preparation 5) demonstrated fast increasing of midazolam serum concentration providing maximal 
midazolam serum concentrations within 7.1 ± 0.6 minutes (range tmax 1.9 min). These findings are 
in accordance with the data published by Illum demonstrating chitosan to promote nasal absorption 
of morphine [Illum, et al. 2002]. Furthermore, nasal morphine preparations containing chitosan 
provided fast onset of therapeutic effect in the treatment of breakthrough pain in cancer patients 
[Pavis, et al. 2002]. As well as therapy of breakthrough pain, treatment of seizures (epileptic or 
febrile) is also a clinical situation where drug administration is difficult and fast onset of therapeutic 
effect is urgently needed.  
Chitosan containing nasal midazolam preparation (Preparation 5) showed most promising 
pharmacokinetic characteristics for the treatment of seizures. Providing anticonvulsive therapy by 
nasal administration of midazolam the local irritation is of secondary importance compared to the 
enormous benefit of this needle-free drug delivery option featuring rapid onset of therapeutic effect. 
However, to elongate shelf life and to reduce local irritation further optimization of chitosan 
containing nasal midazolam preparations is required. 
The performed pharmacodynamic testing during Project II (VAS and CRTT) assessed volunteer’s 
attention and their ability to respond. These tests aimed predicting the time needed to restore 
fitness to drive after procedural anxiolysis with nasally applied midazolam. However, for the 
quantification of the anticonvulsive effects of nasally delivered midazolam more specific 
pharmacodynamic characterization needs to be performed (e.g., electroencephalogram).  
 
To assess the anxiolytic effects of benzodiazepines in healthy volunteers, different testing methods 
have been described in literature [Visser et al., 2003]. But no testing method is specific enough to 
differentiate sedating from anxiolytic effects. Anxiety and panic during MRI examinations is 
impossible to be simulated, since these phenomena involve different components (e.g., fear of 
enclosed places, pain, the unknown situation, as well as apprehension about what the test might 
reveal) [Katz, et al. 1994]. Consequently, evaluation of therapeutic equivalence of two nasal 
midazolam preparations was accomplished with anxious and/or claustrophobic patients undergoing 
MRI examinations and not with healthy volunteers (multicenter trial, Project III).  
Therapeutic equivalence of multidose nasal spray (MD, Preparation 1) and unit dose nasal spray 
(UD, Preparation 3) demonstrated in Project III is in accordance with the congruent serum 
concentrations time profiles attesting bioequivalence for these two preparations. 
However, less required additional doses (total administration of 2 mg midazolam) in the comparator 
group (UD, Preparation 3) cannot be explained by serum concentration time profiles. Drug 
administration with the unit dose system (UD, Preparation 3) is mostly a new experience for the 
patients, while nasal drug administration with the multidose nasal spray (MD, Preparation 1) 
resembles ordinary nasal delivery of common decongestants for the treatment of rhinitis. The 
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unusual application experience may have influenced the subjective assessment of therapeutic 
effect. 
 
As the impact of cyclodextrin derivatives on drug release and absorption kinetics (in vivo) is 
controversially discussed in literature, midazolam was nasally delivered without RMβCD 
(Preparation 1) and with equimolar RMβCD (Preparation 2). In aqueous solutions maximal 5 mg/ml 
midazolam (base) can be solubilized by dissolving midazolam hydrochloride. Therefore, the impact 
of RMβCD on pharmacokinetics of nasally applied midazolam was studied at the concentration of 
5 mg/ml midazolam base (Preparation 1 and Preparation 2). This midazolam concentration is equal 
to Dormicum® 5 mg/ml and only adequate for transmucosal delivery of low-dose midazolam. 
RMβCD, added in equimolar amounts to midazolam, demonstrated neither penetration enhancing 
nor penetration inhibiting effects on transmucosal nasal delivered midazolam. RMβCD proved to be 
an adequate solubilizer in preparations for transmucosal nasal midazolam delivery. 
Bioequivalence was confirmed for all tested nasal administration modalities for nasal delivery of 
1 mg midazolam (Project II). According to Fick’s first law, absorption of 1 mg nasal delivered 
midazolam following nasal administration of half concentration (5 mg/ml) on doubled application 
area (two-sided administration) was equivalent with one-sided administration of doubled midazolam 
concentration (10 mg/ml, Preparation 3). Hence, transmucosal nasal midazolam absorption 
demonstrated direct proportionality to (total) midazolam concentration and to the application area.  
Unlike in vivo midazolam absorption (Project II), in vitro midazolam release was reduced by 
equimolar RMβCD (Project I): doubled midazolam concentration (solubilized with equimolar 
amount of RMβCD) did not result in doubled midazolam release from the donor compartment into 
the receptor compartment (in vitro). Apparently, not the total midazolam but the free midazolam 
concentration determined midazolam release in vitro.  
In the nasal cavities (in vivo) there are a lot of molecules (components of the mucus layer or of the 
cell surfaces) potentially interfering with the cyclodextrin-drug complexes. Therefore, midazolam 
release in vivo is probably facilitated by competitive displacement of complexed midazolam 
molecules [Stella, et al. 1999]. 
The in vitro drug release studies showed different midazolam release for midazolam preparations 
with RMβCD (equimolar) and without RMβCD. However, overall transmucosal nasal midazolam 
uptake, resulting of midazolam release, penetration, and permeation processes, did not reflect the 
differences of midazolam release observed in vitro (Project I). Apparently, in vitro drug release 
studies revealed differences in midazolam release, that in vivo were of inferior importance. Thus, 
drug release studies were not reliable models to predict absorption kinetics of nasally applied 
midazolam preparations. 
 
Osmolality of all proposed preparations for transmucosal nasal midazolam delivery was adjusted to 
physiologic conditions. For preparation proposed by Roelofse et al., containing 20% of βCD to 
solubilize 10 mg/ml midazolam, pH was 5.8. But as this preparation showed reduced systemic 
midazolam bioavailability following nasal administration, adding of excess cyclodextrin was 
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considered as unfavorable. Consequently, by applying only equimolar amounts of RMβCD (2%, 
4%, and 12% to solubilize 5 mg/ml, 10 mg/ml, and 30 mg/ml midazolam) the pH of the nasal 
preparations could not be adapted to physiologic pH due to limited midazolam solubility. Despite 
low pH of the tested preparations (pH 3 to 4), no volunteer did rate the nasal administration as 
painful and nasal irritation was reversible within 30 minutes. 
As the proposed preparations are not supposed for long term therapies but for sporadic application 
(e.g., treatment of status epilepticus and procedural anxiolysis or sedation) some reversible local 
irritation may be tolerable.  
 
For transmucosal nasal drug delivery there is no recommendation whether the dose is preferably 
administered one-sided or two-sided. Commercially available nasal preparations for systemic 
treatment (e.g., Zomig® nasal, AstraZeneca, Zug, Switzerland) are supplied in unit dose systems 
for one-sided administration. The blood vessels inside the lining of the nose become engorged in a 
cyclic fashion, which causes congestion and then decongestion of the linings of each side of the 
nose. This so-called ‘nasal cycle’ is detectable in about 80% of the population [Hasegawa and Kern 
1977]. The impact of this nasal cycle on transmucosal nasal drug delivery is unknown. Against this 
background two-sided nasal drug delivery may be preferable even though one-sided and two-sided 
nasal administration of a given midazolam dose (1 mg) resulted in identical serum concentration 
time profiles.  
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9 Final conclusions 
The developed midazolam preparations presented in this thesis facilitated pharmacokinetic 
characterization of nasally applied midazolam. Reduction of nasal administration volumes 
successfully prevented swallowing of nasally applied preparations. Consequently, the assessed 
pharmacokinetic parameters described exclusive transmucosal nasal midazolam absorption not 
biased by gastrointestinal midazolam uptake. Midazolam metabolites serum concentration profiles 
following nasal midazolam delivery, demonstrated efficient avoidance of first-pass effect. 
Pharmacokinetics of nasally applied midazolam was not adversely affected by equimolar amounts 
of RMβCD to solubilize midazolam. Chitosan hydrochloride promoted transmucosal nasal 
absorption of nasally applied midazolam. Transmucosal nasal midazolam delivery is a convenient 
needle-free drug administration option and demonstrated pharmacokinetic characteristics to 
provide fast onset of therapeutic effects. Pharmacokinetic characteristics predestine chitosan 
containing midazolam preparations for transmucosal nasal midazolam delivery to provide fast 
onset of therapeutic effect. 
High systemic bioavailability of nasally applied midazolam demonstrated the veritable potential of 
transmucosal nasal drug delivery as alternative to invasive drug administration. 
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10.1.1 Pharmacokinetic data of nasally applied midazolam (previous studies) 
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10.2 Project I 
10.2.1 Ratio of cyclodextrin-midazolam complexes 
 
HPbCD Midazolam HPgCD Midazolam RMbCD Midazolam
Molecular weitht (g/mol) 1400 326 1576 326 1310 326
Concentration % 10 10 10
Concentration (mg/ml) 26.2 40.8 33.1
Concentration (g/L) 100.0 26.2 100.0 40.8 100.0 33.1
Concentration (mol/L) 0.07 0.08 0.06 0.13 0.08 0.10
Ratio 1.00 1.13 1.00 1.97 1.00 1.33
HPbCD-Midazolam HPgCD-Midazolam RMbCD-Midazolam
 
 
10.2.2 Accelerated stability testing: Preparation 3 (10 mg/ml) 
 
concentration content concentration content concentration content concentration content
[mg/ml] [%] [mg/ml] [%] [mg/ml] [%] [mg/ml] [%]
0 10.2 100 10.2 100 10.2 100 10.2 100
3 10.4 102 10.8 105 10.2 101 10.1 105
6 11.1 109 10.2 100 9.8 96 9.9 100
9 11.8 116 11.7 115 11.8 115 9.9 115
12 10.0 98 10.0 98 10.2 100 10.0 98
15 10.3 101 10.0 98 9.7 95 10.0 98
18 9.8 96 10.1 99 10.3 101 10.2 99
21 9.8 96 10.2 100 10.2 100 10.1 100
24 9.7 96 10.0 98 10.2 100 10.3 98
27 9.8 96 10.2 100 10.0 98 10.1 100
30 9.9 97 10.1 99 10.3 101 10.1 99
50°C 60°C
day
room temperature 40°C
 
Tage pH color precipitation pH color precipitation pH color precipitation pH color precipitation
0 4.0 colorless no 4.0 colorless no 4.0 colorless no 4.0 colorless no
3 4.0 colorless no 4.0 colorless no 4.0 colorless no 4.0 colorless no
6 4.0 colorless no 4.0 colorless no 4.0 colorless no 4.0 colorless no
9 3.9 colorless no 4.0 colorless no 3.9 colorless no 4.0 colorless no
12 4.0 colorless no 4.0 colorless no 4.0 colorless no 4.0 colorless no
15 4.0 colorless no 4.0 colorless no 4.0 colorless no 4.0 colorless no
18 4.0 colorless no 4.0 colorless no 4.0 colorless no 4.0 colorless no
21 4.0 colorless no 4.0 colorless no 4.0 colorless no 4.0 colorless no
24 4.0 colorless no 4.0 colorless no 4.0 colorless no 4.0 colorless no
27 4.0 colorless no 4.0 colorless no 4.0 colorless no 4.0 colorless no
30 4.0 colorless no 4.0 colorless no 4.0 colorless no 4.0 colorless no
room temperature 40°C 50°C 60°C
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10.2.3 Accelerated stability testing: Preparation 4 (30 mg/ml) 
 
 
concentration content concentration content concentration content concentration content
[mg/ml] [%] [mg/ml] [%] [mg/ml] [%] [mg/ml] [%]
0 30.0 100 30.0 100 30.0 100 30.0 100
3 30.0 100 29.6 99 30.6 102 30.6 102
6 29.3 98 27.7 92 29.7 99 29.5 98
9 30.6 102 30.5 102 30.0 100 30.1 100
12 29.8 99 29.7 99 30.8 103 30.1 100
15 29.7 99 30.5 102 29.5 98 29.5 98
18 30.1 100 30.7 102 30.1 100 30.3 101
21 30.7 102 30.0 100 30.3 101 29.9 100
24 30.5 102 30.3 101 30.2 101 30.4 101
27 30.2 101 30.6 102 30.3 101 29.8 99
30 30.2 101 30.2 101 30.8 103 30.4 101
room temperature 40°C 50°C 60°C
day
 
Tage pH color precipitation pH color precipitation pH color precipitation pH color precipitation
0 3.7 colorless no 3.7 colorless no 3.7 colorless no 3.7 colorless no
3 3.7 colorless no 3.7 colorless no 3.7 colorless no 3.7 colorless no
6 3.7 colorless no 3.7 colorless no 3.7 colorless no 3.7 colorless no
9 3.7 colorless no 3.7 colorless no 3.7 yellowish no 3.7 yellowish no
12 3.7 colorless no 3.7 colorless no 3.7 yellowish no 3.7 yellowish no
15 3.7 colorless no 3.7 colorless no 3.7 yellowish no 3.7 yellowish no
18 3.7 colorless no 3.7 colorless no 3.7 yellowish no 3.7 yellowish no
21 3.7 colorless no 3.7 colorless no 3.7 yellowish no 3.7 yellowish no
24 3.7 colorless no 3.7 colorless no 3.7 yellowish no 3.7 yellowish no
27 3.7 colorless no 3.7 colorless no 3.7 yellowish no 3.6 yellowish no
30 3.7 colorless no 3.7 colorless no 3.7 yellowish no 3.7 yellowish no
room temperature 40°C 50°C 60°C
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10.2.4 Specification: Midazolam UD Nasal Spray 0.5mg (Preparation 1a) 
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10.2.5 Specification: Midazolam MD Nasal Spray 5mg/ml (Preparation 1b) 
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10.2.6 Specification: Cyclodex-Midazolam UD Nasal Spray 0.5mg (Preparation 2) 
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10.2.7 Specification: Cyclodex-Midazolam UD Nasal Spray 1mg (Preparation 3) 
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10.2.8 Specification: Cyclodex-Midazolam UD Nasal Spray 3mg (Preparation 4) 
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10.2.9 Specification: Chitosan-CD-Midazolam UD Nasal Spray 3mg (Preparation 5) 
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10.2.10 Stability report 10 months: Midazolam MD Nasal Spray 5mg/ml 
(Preparation 1b) 
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10.2.11  Stability report 10 months: Cyclodex-Midazolam UD Nasal Spray 1mg 
(Preparation 3) 
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10.2.12 Stability report 6 months: Midazolam UD Nasal Spray 0.5mg (Preparation 1) 
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10.2.13 Stability report 6 months: Cyclodex-Midazolam UD Nasal Spray 0.5mg 
(Preparation 2) 
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10.2.14 Stability report 6 months:  Cyclodex-Midazolam UD Nasal Spray 3mg 
(Preparation 4) 
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10.2.15 Stability report 6 months: Chitosan-CD-Midazolam UD Nasal Spray 3mg 
(Preparation 5) 
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Project II 
10.3.1 Study protocol (without appendix) 
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10.3.2 Case report form: Visit 1 (screening) 
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1.3.3 Case report form: Visit 2 to 7 (study day) 
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10.3.4 Case report form: Visit 8 (follow-up) 
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10.3.7 Serumconcentration of midazolam and main metabolites (original data) 
 
Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L] Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L]
1-V2-t0 nn nn nn 1-V3-t0 nn nn nn
1-V2-t1 107.4 nn nn 1-V3-t1 nn nn nn
1-V2-t2 46.1 nn nn 1-V3-t2 3.6 nn nn
1-V2-t3 25.2 <0.2 nn 1-V3-t3 14.8 nn nn
1-V2-t4 16.5 0.5 nn 1-V3-t4 18.8 <0.2 nn
1-V2-t5 15.8 0.4 nn 1-V3-t5 13.8 0.3 nn
1-V2-t6 15.5 0.5 nn 1-V3-t6 10.7 0.6 nn
1-V2-t7 13.2 0.9 <0.2 1-V3-t7 8.6 0.9 nn
1-V2-t8 11.0 1.0 <0.2 1-V3-t8 7.4 1.2 <0.2
1-V2-t9 8.0 0.9 nn 1-V3-t9 6.9 0.8 nn
1-V2-t10 5.0 0.6 <0.2 1-V3-t10 4.0 0.7 <0.2
1-V2-t11 3.0 0.6 <0.2 1-V3-t11 3.0 0.6 nn
1-V2-t12 2.0 0.3 nn 1-V3-t12 2.0 0.5 nn
1-V2-t13 0.9 0.2 nn 1-V3-t13 0.9 0.2 nn
Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L] Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L]
1-V4-t0 nn nn nn 1-V5-t0 nn nn nn
1-V4-t1 nn nn nn 1-V5-t1 nn nn nn
1-V4-t2 9.2 nn nn 1-V5-t2 6.6 nn nn
1-V4-t3 19.8 nn nn 1-V5-t3 15.5 nn nn
1-V4-t4 23.0 nn nn 1-V5-t4 18.8 <0.2 nn
1-V4-t5 17.7 0.4 nn 1-V5-t5 16.3 0.3 nn
1-V4-t6 14.9 0.9 <0.2 1-V5-t6 12.5 0.6 nn
1-V4-t7 10.2 1.2 <0.2 1-V5-t7 10.1 0.9 <0.2
1-V4-t8 7.4 0.9 <0.2 1-V5-t8 8.6 1.0 nn
1-V4-t9 6.7 1 <0.2 1-V5-t9 7.1 1.1 <0.2
1-V4-t10 3.7 0.8 <0.2 1-V5-t10 4.1 0.8 <0.2
1-V4-t11 2.2 0.5 nn 1-V5-t11 2.3 0.4 <0.2
1-V4-t12 1.6 0.4 nn 1-V5-t12 1.9 0.3 nn
1-V4-t13 0.6 0.3 nn 1-V5-t13 0.8 0.2 nn
Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L] Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L]
1-V6-t0 nn nn nn 1-V7-t0 nn nn nn
1-V6-t1 nn nn nn 1-V7-t1 nn nn nn
1-V6-t2 4.3 nn nn 1-V7-t2 31.7 nn nn
1-V6-t3 12.8 nn nn 1-V7-t3 61.0 nn nn
1-V6-t4 38.9 <0.2 nn 1-V7-t4 65.7 0.5 nn
1-V6-t5 39.9 0.6 nn 1-V7-t5 47.5 1.5 <0.2
1-V6-t6 29.8 1.5 <0.2 1-V7-t6 35.1 2.6 0.3
1-V6-t7 41.7 2.4 0.2 1-V7-t7 27 3.2 0.4
1-V6-t8 27.1 3.5 0.4 1-V7-t8 23.8 3.0 0.4
1-V6-t9 29.2 3.5 0.4 1-V7-t9 18.0 3.0 0.4
1-V6-t10 19.4 3.2 0.4 1-V7-t10 10.5 2.2 0.3
1-V6-t11 10.8 2.3 0.4 1-V7-t11 7.3 1.5 0.3
1-V6-t12 8.0 1.7 0.3 1-V7-t12 5.6 1.3 0.3
1-V6-t13 2.5 0.7 <0.2 1-V7-t13 2.2 0.6 <0.2
Preparation 4 (3mg midazolam) Preparation 5 (3mg midazolam)
Subject 1:  midazolam and metabolites serum concentrations
Dormicum i.v. (1mg midazolam) Preparation 1 (1mg midazolam)
Preparation 2 (1mg midazolam) Preparation 3 (1mg midazolam)
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Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L] Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L]
3-V2-t0 nn nn nn 3-V3-t0 nn nn nn
3-V2-t1 145.6 nn nn 3-V3-t1 1.1 nn nn
3-V2-t2 66.8 <0.2 nn 3-V3-t2 6.4 nn nn
3-V2-t3 42.8 0.7 nn 3-V3-t3 25.7 nn nn
3-V2-t4 33.8 3.3 <0.2 3-V3-t4 37.5 0.2 nn
3-V2-t5 26 3.2 0.2 3-V3-t5 39.9 1 nn
3-V2-t6 22.6 3 0.2 3-V3-t6 34.8 1.8 <0.2
3-V2-t7 17 2.8 0.2 3-V3-t7 25.3 2.2 0.2
3-V2-t8 12.0 2.3 0.2 3-V3-t8 16.2 2 <0.2
3-V2-t9 10.2 1.8 <0.2 3-V3-t9 13.5 1.6 <0.2
3-V2-t10 5.8 0.9 <0.2 3-V3-t10 8.2 1.1 <0.2
3-V2-t11 4.6 0.9 <0.2 3-V3-t11 4.9 0.8 <0.2
3-V2-t12 2.7 0.4 nn 3-V3-t12 3.4 0.6 <0.2
3-V2-t13 1.2 0.2 nn 3-V3-t13 1.9 0.3 nn
Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L] Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L]
3-V4-t0 nn nn nn 3-V5-t0 nn nn nn
3-V4-t1 nn nn nn 3-V5-t1 nn nn nn
3-V4-t2 7.7 nn nn 3-V5-t2 2.5 nn nn
3-V4-t3 22.9 nn nn 3-V5-t3 11.9 nn nn
3-V4-t4 29.1 0.3 nn 3-V5-t4 24.1 nn nn
3-V4-t5 33.5 1.1 nn 3-V5-t5 24.9 0.3 nn
3-V4-t6 28.6 1.9 <0.2 3-V5-t6 27.1 0.7 nn
3-V4-t7 28.1 2.8 <0.2 3-V5-t7 25.5 1.4 <0.2
3-V4-t8 16.2 2.7 <0.2 3-V5-t8 19.1 1.8 <0.2
3-V4-t9 13.2 2.4 0.2 3-V5-t9 12.6 1.7 <0.2
3-V4-t10 7.9 1.7 <0.2 3-V5-t10 7.8 1.2 <0.2
3-V4-t11 4.6 1 <0.2 3-V5-t11 5.6 0.8 <0.2
3-V4-t12 3.6 0.8 <0.2 3-V5-t12 3.6 0.5 <0.2
3-V4-t13 2 0.5 nn 3-V5-t13 1.7 0.5 nn
Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L] Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L]
3-V6-t0 nn nn nn 3-V7-t0 nn nn nn
3-V6-t1 <0.5 nn nn 3-V7-t1 nn nn nn
3-V6-t2 9.4 nn nn 3-V7-t2 16.8 nn nn
3-V6-t3 41 nn nn 3-V7-t3 91.1 nn nn
3-V6-t4 88.5 0.6 nn 3-V7-t4 102.8 0.8 nn
3-V6-t5 89.8 2.2 0.2 3-V7-t5 71.9 2.5 <0.2
3-V6-t6 80.1 4.2 0.4 3-V7-t6 66.4 4 0.3
3-V6-t7 57.7 6.5 0.6 3-V7-t7 49.8 4 0.3
3-V6-t8 44.6 6.1 0.6 3-V7-t8 36.3 4.5 0.4
3-V6-t9 35.2 6 0.6 3-V7-t9 28.3 4.3 0.4
3-V6-t10 21.6 4.4 0.6 3-V7-t10 20.2 3 0.3
3-V6-t11 14.3 2.5 0.4 3-V7-t11 12.2 2.1 0.3
3-V6-t12 10.8 1.9 0.3 3-V7-t12 8.3 1.4 0.2
3-V6-t13 5.9 1.3 0.2 3-V7-t13 5.9 0.8 <0.2
Preparation 4 (3mg midazolam) Preparation 5 (3mg midazolam)
Subject 3:  midazolam and metabolites serum concentrations
Dormicum i.v. (1mg midazolam) Preparation 1 (1mg midazolam)
Preparation 2 (1mg midazolam) Preparation 3 (1mg midazolam)
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Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L] Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L]
4-V2-t0 nn nn nn 4-V3-t0 nn nn nn
4-V2-t1 198.8 nn nn 4-V3-t1 nn nn nn
4-V2-t2 54.3 nn nn 4-V3-t2 5.4 nn nn
4-V2-t3 29.2 0.5 nn 4-V3-t3 15.8 nn nn
4-V2-t4 24.9 1.9 <0.2 4-V3-t4 23.1 <0.2 nn
4-V2-t5 17.9 2.2 <0.2 4-V3-t5 18.7 0.5 nn
4-V2-t6 19 1.9 <0.2 4-V3-t6 18.1 0.8 nn
4-V2-t7 14.8 1.7 <0.2 4-V3-t7 12.7 1.2 <0.2
4-V2-t8 11.8 1.5 <0.2 4-V3-t8 9.9 1.3 <0.2
4-V2-t9 9.3 1.3 <0.2 4-V3-t9 6.6 1.5 <0.2
4-V2-t10 4.8 0.8 <0.2 4-V3-t10 4.3 0.8 <0.2
4-V2-t11 3.4 0.5 <0.2 4-V3-t11 3.5 0.6 <0.2
4-V2-t12 2.4 0.4 nn 4-V3-t12 2.3 0.4 nn
4-V2-t13 1.3 <0.2 nn 4-V3-t13 1.5 0.4 nn
Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L] Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L]
4-V4-t0 nn nn nn 4-V5-t0 nn nn nn
4-V4-t1 nn nn nn 4-V5-t1 nn nn nn
4-V4-t2 8.6 nn nn 4-V5-t2 6.4 nn nn
4-V4-t3 21 nn nn 4-V5-t3 15.8 nn nn
4-V4-t4 29.2 <0.2 nn 4-V5-t4 30.7 0.2 nn
4-V4-t5 25.6 0.5 nn 4-V5-t5 30.1 0.7 nn
4-V4-t6 25.2 0.7 nn 4-V5-t6 24.7 1.3 <0.2
4-V4-t7 20.8 1.1 <0.2 4-V5-t7 20 2.5 <0.2
4-V4-t8 15.5 1.2 <0.2 4-V5-t8 13.4 2.1 0.2
4-V4-t9 11.7 1 <0.2 4-V5-t9 10 1.5 0.2
4-V4-t10 7.4 0.8 <0.2 4-V5-t10 5.4 0.8 <0.2
4-V4-t11 4.7 0.5 <0.2 4-V5-t11 3.1 0.6 <0.2
4-V4-t12 3.2 0.5 <0.2 4-V5-t12 2.6 0.4 <0.2
4-V4-t13 1.8 0.3 nn 4-V5-t13 1 0.2 <0.2
Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L] Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L]
4-V6-t0 nn nn nn 4-V7-t0 nn nn nn
4-V6-t1 nn nn nn 4-V7-t1 nn nn nn
4-V6-t2 10.6 nn nn 4-V7-t2 1.9 nn nn
4-V6-t3 43 nn nn 4-V7-t3 72.1 nn nn
4-V6-t4 56.2 0.3 nn 4-V7-t4 66.4 1 nn
4-V6-t5 55.3 1.2 <0.2 4-V7-t5 65.6 4 0.3
4-V6-t6 61.8 2.3 0.3 4-V7-t6 62.1 6.8 0.5
4-V6-t7 49.5 3.4 0.4 4-V7-t7 37.2 6.4 0.6
4-V6-t8 35.5 3.5 0.4 4-V7-t8 23 4.4 0.4
4-V6-t9 31.1 3.7 0.5 4-V7-t9 22.1 4.6 0.5
4-V6-t10 16.1 2.4 0.4 4-V7-t10 13.4 3 0.4
4-V6-t11 11.4 1.8 0.4 4-V7-t11 9 1.9 0.3
4-V6-t12 8.8 1.2 0.3 4-V7-t12 5.7 1.3 0.3
4-V6-t13 3.8 0.6 <0.2 4-V7-t13 3.1 0.7 <0.2
Preparation 4 (3mg midazolam) Preparation 5 (3mg midazolam)
Subject 4:  midazolam and metabolites serum concentrations
Dormicum i.v. (1mg midazolam) Preparation 1 (1mg midazolam)
Preparation 2 (1mg midazolam) Preparation 3 (1mg midazolam)
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Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L] Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L]
6-V2-t0 nn nn nn 6-V3-t0 nn nn nn
6-V2-t1 15.4 nn nn 6-V3-t1 nn nn nn
6-V2-t2 61 nn nn 6-V3-t2 9.8 nn nn
6-V2-t3 32.5 nn nn 6-V3-t3 21.9 nn nn
6-V2-t4 23.4 0.7 nn 6-V3-t4 27.1 0.2 nn
6-V2-t5 20.1 1.5 nn 6-V3-t5 20.7 0.7 nn
6-V2-t6 17.2 1.5 <0.2 6-V3-t6 18.2 1.3 <0.2
6-V2-t7 15.9 1.5 <0.2 6-V3-t7 13.5 1.5 <0.2
6-V2-t8 12.1 1.5 <0.2 6-V3-t8 9.5 1.5 <0.2
6-V2-t9 10.7 1.4 <0.2 6-V3-t9 8.3 1.5 <0.2
6-V2-t10 6.5 1 <0.2 6-V3-t10 5.3 1.1 <0.2
6-V2-t11 4.0 0.7 <0.2 6-V3-t11 3.0 0.7 nn
6-V2-t12 2.7 0.5 nn 6-V3-t12 2.1 0.5 nn
6-V2-t13 1.2 0.2 nn 6-V3-t13 0.8 0.2 nn
Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L] Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L]
6-V4-t0 nn nn nn 6-V5-t0 nn nn nn
6-V4-t1 nn nn nn 6-V5-t1 2.6 nn nn
6-V4-t2 8.7 nn nn 6-V5-t2 10.4 nn nn
6-V4-t3 28.6 nn nn 6-V5-t3 16.2 nn nn
6-V4-t4 37.9 <0.2 nn 6-V5-t4 17.1 nn nn
6-V4-t5 28.2 0.5 nn 6-V5-t5 26.5 0.2 nn
6-V4-t6 22.6 0.9 nn 6-V5-t6 24.9 0.5 nn
6-V4-t7 17.7 1.3 <0.2 6-V5-t7 15.3 0.9 nn
6-V4-t8 12.6 1.2 <0.2 6-V5-t8 13.1 1.0 <0.2
6-V4-t9 9.8 0.9 <0.2 6-V5-t9 10.8 1 <0.2
6-V4-t10 5.5 0.8 <0.2 6-V5-t10 6.9 0.8 <0.2
6-V4-t11 4.6 0.7 <0.2 6-V5-t11 3.9 0.6 <0.2
6-V4-t12 2.7 0.4 nn 6-V5-t12 2.6 0.5 nn
6-V4-t13 1.2 0.2 nn 6-V5-t13 1.1 0.4 nn
Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L] Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L]
6-V6-t0 nn nn nn 6-V7-t0 nn nn nn
6-V6-t1 6-V7-t1 <0.5 nn nn
6-V6-t2 6-V7-t2 22.5 nn nn
6-V6-t3 6-V7-t3 64.6 nn nn
6-V6-t4 54.1 <0.2 nn 6-V7-t4 77.5 0.4 nn
6-V6-t5 51.3 1.3 <0.2 6-V7-t5 58.3 0.9 <0.2
6-V6-t6 57.7 2.4 <0.2 6-V7-t6 48.9 2.1 0.2
6-V6-t7 46.2 3.7 0.3 6-V7-t7 35.7 3.8 0.3
6-V6-t8 35.7 3.9 0.4 6-V7-t8 28.9 2.6 0.3
6-V6-t9 28.9 3.3 0.4 6-V7-t9 23.9 2.3 0.3
6-V6-t10 17.8 3.3 0.4 6-V7-t10 17 2.6 0.4
6-V6-t11 11.3 2.3 0.4 6-V7-t11 12.8 2.1 0.3
6-V6-t12 7.4 1.5 0.3 6-V7-t12 8.8 1.5 0.3
6-V6-t13 2.8 0.8 0.1 6-V7-t13 3.1 0.6 <0.2
Preparation 4 (3mg midazolam) Preparation 5 (3mg midazolam)
Subject 6:  midazolam and metabolites serum concentrations
Dormicum i.v. (1mg midazolam) Preparation 1 (1mg midazolam)
Preparation 2 (1mg midazolam) Preparation 3 (1mg midazolam)
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Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L] Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L]
9-V2-t0 nn nn nn 9-V3-t0 nn nn nn
9-V2-t1 2.5 nn nn 9-V3-t1 nn nn nn
9-V2-t2 25.7 nn nn 9-V3-t2 8.1 nn nn
9-V2-t3 22.3 nn nn 9-V3-t3 19.7 nn nn
9-V2-t4 16.4 0.3 nn 9-V3-t4 16.3 nn nn
9-V2-t5 15.1 0.6 nn 9-V3-t5 18.6 0.2 nn
9-V2-t6 14.3 1 nn 9-V3-t6 16.7 0.5 nn
9-V2-t7 12.7 1.2 <0.2 9-V3-t7 13 0.8 nn
9-V2-t8 9.7 1.1 <0.2 9-V3-t8 9.7 0.9 nn
9-V2-t9 8.1 1 <0.2 9-V3-t9 8.3 0.9 nn
9-V2-t10 4.3 0.6 <0.2 9-V3-t10 5.0 0.7 nn
9-V2-t11 2.9 0.4 nn 9-V3-t11 3.4 0.4 nn
9-V2-t12 2.1 0.4 nn 9-V3-t12 2.6 0.3 nn
9-V2-t13 1.3 0.2 nn 9-V3-t13 1.6 0.2 nn
Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L] Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L]
9-V4-t0 nn nn nn 9-V5-t0 nn nn nn
9-V4-t1 nn nn nn 9-V5-t1 nn nn nn
9-V4-t2 3.9 nn nn 9-V5-t2 6 nn nn
9-V4-t3 16 nn nn 9-V5-t3 18.3 nn nn
9-V4-t4 19.5 <0.2 nn 9-V5-t4 26.5 nn nn
9-V4-t5 16.1 0.3 nn 9-V5-t5 23.4 0.5 nn
9-V4-t6 12.1 0.4 nn 9-V5-t6 19 0.8 nn
9-V4-t7 11.1 0.7 <0.2 9-V5-t7 12.8 1.1 nn
9-V4-t8 9.2 0.8 nn 9-V5-t8 10.2 1.1 nn
9-V4-t9 6.8 0.6 nn 9-V5-t9 8 1.1 <0.2
9-V4-t10 3.9 0.5 nn 9-V5-t10 4.9 0.7 nn
9-V4-t11 2.3 0.3 nn 9-V5-t11 2.8 0.5 nn
9-V4-t12 2.1 0.3 nn 9-V5-t12 2.3 0.4 nn
9-V4-t13 1.2 <0.2 nn 9-V5-t13 1.1 0.3 nn
Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L] Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L]
9-V6-t0 nn nn nn 9-V7-t0 nn nn nn
9-V6-t1 nn nn nn 9-V7-t1 1 nn nn
9-V6-t2 9.6 nn nn 9-V7-t2 11.9 nn nn
9-V6-t3 39.7 nn nn 9-V7-t3 59.9 nn nn
9-V6-t4 66.2 0.3 nn 9-V7-t4 60.2 1.2 nn
9-V6-t5 44.4 0.5 nn 9-V7-t5 43.1 2.8 <0.2
9-V6-t6 43.5 1.9 <0.2 9-V7-t6 38.9 3.9 0.2
9-V6-t7 35.4 2.7 0.2 9-V7-t7 28 3.7 0.3
9-V6-t8 23.7 2.5 0.2 9-V7-t8 18.8 3.4 0.3
9-V6-t9 20.4 2.4 0.2 9-V7-t9 18.3 3.4 0.3
9-V6-t10 10 2 <0.2 9-V7-t10 9.6 2.4 0.2
9-V6-t11 7.5 1.3 <0.2 9-V7-t11 6.5 1.7 <0.2
9-V6-t12 5.4 1 <0.2 9-V7-t12 5.2 1.2 <0.2
9-V6-t13 2.7 0.5 nn 9-V7-t13 2.8 0.5 nn
Preparation 4 (3mg midazolam) Preparation 5 (3mg midazolam)
Subject 9:  midazolam and metabolites serum concentrations
Dormicum i.v. (1mg midazolam) Preparation 1 (1mg midazolam)
Preparation 2 (1mg midazolam) Preparation 3 (1mg midazolam)
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Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L] Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L]
11-V2-t0 nn nn nn 11-V3-t0 nn nn nn
11-V2-t1 42.9 nn nn 11-V3-t1 nn nn nn
11-V2-t2 48.7 nn nn 11-V3-t2 13.2 nn nn
11-V2-t3 32 nn nn 11-V3-t3 26.5 nn nn
11-V2-t4 18.8 0.2 nn 11-V3-t4 32.9 nn nn
11-V2-t5 17.3 0.7 nn 11-V3-t5 25.7 0.3 nn
11-V2-t6 14.3 0.9 nn 11-V3-t6 20.7 0.7 nn
11-V2-t7 16.1 1.1 <0.2 11-V3-t7 15.5 1 <0.2
11-V2-t8 11.2 1.1 <0.2 11-V3-t8 11.9 1.1 <0.2
11-V2-t9 11.0 1 <0.2 11-V3-t9 9.9 0.9 <0.2
11-V2-t10 6.8 0.8 <0.2 11-V3-t10 6.5 0.8 <0.2
11-V2-t11 4.0 0.6 <0.2 11-V3-t11 4.3 0.6 <0.2
11-V2-t12 2.8 0.5 nn 11-V3-t12 3.0 0.5 <0.2
11-V2-t13 0.9 0.2 nn 11-V3-t13 1.2 <0.2 nn
Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L] Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L]
11-V4-t0 nn nn nn 11-V5-t0 nn nn nn
11-V4-t1 0.7 nn nn 11-V5-t1 nn nn nn
11-V4-t2 17.2 nn nn 11-V5-t2 7.9 nn nn
11-V4-t3 30.2 nn nn 11-V5-t3 32.8 nn nn
11-V4-t4 25.8 <0.2 nn 11-V5-t4 29.5 <0.2 nn
11-V4-t5 22.2 0.5 nn 11-V5-t5 22.6 0.4 nn
11-V4-t6 19.6 0.9 nn 11-V5-t6 24.2 0.7 nn
11-V4-t7 15.8 1.2 nn 11-V5-t7 18.1 1.1 <0.2
11-V4-t8 12.4 1.3 <0.2 11-V5-t8 14.1 1.3 <0.2
11-V4-t9 11.2 1.3 <0.2 11-V5-t9 12.7 1.2 <0.2
11-V4-t10 5.8 0.9 <0.2 11-V5-t10 7 1 <0.2
11-V4-t11 3.9 0.6 <0.2 11-V5-t11 4.3 0.6 <0.2
11-V4-t12 2.9 0.4 <0.2 11-V5-t12 3.4 0.5 <0.2
11-V4-t13 1.1 0.2 nn 11-V5-t13 1.5 0.2 nn
Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L] Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L]
11-V6-t0 nn nn nn 11-V7-t0 nn nn nn
11-V6-t1 nn nn nn 11-V7-t1 nn nn nn
11-V6-t2 23.7 nn nn 11-V7-t2 44.1 nn nn
11-V6-t3 91.9 nn nn 11-V7-t3 96.9 nn nn
11-V6-t4 98.3 <0.2 nn 11-V7-t4 98.2 0.3 nn
11-V6-t5 77.2 0.8 nn 11-V7-t5 79.2 1.8 <0.2
11-V6-t6 62.6 2.6 0.2 11-V7-t6 54.1 3.1 0.2
11-V6-t7 51.6 3 0.3 11-V7-t7 42.8 3.9 0.4
11-V6-t8 38.5 2.6 0.3 11-V7-t8 29.1 3.3 0.3
11-V6-t9 33.2 2.7 0.3 11-V7-t9 27.3 2.8 0.3
11-V6-t10 18.1 2 0.3 11-V7-t10 17.1 2.5 0.2
11-V6-t11 11.7 1.6 0.3 11-V7-t11 10.6 1.9 0.2
11-V6-t12 8.1 1.1 <0.2 11-V7-t12 7.6 1.2 0.2
11-V6-t13 3.5 0.4 <0.2 11-V7-t13 3.2 0.5 <0.2
Preparation 4 (3mg midazolam) Preparation 5 (3mg midazolam)
Subject 11:  midazolam and metabolites serum concentrations
Dormicum i.v. (1mg midazolam) Preparation 1 (1mg midazolam)
Preparation 2 (1mg midazolam) Preparation 3 (1mg midazolam)
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Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L] Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L]
13-V2-t0 nn nn nn 13-V3-t0 nn nn nn
13-V2-t1 19.4 nn nn 13-V3-t1 nn nn nn
13-V2-t2 64 nn nn 13-V3-t2 10.8 nn nn
13-V2-t3 34.3 <0.2 nn 13-V3-t3 41.8 nn nn
13-V2-t4 25.9 1 <0.2 13-V3-t4 34.2 0.2 nn
13-V2-t5 22.7 1.4 <0.2 13-V3-t5 31.8 0.8 nn
13-V2-t6 21.1 1.4 0.2 13-V3-t6 22.6 1 <0.2
13-V2-t7 18.2 1.3 0.2 13-V3-t7 21.7 1.4 <0.2
13-V2-t8 13.3 1.0 0.2 13-V3-t8 13.7 1.2 <0.2
13-V2-t9 13.1 0.9 0.2 13-V3-t9 12.4 1.2 0.2
13-V2-t10 7.9 0.8 <0.2 13-V3-t10 8.6 0.9 <0.2
13-V2-t11 6.0 0.6 <0.2 13-V3-t11 5.6 0.6 <0.2
13-V2-t12 4.2 0.4 <0.2 13-V3-t12 4.2 0.6 <0.2
13-V2-t13 1.9 <0.2 nn 13-V3-t13 1.5 0.2 nn
Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L] Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L]
13-V4-t0 nn nn nn 13-V5-t0 nn nn nn
13-V4-t1 nn nn nn 13-V5-t1 nn nn nn
13-V4-t2 9.7 nn nn 13-V5-t2 1.3 nn nn
13-V4-t3 38.3 nn nn 13-V5-t3 6.1 nn nn
13-V4-t4 38.1 <0.2 nn 13-V5-t4 32.1 nn nn
13-V4-t5 29.8 0.4 nn 13-V5-t5 27.9 0.2 nn
13-V4-t6 24.1 0.9 <0.2 13-V5-t6 25.3 0.5 nn
13-V4-t7 20 1.2 <0.2 13-V5-t7 16.5 0.5 nn
13-V4-t8 15.5 0.8 <0.2 13-V5-t8 14.6 0.7 <0.2
13-V4-t9 13.6 0.9 <0.2 13-V5-t9 12.4 0.7 <0.2
13-V4-t10 8.3 0.8 <0.2 13-V5-t10 9 0.7 <0.2
13-V4-t11 5.9 0.6 <0.2 13-V5-t11 5.8 0.5 <0.2
13-V4-t12 4.5 0.4 <0.2 13-V5-t12 4.4 0.5 nn
13-V4-t13 1.9 0.2 <0.2 13-V5-t13 1.9 0.2 nn
Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L] Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L]
13-V6-t0 nn nn nn 13-V7-t0 nn nn nn
13-V6-t1 nn nn nn 13-V7-t1 nn nn nn
13-V6-t2 0.5 nn nn 13-V7-t2 6.1 nn nn
13-V6-t3 14.3 nn nn 13-V7-t3 63.1 nn nn
13-V6-t4 67.7 nn nn 13-V7-t4 68.6 0.3 nn
13-V6-t5 66.3 0.4 nn 13-V7-t5 56.2 1.4 <0.2
13-V6-t6 63.5 1.1 <0.2 13-V7-t6 52.3 2.7 0.3
13-V6-t7 52.1 2.7 0.3 13-V7-t7 46.7 3.1 0.4
13-V6-t8 41.6 2.6 0.3 13-V7-t8 38.1 2.9 0.5
13-V6-t9 41.9 3.7 0.4 13-V7-t9 36.2 3.1 0.5
13-V6-t10 31.2 3.3 0.6 13-V7-t10 21.2 2.1 0.5
13-V6-t11 19.7 2.3 0.5 13-V7-t11 17 2 0.4
13-V6-t12 13.6 1.6 0.4 13-V7-t12 12 1.4 0.4
13-V6-t13 5.8 0.7 0.2 13-V7-t13 5.1 0.6 <0.2
Preparation 4 (3mg midazolam) Preparation 5 (3mg midazolam)
Subject 13:  midazolam and metabolites serum concentrations
Dormicum i.v. (1mg midazolam) Preparation 1 (1mg midazolam)
Preparation 2 (1mg midazolam) Preparation 3 (1mg midazolam)
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Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L] Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L]
14-V2-t0 nn nn nn 14-V3-t0 nn nn nn
14-V2-t1 49.9 nn nn 14-V3-t1 nn nn nn
14-V2-t2 47.9 nn nn 14-V3-t2 2.7 nn nn
14-V2-t3 26.1 0.3 nn 14-V3-t3 12.4 nn nn
14-V2-t4 25.6 1.3 <0.2 14-V3-t4 16.4 nn nn
14-V2-t5 21.7 1.7 <0.2 14-V3-t5 20 0.4 nn
14-V2-t6 18.3 1.8 <0.2 14-V3-t6 21.7 1.2 <0.2
14-V2-t7 16.1 1.8 <0.2 14-V3-t7 16.7 1.4 <0.2
14-V2-t8 12.8 1.8 <0.2 14-V3-t8 12.6 1.4 <0.2
14-V2-t9 11.1 1.6 <0.2 14-V3-t9 11.3 1.4 <0.2
14-V2-t10 6.8 1.2 <0.2 14-V3-t10 7.7 1.4 <0.2
14-V2-t11 4.8 1.1 <0.2 14-V3-t11 4.9 0.9 <0.2
14-V2-t12 3.9 0.8 <0.2 14-V3-t12 3.8 0.8 <0.2
14-V2-t13 2.3 0.3 nn 14-V3-t13 2.5 0.4 nn
Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L] Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L]
14-V4-t0 nn nn nn 14-V5-t0 nn nn nn
14-V4-t1 nn nn nn 14-V5-t1 nn nn nn
14-V4-t2 10.5 nn nn 14-V5-t2 2.6 nn nn
14-V4-t3 26.5 nn nn 14-V5-t3 19.6 nn nn
14-V4-t4 28.8 0.3 nn 14-V5-t4 36.7 <0.2 nn
14-V4-t5 26.4 1 nn 14-V5-t5 30.7 1 nn
14-V4-t6 21.8 1.3 <0.2 14-V5-t6 23.3 1.6 <0.2
14-V4-t7 16.9 1.4 nn 14-V5-t7 16.8 2.2 <0.2
14-V4-t8 12.8 1.4 <0.2 14-V5-t8 11.4 1.9 <0.2
14-V4-t9 10.2 1.4 <0.2 14-V5-t9 9.4 1.8 <0.2
14-V4-t10 6.8 1.1 <0.2 14-V5-t10 5.6 1.1 <0.2
14-V4-t11 5.4 1 <0.2 14-V5-t11 4.6 0.9 <0.2
14-V4-t12 4 0.8 <0.2 14-V5-t12 4 0.9 <0.2
14-V4-t13 2.3 0.5 nn 14-V5-t13 2 0.4 nn
Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L] Identification
midazolam              
[ug/L]
α-hy-midazolam              
[ug/L]
4-hy-midazolam              
[ug/L]
14-V6-t0 nn nn nn 14-V7-t0 nn nn nn
14-V6-t1 nn nn nn 14-V7-t1 nn nn nn
14-V6-t2 3.1 nn nn 14-V7-t2 9.3 nn nn
14-V6-t3 26.1 nn nn 14-V7-t3 83.0 nn nn
14-V6-t4 67.9 <0.2 nn 14-V7-t4 71.9 1 nn
14-V6-t5 69.3 1 <0.2 14-V7-t5 53 2.8 0.3
14-V6-t6 57.7 2.2 0.2 14-V7-t6 42.9 3.9 0.3
14-V6-t7 46.5 3.7 0.4 14-V7-t7 34.3 4.6 0.4
14-V6-t8 23.7 2.2 0.3 14-V7-t8 27.7 4.5 0.4
14-V6-t9 25.7 2.9 0.3 14-V7-t9 24.6 5.7 0.5
14-V6-t10 20.6 3.2 0.5 14-V7-t10 15.9 3.5 0.4
14-V6-t11 14.6 2.5 0.4 14-V7-t11 12.9 2.8 0.3
14-V6-t12 11.7 2.2 0.4 14-V7-t12 9.9 2.2 0.3
14-V6-t13 6.8 1.1 0.3 14-V7-t13 4.7 0.8 0.2
Preparation 4 (3mg midazolam) Preparation 5 (3mg midazolam)
Subject 14:  midazolam and metabolites serum concentrations
Dormicum i.v. (1mg midazolam) Preparation 1 (1mg midazolam)
Preparation 2 (1mg midazolam) Preparation 3 (1mg midazolam)
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10.3.8 Midazolam serum concentration time profiles (all subjects) 
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Figure 10-3: Overlayed midazolam serum concentration time profile after i.v. and nasal administration 
of 1 mg midazolam (Dormicum® and Preparation 1, 2, and 3), nasal administration of 3 mg 
(Preparation 4 and 5) to 8 healthy volunteers. 
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10.3.9 Nasal delivery of 1 mg midazolam (Preparation 1, 2, and 3) 
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Figure 10-4: Nasal administration of 1 mg (Preparation 1, 2, and 3) to 8 healthy volunteers. 
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10.3.10 Nasal delivery of 3 mg midazolam (Preparation 4 and 5) 
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Figure 10-5: Nasal administration of 3 mg (Preparation 4 and 5) to 8 healthy volunteers.  
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10.4. Project III 
10.4.1 Case report form (radiologist) 
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10.4.2 Case report form (radiologic technician) 
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10.4.3 Flowchart: multicenter trial 
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10.4.4 Instruction material 
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